# EFFECT OF TERMINALIA ARJUNA AND EMBLICA OFFICINALIS EXTRACT ON CARDIOVASCULAR SYSTEM IN ALBINO WISTER RATS



Thesis submitted to the

BLDE University, Vijayapur, Karnataka, INDIA

For the award of

# DOCTOR OF PHILOSOPHY (MEDICAL)

In

## **ANATOMY**

By

## **BHEEMSHETTY S. PATIL**

Reg No. 10PhD001

Department of Anatomy

Under the Guidance of

Dr. S. D. Desai.

Prof. of Anatomy Principal

Shridevi Institute of Medical Science & Research Hospital, Tumkur.

Shri B. M. Patil Medical College, Hospital and Research centre, BLDE University, Vijayapur, Karnataka. INDIA.

November-2015

# EFFECT OF TERMINALIA ARJUNA AND EMBLICA OFFICINALIS EXTRACT ON CARDIOVASCULAR SYSTEM IN ALBINO WISTER RATS



Thesis submitted to

BLDE University, Vijayapur, Karnataka, INDIA

Under the faculty of medicine

For the award of the

# DOCTOR OF PHILOSOPHY (MEDICAL)

In

## **ANATOMY**

By

## **BHEEMSHETTY S. PATIL**

Reg No. 10PhD001

## **Department of Anatomy**

Shri B. M. Patil Medical College, Hospital and Research centre, BLDE University, Vijayapur, Karnataka. INDIA.

November- 2015

DECLARATION BY THE CANDIDATE

I hereby declare that this thesis entitled "Effect of Terminalia Arjuna and Emblica

Officinalis extract on Cardiovascular system in albino Wister rats." is a bonafide and genuine

research work carried out by me under the guidance of Dr. S. D. Desai, Principal Shridevi

Institute of Medical Science & Research Hospital, Tumkur. Karnataka, India. No part of this

thesis has been formed the bases for the award of any degree or fellowship previously.

Date:

Signature of the candidate

Place: Vijayapur.

**Bheemshetty S. Patil** 

Ph.D. Scholar Reg No. 10PhD001 Department of Anatomy Shri B. M. Patil Medical College, Hospital and Research Centre, BLDE University, Vijayapur, Karnataka. INDIA.

## **BLDE UNIVERSITY**

Bijapur, Karnataka, India



# Certificate

This is to certify that this thesis entitled "Effect of *Terminalia Arjuna and Emblica Officinalis* extract on Cardiovascular system in albino Wister rats." is a bonafide research work carried out by Dr. Bheemshetty S. Patil under our supervision and guidance in the Department of Anatomy Shri. B. M. Patil Medical College, Hospital and Research Center, Vijayapura, Karnataka, India. In the fulfilment of the requirements for the degree of Doctor of Philosophy in Anatomy.

Dr. S. D. Desai

Guide
Prof. of Anatomy
Principal Sridevi Institute of Medical
Science and Research Hospital, TUMKUR. Karnataka

Dr. B. M. Bannur

Prof & Head of Anatomy
Shri. B. M. Patil Medical College, and
Hospital and Research centre,
BLDE University, Vijayapur

Dr. M. S. Biradar

Principal, Dean, Faculty of Medicine Shri. B. M. Patil Medical College, and Hospital and Research centre, BLDE University, Vijayapur

# BLDE UNIVERSITY SHRI B. M. PATIL MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTER



## Copyright

## Declaration by the candidate

I hereby declare that the BLDE University's Shri B. M. Patil Medical College, Hospital and Research Center, Vijayapur Karnataka, shall have the rights to preserve, use and disseminate this declaration/thesis in print or electronic format for academic/research purpose.

C	BLDE Uni	versity's Sh	ri B. M	. Patil	Medical	College,	Hospital	and
Resea	rch Center,	Vijayapura	Karnata	aka,				

Date: Signature of the candidate

Place: Vijayapur. Bheemshetty S. Patil

Ph.D. Scholar
Reg No. 10PhD001
Department of Anatomy
Shri B. M. Patil Medical College,
Hospital and Research Centre,
BLDE University, Vijayapur,
Karnataka. INDIA.

## **ACKNOWLEDGEMENT**

At the outset, I would like to express my deep sense of gratitude and heartfelt thanks to my research guide **Dr. S. D. Desai,** Prof. of Anatomy, Principal Shridevi Institute of Medical Sciences & Research Hospital Tumakur His encouragement, timely advice, valuable suggestions and undying optimism have been a source of constant strength to me. I thank him for the freedom of thought & expression granted and for his trust, which was generously bestowed upon me. Who, with him friendly care made this onerous task of research work look very easy.

I express my sincere gratitude to my research teacher, **Prof Dr. Kusal K. Das**, Dept of Physiology Shri B. M. Patil Medical College, Hospital and Research Centre and Visiting prof School of Medicine University of Leads UK. Who is well known for his professionalism, commitments and value added practices. Who with his critic care, support, encouragement and necessary facilities made this task come true.

I earnestly thank **Dr. R. M. Potekar.** Prof, Dept of Pathology Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for his constant support, care, and encouragement towards histopathological analysis during my research work and sparing his valuable time.

I express My special thanks to Dr..M.S. Biradar Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, For his constant support, care, and encouragement.

I am also thankful to Dr. Tejaswini V. PhD Committee Chairperson BLDE University's Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for her constant help and Kind support during the project.

I also thank Dr. Vijayakumar Kalyanapgol Medical superintendent Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for his constant support encouragement.

I am thankful to my beloved teacher Dr. Sathyaprasad V. Prof, Dept of Anatomy MNR Medical College Sangareddy AP, during my study, who taught me the value of hard work, practices of ethics, values and dedication which helped me to achieve the impossible in life.

I wish to thank Dr. B.M. Bannur, Professor and Head, Dept. of Anatomy Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for his help and Kind support during the project.

I also thank Dr. R. S Wali, Professor and Head, Dr. Akram Naikwadi Dr. Ambudasu Bharat Mr.Bhairkadar Gujrati Dept. of Pharmacology Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for providing animals and animal house for research work.

I thank to Dr. Baswaraj B. Devarnavdagi, Professor and Head, Dr. Neelima Dongre, Dr Baswaraj Aski, Dr, Indira Hundekari and all the staff of Dept. of Biochemistry Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for providing his constant support in research work.

I thank to Dr. B. R Yellikar, Professor and Head, and Mrs Jassy Joseph (Tech) Dept. of Pathology Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for their constant support in research work.

I thank to Dr. Manjunath Aithala, Professor and Head, Dept. of Physiology Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for his constant support encouragement.

I thank to Dr. Shivakumar H, Professor and Head, Mr Nanjappiah. H.M and Mr V. P. Patil Dept. Of Pharmacoly BLDEA's College of Pharmacy Vijayapura, for his support, guidance and timely advice during this project.

I thank to Dr. Navanath Kalyani, Principal BLDEA's College of Pharmacy Vijayapura, for his constant support encouragement.

I thank to Dr Shailaja Patil Prof Mrs Vijaya Sorgavi and Mr. Shahanawaz, Lecturer Dept. of Preventive and social Medicine Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura, for his constant support in statistical analysis

I also wish to thank my senior staff and colleagues, Dr. R. S. Bulagouda, Dr. Ishwar B. Bagoji and Dr. Gavisiddappa A Hadimani for their timely help whenever there was a need and constant support throughout the project

I also thank to my PhD, PG colleagues and friends Dr. Kanthe Pallavi, Mr. Satish Patil deputy Reg Dr Himanshu, Dr. Satish G Patil, Dr Sowmya K, Mr Chandramouli Reddy

I also wish to thank the technical staff of Dept. Anatomy, Biochemistry, Pathology, Pharmacology Shri. B. M. Patil Medical College Hospital & Research Centre, Vijayapura and BLDEA's College of Pharmacy, for their help in various characterization and evaluation studies of my research work

I would also like to thank all the persons who have bestowed on me love and affection when I needed them the most.

Lastly, I am grateful to Dr Pallavi B. Patil, my wife, Aditi B. Patil my daughter, Anvit B. Patil my son, Shri Sidramappa S. Patil my father, Smt. Punnyavati S. Patil my mother and all my family members who boosted my confidence from time to time during this endeavour and for tolerating all my eccentricities in the name of concentration. I don't have enough words to thank them for what they have done in shaping me.

••••

# **INDEX**

S.No	CONTENTS	PAGE NO
1	List of Tables	i
2	List of Figures	ii
3	List of Abbreviations	iii - V
4	ABSTRACT	1 - 2
5	CHAPTER 1: INTRODUCTION	3 - 4
6	Bibliography	5 - 6
7	CHAPTER 2: AIM AND OBJECTIVES OF STUDY	7 - 8
8	Aim	7
9	Objectives	7
10	Hypothesis	8
11	CHAPTER 3 : REVIEW OF LITERATURE	9 - 35
12	Anatomy of Cardiac Musculature	9
13	Development of Heart	10
14	Anatomy of Myocardium	10
15	Gross features of Vessel Wall	11
16	Anatomy of Elastic arteries	11
17	Smooth muscular arteries	12
18	Cardiovascular diseases	13
19	Hyperlipidemia	13
20	Major Lipids in the body	
	<ol> <li>Triglycerides</li> <li>Cholesterol</li> <li>Phospolipids</li> </ol>	14
21	Lipoproteins	15
22	Pathway for Lipid transport	16 - 17
23	Atherosclerosis	18
24	Role of lipids in atherogenic process	18
25	Pathogenesis of atherosclerosis	18
26	Need for novel natural hypolipidemic agent	20
27	Title profile of Terminalia Arjuna (Arjuna) and biological activities  1. Title of the plant 2. Classification 3. Regional names 4. Botanical details 5. Etheno medical uses 6. Distribution and habitat 7. Chemical composition	21 - 24

28         Plant profile of Emblica Officinalis (Amla) and its biological activities           1. Title of the plant         2. Classification           3. Regional names         25 - 27           4. Botanical details         5. Distribution and habitat           6. Chemical composition         7. Etheno medical uses           29         Terminalia Arjuna (Arjuna)         27 - 28           30         Cardioprotective effect         27           31         Hypolipidemic and antiatherogenic activity         28           32         Emdothelial dysfunction         28           33         Emblica Officinalis (Amla)         29 - 30           34         Cardioprotective activity of Emblica Officinalis (Amla)         29 - 30           35         Role of Emblica Officinalis (Amla)         29           36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36 - 66           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36 - 66           41         Extraction of Drugs         36 - 66           42         Phytochemical screening and preliminary stu			1
2. Classification       25 - 27         4. Botanical details       25 - 27         4. Botanical details       5. Distribution and habitat         6. Chemical composition       7. Etheno medical uses         29 Terminalia Arjuna (Arjuna)       27 - 28         30 Cardioprotective effect       27         31 Hypolipidemic and antiatherogenic activity       28         32 Endothelial dysfunction       28         33 Emblica Officinalis (Amla)       29 - 30         34 Cardioprotective activity of Emblica Officinalis (Amla)       29         35 Role of Emblica Officinalis (Amla) in hyperlipidemia       29         36 Hepatoprotective effect       30         37 Bibliography       31 - 35         38 CHAPTER 4: MATERIAL AND METHODS       36 - 66         39 Experimental animals       36         40 Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)       36         41 Extraction of Drugs       36         42 Phytochemical screening and preliminary studies       37 - 41         43 Study design       41         44 Preparation of Iso-caloric and Hyperlipidemic diet       42         45 GENERAL       43         46 Sample collection       43         47 Cervical dislocation method       43      <	28	Plant profile of Emblica Officinalis (Amla) and its biological activities	
3. Regional names       25 - 27         4. Botanical details       5. Distribution and habitat         6. Chemical composition       7. Etheno medical uses         29       Terminalia Arjuna (Arjuna)       27 - 28         30       Cardioprotective effect       27         31       Hypolipidemic and antiatherogenic activity       28         32       Endothelial dysfunction       28         33       Emblica Officinalis (Amla)       29 - 30         34       Cardioprotective activity of Emblica Officinalis (Amla)       29         35       Role of Emblica Officinalis (Amla) in hyperlipidemia       29         36       Hepatoprotective effect       30         37       Bibliography       31 - 35         38       CHAPTER 4: MATERIAL AND METHODS       36 - 66         39       Experimental animals       36         40       Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)       36         41       Extraction of Drugs       36         42       Phytochemical screening and preliminary studies       37 - 41         43       Study design       41         44       Preparation of Iso-caloric and Hyperlipidemic diet       42         45       GENERAL		1. Title of the plant	
4. Botanical details 5. Distribution and habitat 6. Chemical composition 7. Etheno medical uses  29 Terminalia Arjuna (Arjuna) 27-28  30 Cardioprotective effect 27  31 Hypolipidemic and antiatherogenic activity 28  32 Endothelial dysfunction 28  33 Emblica Officinalis (Amla) 29-30  34 Cardioprotective activity of Emblica Officinalis (Amla) 29  35 Role of Emblica Officinalis (Amla) in hyperlipidemia 29  36 Hepatoprotective effect 30  37 Bibliography 31-35  38 CHAPTER 4: MATERIAL AND METHODS 36-66  39 Experimental animals 36  40 Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla) 36  41 Extraction of Drugs 36  42 Phytochemical screening and preliminary studies 37-41  43 Study design 44 Preparation of Iso-caloric and Hyperlipidemic dict 45 GENERAL 46 Sample collection 43  47 Cervical dislocation method 48 Hematology 49  Lipid profile 44-47  50 Liver function test 47-52  51 Serum electrolyte 52  Glucose estimation 53-55		2. Classification	
4. Botanical details         5. Distribution and habitat         6. Chemical composition         7. Etheno medical uses         29       Terminalia Arjuna (Arjuna)       27 - 28         30       Cardioprotective effect       27         31       Hypolipidemic and antiatherogenic activity       28         32       Endothelial dysfunction       28         33       Emblica Officinalis (Amla)       29 - 30         34       Cardioprotective activity of Emblica Officinalis (Amla)       29         35       Role of Emblica Officinalis (Amla) in hyperlipidemia       29         36       Hepatoprotective effect       30         37       Bibliography       31 - 35         38       CHAPTER 4: MATERIAL AND METHODS       36 - 66         39       Experimental animals       36         40       Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)       36         41       Extraction of Drugs       36         42       Phytochemical screening and preliminary studies       37 - 41         43       Study design       41         44       Preparation of Iso-caloric and Hyperlipidemic diet       42         45       GENERAL         46       Sa		3. Regional names	
5. Distribution and habitat       6. Chemical composition         7. Etheno medical uses         29 Terminalia Arjuna (Arjuna)       27 - 28         30 Cardioprotective effect       27         31 Hypolipidemic and antiatherogenic activity       28         32 Endothelial dysfunction       28         33 Emblica Officinalis (Amla)       29 - 30         34 Cardioprotective activity of Emblica Officinalis (Amla)       29         35 Role of Emblica Officinalis (Amla) in hyperlipidemia       29         36 Hepatoprotective effect       30         37 Bibliography       31 - 35         38 CHAPTER 4: MATERIAL AND METHODS       36 - 66         39 Experimental animals       36         40 Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)       36         41 Extraction of Drugs       36         42 Phytochemical screening and preliminary studies       37 - 41         43 Study design       41         44 Preparation of Iso-caloric and Hyperlipidemic diet       42         45 GENERAL       43         46 Sample collection       43         47 Cervical dislocation method       43         48 Hematology       44         49 Lipid profile       44 - 47         50 Liver function test       <		4 Botanical details	25 - 27
6. Chemical composition         7. Etheno medical uses         29 Terminalia Arjuna (Arjuna)       27 - 28         30 Cardioprotective effect       27         31 Hypolipidemic and antiatherogenic activity       28         32 Endothelial dysfunction       28         33 Emblica Officinalis (Amla)       29 - 30         34 Cardioprotective activity of Emblica Officinalis (Amla)       29         35 Role of Emblica Officinalis (Amla) in hyperlipidemia       29         36 Hepatoprotective effect       30         37 Bibliography       31 - 35         38 CHAPTER 4: MATERIALAND METHODS       36 - 66         39 Experimental animals       36         40 Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)       36         41 Extraction of Drugs       36         42 Phytochemical screening and preliminary studies       37 - 41         43 Study design       41         44 Preparation of Iso-caloric and Hyperlipidemic dict       42         45 GENERAL       43         46 Sample collection       43         47 Cervical dislocation method       43         48 Hematology       44         49 Lipid profile       44 - 47         50 Liver function test       47 - 52 <t< td=""><td></td><td></td><td></td></t<>			
7. Etheno medical uses           29 Terminalia Arjuna (Arjuna)         27 - 28           30 Cardioprotective effect         27           31 Hypolipidemic and antiatherogenic activity         28           32 Endothelial dysfunction         28           33 Emblica Officinalis (Amla)         29 - 30           34 Cardioprotective activity of Emblica Officinalis (Amla)         29           35 Role of Emblica Officinalis (Amla) in hyperlipidemia         29           36 Hepatoprotective effect         30           37 Bibliography         31 - 35           38 CHAPTER 4: MATERIALAND METHODS         36 - 66           39 Experimental animals         36           40 Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41 Extraction of Drugs         36           42 Phytochemical screening and preliminary studies         37 - 41           43 Study design         41           44 Preparation of Iso-caloric and Hyperlipidemic dict         42           45 GENERAL         43           46 Sample collection         43           47 Cervical dislocation method         43           48 Hematology         44           49 Lipid profile         44 - 47           50 Ever uncelectrolyte         52			
29         Terminalia Arjuna (Arjuna)         27 - 28           30         Cardioprotective effect         27           31         Hypolipidemic and antiatherogenic activity         28           32         Endothelial dysfunction         28           33         Emblica Officinalis (Amla)         29 - 30           34         Cardioprotective activity of Emblica Officinalis (Amla)         29           35         Role of Emblica Officinalis (Amla) in hyperlipidemia         29           36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         43           46         Sample collection         43           47         Cervical dislocation metho		•	
30         Cardioprotective effect         27           31         Hypolipidemic and antiatherogenic activity         28           32         Endothelial dysfunction         28           33         Emblica Officinalis (Amla)         29 - 30           34         Cardioprotective activity of Emblica Officinalis (Amla)         29           35         Role of Emblica Officinalis (Amla) in hyperlipidemia         29           36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         43           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44			
Hypolipidemic and antiatherogenic activity   28	29	Terminalia Arjuna (Arjuna)	27 - 28
32         Endothelial dysfunction         28           33         Emblica Officinalis (Amla)         29 - 30           34         Cardioprotective activity of Emblica Officinalis (Amla)         29           35         Role of Emblica Officinalis (Amla) in hyperlipidemia         29           36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         43           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52 <tr< td=""><td>30</td><td>Cardioprotective effect</td><td>27</td></tr<>	30	Cardioprotective effect	27
33         Emblica Officinalis (Amla)         29 - 30           34         Cardioprotective activity of Emblica Officinalis (Amla)         29           35         Role of Emblica Officinalis (Amla) in hyperlipidemia         29           36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         43           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52	31	Hypolipidemic and antiatherogenic activity	28
34         Cardioprotective activity of Emblica Officinalis (Amla)         29           35         Role of Emblica Officinalis (Amla) in hyperlipidemia         29           36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIALAND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         42           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52           52         Glucose estimation         52           53 <td>32</td> <td>Endothelial dysfunction</td> <td>28</td>	32	Endothelial dysfunction	28
35         Role of Emblica Officinalis (Amla) in hyperlipidemia         29           36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         43           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52           52         Glucose estimation         52           53         Estimation of Nitric Oxide (NO)         53 - 55	33	Emblica Officinalis (Amla)	29 - 30
36         Hepatoprotective effect         30           37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         43           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52           52         Glucose estimation         52           53         Estimation of Nitric Oxide (NO)         53 - 55	34	Cardioprotective activity of Emblica Officinalis (Amla)	29
37         Bibliography         31 - 35           38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         42           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52           52         Glucose estimation         52           53         Estimation of Nitric Oxide (NO)         53 - 55	35	Role of Emblica Officinalis (Amla) in hyperlipidemia	29
38         CHAPTER 4: MATERIAL AND METHODS         36 - 66           39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         42           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52           52         Glucose estimation         52           53         Estimation of Nitric Oxide (NO)         53 - 55	36	Hepatoprotective effect	30
39         Experimental animals         36           40         Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)         36           41         Extraction of Drugs         36           42         Phytochemical screening and preliminary studies         37 - 41           43         Study design         41           44         Preparation of Iso-caloric and Hyperlipidemic diet         42           45         GENERAL         43           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52           52         Glucose estimation         52           53         Estimation of Nitric Oxide (NO)         53 - 55	37	Bibliography	31 - 35
40       Authentication of drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)       36         41       Extraction of Drugs       36         42       Phytochemical screening and preliminary studies       37 - 41         43       Study design       41         44       Preparation of Iso-caloric and Hyperlipidemic diet       42         45       GENERAL         46       Sample collection       43         47       Cervical dislocation method       43         48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	38	CHAPTER 4: MATERIAL AND METHODS	36 - 66
Officinalis (Amla)       36         41       Extraction of Drugs       36         42       Phytochemical screening and preliminary studies       37 - 41         43       Study design       41         44       Preparation of Iso-caloric and Hyperlipidemic diet       42         45       GENERAL       43         46       Sample collection       43         47       Cervical dislocation method       43         48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	39	Experimental animals	36
42       Phytochemical screening and preliminary studies       37 - 41         43       Study design       41         44       Preparation of Iso-caloric and Hyperlipidemic diet       42         45       GENERAL       43         46       Sample collection       43         47       Cervical dislocation method       43         48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	40		36
43       Study design       41         44       Preparation of Iso-caloric and Hyperlipidemic diet       42         45       GENERAL         46       Sample collection       43         47       Cervical dislocation method       43         48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	41	Extraction of Drugs	36
44       Preparation of Iso-caloric and Hyperlipidemic diet       42         45       GENERAL         46       Sample collection       43         47       Cervical dislocation method       43         48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	42	Phytochemical screening and preliminary studies	37 - 41
45         GENERAL           46         Sample collection         43           47         Cervical dislocation method         43           48         Hematology         44           49         Lipid profile         44 - 47           50         Liver function test         47 - 52           51         Serum electrolyte         52           52         Glucose estimation         52           53         Estimation of Nitric Oxide (NO)         53 - 55	43	Study design	41
46       Sample collection       43         47       Cervical dislocation method       43         48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	44	Preparation of Iso-caloric and Hyperlipidemic diet	42
47       Cervical dislocation method       43         48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	45	GENERAL	
48       Hematology       44         49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	46	Sample collection	43
49       Lipid profile       44 - 47         50       Liver function test       47 - 52         51       Serum electrolyte       52         52       Glucose estimation       52         53       Estimation of Nitric Oxide (NO)       53 - 55	47	Cervical dislocation method	43
50 Liver function test 47 - 52 51 Serum electrolyte 52 52 Glucose estimation 52 53 Estimation of Nitric Oxide (NO) 53 - 55	48	Hematology	44
51Serum electrolyte5252Glucose estimation5253Estimation of Nitric Oxide (NO)53 - 55	49	1 1	44 - 47
52Glucose estimation5253Estimation of Nitric Oxide (NO)53 - 55	50	Liver function test	47 - 52
53 Estimation of Nitric Oxide (NO) 53 - 55	51	Serum electrolyte	52
	52	Glucose estimation	52
54   SPECIAL	53	Estimation of Nitric Oxide (NO)	53 - 55
	54	SPECIAL	

56	Histology: Hematoxylin and eosin and special stain Verhoeff's	56 - 60
57	Vascular Integrity Parameter	61
58	Morphometry of arterial wall	61
59	Normalized Wall Index	62
60	Description of Camera	62 - 63
61	Bibliography	64 - 66
62	Statistical Analysis	67
63	CHAPTER 5 : RESULT	68 - 105
64	Phytochemistry	68
65	Gravimetry	69
66	Biochemical Investigation	
	1.Lipid profile	
	2.Liver function test	70 - 72
	3.Serum electrolyte	
	4.Glucose Regulations	
67	Histology of Atrium	73 - 76
68	Histology of Ventricle	77 - 79
69	Histology of Elastic artery	80 - 86
70	Histology of Muscular artery	87 - 93
71	Histology of Coronary artery	94 - 99
72	Vascular integrity based on histological profile	100
73	Estimation of Elastic artery Thickness and Lumen diameter	100 - 102
74	Estimation of Muscular artery Thickness	102
75	Estimation of Coronary artery Thickness and Lumen diameter	103 - 104
76	Normalized Wall Index	104 - 105
77	CHAPTER 6 DISCUSSION	106 - 114
78	Bibliography	115 -117
79	CHAPTER 7 : SUMMARY AND CONCLUSION	118 - 119
80	LIMITATION AND FUTURE DIRECTION	120
81	PUBLICATIONS	
82	PRESENTATIONS	
83	INSTITUTIONAL ANAMAL ETHICAL CLEARENCE	

# LIST OF TABLES

S. No.	TABLES	PAGE NO
1	Groups Dosage and Food for feeding	41
2	Total Bilirubin working standard	51
3	Glucose estimation	53
4	Nitric Oxide Procedure Part I	54
5	Nitric Oxide Procedure Part III	55
6	Phytochemical Screening	68
7	Gravimetry	69
8	Heamatolgy	70
9	Lipid Profile	70
10	Liver Function Test	71
11	Serum Electrolyte	72
12	Glucose Regulation	72
13	Estimation of Elastic Artery wall Thickness	100
14	Morphometry of Elastic arterial Lumen	102
15	Estimation of Muscular Artery wall Thickness	102
16	Estimation of Coronary Arterial wall Thickness	103
17	Analysis of Coronary Arterial Lumen	104
18	Normalized wall Index	104
19	Serum Nitric Oxide	105
20	Flow Chart Summary	118

## LIST OF FIGURES

S. NO	FIGURES	PAGE NO
1	Heart Anterior View	9
2	Heart Posterior View	9
3	Lipoprotein Metabolism	17
4	Cross section view of an artery depicting steps in development of an atheroma from left to right	20
5	Arjuna fruit and tree	21
6	Arjunelin, arjunolic acid, arjunolic acid	23
7	Amla tree and fruits	25
8	Extraction of drugs by Soxhlet apparatus	37
9	Microtome	57
10	Water bath	57
11	Hot plate	57
12	Automatic tissue processor	57
13	Slide prepared for staining process	57
14	Special stain chemicals for Veheroff's	60
15	Veheroff's Hematoxillin	60
16	Veheroff's stain	60
17	MIPS	63
18	Microstructure of Atrium H&E stain in 10X and 40X (10 figures)	74 - 75
19	Microstructure of Ventricle H&E stain in 10X and 40X (10 figures)	77 - 78
20	Microstructure of Elastic Artery H&E and Veheroff's stain in 10X and 40X (20 figures)	80 - 84
21	Microstructure of Muscular Artery H&E and Veheroff's stain in 10X and 40X (20 figures)	87 - 91
22	Microstructure of Coronary artery H&E stain in 10X and 40X (10 figures)	94 - 98
23	Elastic Arterial Wall Thikeness Measurement	101
24	Coronary Arterial Wall Thickness Measurement	103
25	Measurement of Lumen Diameter Transverse & Anterioposterior.	105
	Arterial Lumen Area Measurement	

## **ABBREVIATIONS**

% - Percent

μm - Micrometer

μl - Micro liter

mmol/L - Milimole/Liter

μmol/L - Micromole/Liter

nm - Nanometre

ml - Millilitre

gms - Grams

gm - Gram

g/dl - Grams/Desi litre

g/L - Grams/Litre

mg/kg - Milligram/Kilogram

IP - Indian Pharmaceuticals

B.wt - Body weight

HR - Hour

IAEC - Institutional Animal Ethical Committee

ICMR - Indian Council of Medical Research

CPCSEA - Committee for the Purpose of Control and Supervision

of Experiments on Animals (India)

TLC - Thin Liquid Chromatography

Hel - Hydrochloride

Conc - Concentration

Na<sup>+</sup> - Sodium

K<sup>+</sup> - Potassium

Ca<sup>++</sup> - Calcium

Hb% - Haemoglobin Percentage

RBC - Red Blood Corpuscles

WBC - White Blood Corpuscles

PCV - Packed Cell Volume

MCHC - Mean Corpuscular Hemoglobin Concentration

TC - Total Cholesterol

TGs - Trygleseroids

TG - Trygleseroid

LDL - Low Density Lipoprotein

HDL - High Density Lipoprotein

HDL2 - High Density Lipoprotein 2

HDL3 - High Density Lipoprotein 3

ILDL - Intermediate Low Density Lipoprotein

IDL - Intermediate Density Lipoprotein

IHD - Ischaemic Heart Disease

FFA - Free Fatty Acids

VLDL - Very Low Density Lipoprotein

ApoB - Apolipoprotein B

Ox LDL - Oxidised low density lipoproteins

OxLDLS - Oxidatively Modified Low Density Lipoprotein.

MCP1 - Monocyte Chemotactic Protein-1

CSF - Cerebro Spinal Fluid

NO - NITRIC OXIDE

TNF Alpha - Tumor Necrosis Factor Alpha

MIP1 Alpha - Macrophage Inflammatory Protein 1-alpha

VCAM1 - Vascular cell adhesion molecule-1

ICAM1 - Intercellular Adhesion Molecule 1

SMCs - Smooth Muscle Cells

ROS - Reactive Oxygen Spaces

HMG CoA - Hydroxy Methyl Glutaryl-CoA Reductase

H<sub>2</sub>O - Water

H<sub>2</sub>O<sub>2</sub> - Hydrogen Peroxide

O<sub>2</sub> - Oxygen

ATP - Adenosine Tri Phosphate

ADP - Adinosine Di Phosphate

Rpm - Rotation Per Minute

SGOT - Serum Glutamic Oxaloacetic Transaminase,

SGPT - Serum Glutamic Pyruvic Transaminase,

ALP - Alkaline Phosphatase Level

ALT - Alanine Transaminase

LDH - Lactate Dehydrogenase

NAD - Nicotinamide Adenine Dinucleotide.

••••••••

**ABSTRACT** 

## **ABSTRACT**

**Background:** Hyperlipidemia is the key factor in the development of atherosclerosis, liver disorders and oxidative stress. For treatment of atherosclerosis and various cardiovascular diseases, much attention has been focused on the use of natural products that have very few side effects. *Terminalia Arjuna (Arjuna) and Embilica Officinalis (Amla)* occupy the pride of place in the context of such medicinal values. *Terminalia Arjuna (Arjuna)* is herbal tree of combretaceae family. Bark of *Terminalia Arjuna (Arjuna)* contains hypolipidemic agents and flavonoids such as arjunolic acid, arjun glycosides, arjunone with rich antioxidative properties. It serves as a cardiac tonic.

Embilica Officinalis (Amla) is also known as Amla or Indian gooseberry acts as antihyperlipidemic and antioxidant. Its active ingredients contain tannins, gallic acids and flavonoids.

**Aims and Objective**: The aim of the present study was to assess the effect of ethanolic extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on cardiovascular system and histological alteration of heart, elastic artery, muscular artery and coronary artery of albino rats fed with high fat diet.

Materials and methods: Extraction of *Terminalia Arjuna (Arjuna) and Emblica Officinalis* (*Amla*) by soxhlet apparatus using 99% ethanol at 60° temp for 22hrs and phytochemical analysis was done. Group 1 served as normal control/Iso-caloric diet. Group 2 fed with hyperlipidemic diet. Group 3 fed with hyperlipidemic diet and treated with *Terminalia Arjuna (Arjuna)* for 21 days. Group 4 fed with hyperlipidemic diet and treated with *Embilica Officinalis (Amla)* 21 days and Group 5 fed with hyperlipidemic diet and treated with *Terminalia Arjuna (Arjuna) and Embilica Officinalis (Amla)* for 21 days

Abstract Page 1

Dose of ethonolic extract of *Terminalia Arjuna (Arjuna)*: (500mg/kg body weight daily) and *Emblica Officinalis (Amla)* (100mg/kg body weight daily).

The results: Significant percent body weight gain in group 2(Hyperlipidemic diet fed rats), however these changes were not observed in hyperlipidemic rats treated with *Terminalia Arjuna* (*Arjuna*) and *Emblica Officinalis* (*Amla*). There was significant improvement in coronary arterial wall thickness and lumen diameter. Coronary artery showed early fatty changes in hyperlipidemic rats group 2, which brought back to normal in group 3, 4 and 5. (Group 3 rats fed with hyperlipidemic diet and treated with *Terminalia Arjuna* (*Arjuna*), group 4 rats fed with hyperlipidemic diet and treated with *Emblica Officinalis* (*Amla*) and group 5 rats fed with hyperlipidemic diet and treated with *Terminalia Arjuna* (*Arjuna*) and *Emblica Officinalis* (*Amla*)).

**Conclusion:** Results indicate both these two drugs are cardioprotective against hyperlipidemia induced alteration of cardiovascular pathophysiology.

Abstract Page 2

# **CHAPTER 1**

**INTRODUCTION** 

### **INTRODUCTION:**

Hyperlipidemia shares

remarkably in the manifestation and development of atherosclerosis and coronary heart diseases (CHD)<sup>1</sup>. Atherosclerosis causing to coronary artery have presumed a serious disease. It is the prime cause of mortality and morbidity worldwide<sup>2</sup>. Atherosclerosis is a multifactorial disease and about 250 different risk factors have been recognized<sup>3</sup>. Among the several factors high fat diet, unhealthy life style, smoking, family history of hypertension and increased LDL levels are the culprits for the onset of CHDs<sup>1</sup>. Epidemiological studies have revealed a positive significant correlation between Coronary Artery Disease (CAD) and plasma cholesterol concentration<sup>4</sup>. Intake of diet with high saturated fat and cholesterol has been proved to be the predominant factor in the progress of atherosclerosis. Experimental studies have proved high fat diet may be connected with increased oxidative stress in mammals<sup>5</sup>.

Reducing levels of increased lipids mainly low density lipoproteins (LDL) and triglycerides by dietary interventions or by the drug could reduce the risk of CHD<sup>1</sup>.

Synthetic anti hyperlipidemic drugs like statin and synthetic antioxidant like probicol are drug of choice to cure atherosclerosis and its associated complication<sup>6</sup>. Even though statins have been proved effective in lowering increased LDL levels have found side effects<sup>6</sup>. Statins are fundamentally enzyme inhibitor that is HMG CoA.

It is likely that modern medicinal system is curing on one hand and causing side effects on the other hand<sup>7</sup>. Nowadays enhanced interest in natural products has encouraged the search for new hypolipidemic drugs and therapies from these natural sources. Many herbal medicinal products are much efficient in lowering increased lipid levels in body with very low side effects<sup>1</sup>.

Hence, for treatment of atherosclerosis and various cardiovascular diseases, much attention has been focused on the use of natural products that have very few side effects<sup>8</sup>. *Terminalia Arjuna (Arjuna) and Embilica Officinalis (Amla)* occupy the pride of place in the context of such medicinal values. Recently there has been renewed interest in these plants because of its multimode cardioprotective activities.

Terminalia Arjuna (Arjuna) (Family: Combretaceae), used in traditional medicine for treating ulcers, wound healing<sup>9</sup>, and also for antibacterial<sup>10</sup>, antimutagenic/ anticarcinogenic<sup>11</sup>, antioxidant and hypocholesterolemic activities<sup>12</sup>. The active constituents of *Terminalia include tannins, triterpenoids* saponins (arjunolic acid, arjunic acid, arjungenin, arjunglycosides), flavonoids (arjunone, arjunolone, luteolin), gallic acid, oligomericproanthocyanidinspolyphenols, calcium, magnesium, zinc and copper<sup>13</sup>.

*Terminalia Arjuna*(*Arjuna*) acts on cardiac muscles and improves pumping action of heart. It is used as a cardiac tonic<sup>14</sup>. As *Emblica Officinalis* (*Amla*), a strong antioxidant and found to have influences on the regulation of lipid metabolism<sup>15</sup>.

In search of relative safer alternative compound to fight against cardiovascular risks and diseases especially in case of exposure to high dietary fat consumption, the present study has undertaken to find out cardioprotective efficacy of *Terminalia Arjuna(Arjuna)* and *Emblica Officinalis(Amla)* on experimental model

## **REFERENCES:**

- 1) Choudhary M I, Nahid S, Jalil S, Alamb J M, Rehman A. Effect of Ethanolic extract of *Iris germanica* on lipid profile of rats on high fat diet. Journal of Ethnopharmacology 2005; 98: 217-20.
- 2) Sharma N, Sharma P, Jasuja N D, Joshi S C. Hypocholesterolemic and Antioxidant Potentials of Some Plants and Herbs: A Review. Research and Reviews: Journal of Zoological Sciences 2013; 1(2): 26-42.
- 3) Kabiri N, Asgary S, Madani H, Mahzouni P. Effects of *Amaranthuscaudatus*l. Extract and lovastatin on atherosclerosis in hypercholesterolemic rabbits. Journal of Medicinal Plants and Research.2010; 4:355-61.
- 4) Subramaniam S, Subramaniam R, Rajapandian S, Uthrapathi S, Victor R, Dubey G P. Anti-Atherogenic Activity of Ethanolic Fraction of *Terminaliaarjuna* Bark on Hypercholesterolemic Rabbits. Evidence-Based Complementary and Alternative Medicine 2009; 2011
- 5) VizaquezFreire LMJ, Lamela M, Calleja J M. Hypolipidemic activity of a polysaccharide extract from *FucusVesiculosus*. Phytotheropatic Research 1996; 10: 647-50
- 6) Lankin VZ, Tikhaze AK, Kukharchuk VVet al. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Molicular Cell Biochemistry 2003; 249 (1-2): 129–140.
- 7) Sharma S, Sharma D, Agarwal N. Diminishing effect of *Arjuna* tree bark on the lipid and oxidative stress status of high fat high cholestrol fed rats and development of certain

dietary recipes containing the tree bark for human consumption. Research in Pharmacy 2012; 2(4): 22-30.

- 8) Cooke JP. Nutriceuticals for cardiovascular health.American Journal of Cardiology 1998; 82(9)
- 9) Rane MM, Mengi SA. Comparative effect of oral administration and topical application of alcoholic extract of *TerminaliaArjuna*bark on incision and excision wounds in rats. Fitoterapia 2003; 74 (6): 553–58.
- 10) Samy RP, Ignacimuthu S, Sen A. Screening of 34 Indian medicinal plants for antibacterial properties. Journal of Ethnopharmacology 1998; 62 (2): 173–81.
- 11) Lampronti I, Khan MTH, Borgatti M, Bianchi N,Gambari R. Inhibitory effects of Bangladeshi medicinal plant extracts on interactions between transcription factors and target DNA sequences. Evidence-Based Complementary and Alternative Medicine 2008; 5 (3): 303–12.
- 12) Gupta R, Singhal S, Goyle A, Sharma VN. Antioxidant and hypocholesterolemic effects of *TerminaliaArjuna*tree bark powder: a randomized placebo-controlled trial. Journal of Association of Physicians of India 2001; 49: 231–35.
- 13) Miller AL. Botanical influences on cardiovascular disease. Alternative Medicine Review 1998; 3 (6): 422–31.
- 14) SivalokanathanS. Effects of *TerminaliaArjuna* bark extract on apoptosis of human hepatoma cell line HepG2. World Journal of Gastroenterology 2006;21 (7): 1018-24.
- 15) Baliga MS, Dsouza JJ. Amla (*Emblicaofficinalis*Gaertn), a wonder berry in the treatment and prevention of cancer, European Journal of Cancer Prevention 2011; 20 (3): 225-39.

# **CHAPTER 2**

# AIM AND OBJECTIVES OF STUDY

## AIM AND OBJECTIVES OF STUDY

## Aim:

To assess the effect of ethanolic extract of *Terminalia Arjuna (Arjuna)* and *Emblica Officinalis (Amla)* on the cardiovascular system of albino Wistar rats fed with hyperlipidemic diet.

## **Objective:**

To study the effect of ethanolic extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis* (*Amla*) in hyperlipidemic rats on

- a. Lipid profile
- b. Liver function
- c. Histology/architecture of Atrium, Ventricle, and vessels
- d. Vascular Integrity

Aim and Objectives Page 7

## **HYPOTHESIS:**

## Hyperlipidemic diet


- 1. Hyperlipidemic diet influences metabolic functions
- 2. Hyperlipidemic diet makes an adverse effect on the cardiovascular system


Both *Terminalia Arjuna* (Arjuna) and *Emblica Officinalis (Amla)* protect cardiovascular integrity against hyperlipidemia

Hypothesis Page 8

# **CHAPTER 3**

**REVIEW OF LITERATURE** 





## **HEART ANTERIOR VIEW**

## **HEART POSTERIOR VIEW**

## **Anatomy of Cardiac musculature:**

Cardiac muscle is present only in the heart, and in the walls of large vessels where they enter the heart. It consists of a branching network of individual cells that are linked electrically and mechanically to function as a unit. Compared with skeletal muscle, cardiac muscle is much less powerful but far more resistant to fatigue. It is provided with a continuous supply of energy by several blood vessels (Coronary artery) around the fibres, and plenty mitochondria within them. Cardiac muscle differs structurally and functionally from skeletal muscle in some important aspects. That is, for example, intrinsically capable of rhythmic contraction, with a rate and strength which is nevertheless responsive to hormonal and autonomic nervous control<sup>1</sup>.

## **Development of Heart:**

The cardiac myocytes differentiate from the splanchnic coelomic cells of the pericardium initially subjacent to the endoderm. Myogenic activity starts at the early stage of 10, 22 days gestation, when the embryo has 4 somites. At the same time presumptive cardiac myocytes express contractile proteins like myosin, actin, troponin and other<sup>2</sup>.

The cardiac myocytes do not conect with their adjacent to form a syncytium as occurs in skeletal muscle, but remain mononucleated, branched cells connected via intercellular junctions<sup>2</sup>.

## **Anatomy of Myocardium:**

In a normal adult the myocardium, the muscular component of the heart, constitutes the bulk of its tissues. It consists predominantly of cardiac muscle cells, which are usually 120  $\mu$ m long and 20–30  $\mu$ m in diameter<sup>3</sup>.

Every cell has one to two large nuclei, lodge the central part of the cell, but in skeletal muscle has multiple, peripherally situated nuclei. These cells are branched at their ends, and the branches of neighbour cells are so tightly associated that the compound microscopic appearance is on a network of branching and anastomosing fibres. All cells are bound together by elaborate junctional complexes, the intercalated<sup>3</sup>.

Fine fibrocollagenous connective tissue is found between cardiac muscle fibres. Although this is equivalent to the endomysium of skeletal muscle, it is less regularly organized because of the complex three-dimensional geometry imposed by the branching cardiac cells. Multiple capillaries and some nerve fibres are found within this layer. Scracthy connective tissue, equivalent to the perimysium of skeletal muscle, separates the larger bundles of muscle fibres,

and is particularly well developed near the condensations of dense fibrous connective tissue that form the 'skeleton' of the heart<sup>3</sup>.

The ventricles of the heart are collected of spiralling layers of fibres which run in various directions. Consequently, histological sections of ventricular muscle naturally contain the profiles of cells cut in a variety of orientations. A progressing arrangement of cardiac muscle fibres is obtained only in the papillary muscles and trabeculae carneae3

## **Gross features of vessel walls:**

Artrial and veneous blood vessels, irrespective of size, without capillaries and venules, have walls consisting of three concentric layers (tunicae). The tunica intima, is the innermost layer. The endothelium is the main component, lines the entire lumen vascular, including the endocardium, and the lymph vessels. The tunica media is made of muscle (Smooth muscle) tissue, elastic fibres and collagen. This is the thickest layer in arteries, the media is absent in capillaries and is comparatively thin in veins. The tunica adventitia is the outer layer of the vessel, and consists of connective tissue, nerves and vessel capillaries vasa vasorum. It links the vessels into the surrounding tissues. Vessels change in the relative thicknesses and detailed compositions of their layers and, in the smallest vessels, the number of layers represented<sup>4</sup>.

## **Elastic/Large arteries:**

The best example for elastic artery is a arta and its largest branches are brachiocephalic, common carotid, subclavian and common iliac arteries are also called large elastic arteries which conduct blood to the medium-sized distributing arteries. The tunica intima is made of an endothelium, resting on a basal lamina, and a subendothelial connective tissue layer. The innermost layer or endothelial cells are flat with prominent nuclei, elongated and polygonal in outline, with their long axes parallel to the direction of blood flow. The subendothelial layer of

blood vessel is well developed, consists of elastic fibres and type I collagen fibrils, fibroblasts and small, smooth muscle-like myointimal cells. The hindmost adhered lipid with age and in an ultimate form, this feature contributes to atherosclerotic (fatty) changes in the tunica intima. Wall thickening of the tunica intima progresses with age and is more marked in the distal than in the proximal segment of the aorta<sup>4</sup>.

Internal elastic lamina is prominent, sometimes divides and lies between tunica intima and tunica media. The elastic lamina is smooth, measures about 1µm in thickness, and, with the elastic lamellae of the tunica media, is stretched under the effect of systolic pressure, recoiling elastically in diastole. The elastic arteries thus have effect of sustaining blood flow despite the pulsatile cardiac output. They also smooth out the cyclical pressure wave. Tunica media has a markedly layered architecture, in which fenestrated layers of elastin alternate with interlamellar smooth muscle cells, collagen and fine elastic fibres. The position is very regular, such that each elastic lamella and adjacent interlamellar zone is regarded as a 'lamellar unit' of the media. In the human aorta there are approximately 52 lamellar units, measuring about 11µm in thickness. Number and thickness of lamellar units increases during postnatal development, from 40 at birth. The adventitia is well developed. In addition to collagen and elastic fibres, it contains flattened fibroblasts with extremely long, thin processes, macrophages and mast cells, nerve bundles and lymphatic vessels<sup>4</sup>.

### **Smooth muscular arteries:**

Smooth muscular arteries are identify by the dominance of smooth muscle in the tunica media. The tunica intima consists of an endothelium, similar to that of elastic/large arteries, which overlies on a basal lamina and subendothelial connective tissue. The internal elastic lamina muscular artery is a distinct, thin layer, sometimes duplicated and sometimes absent. It is

arranged into wavy folds as a result of contraction of smooth muscle in the tunica media. Around 75% of the mass of the tunica media consists of smooth muscle cells, which run spirally or circumferentially around the blood vessel wall. The maximum part of the extracellular matrix is therefore less than in large arteries, however, fine, elastic fibres which run mainly parallel to the muscle cells are present. An external elastic lamina, consists of sheets of elastic fibres, forms a decreased compact layer than the internal elastic lamina, and separates the tunica media from the tunica adventitia in the larger muscular arteries. The adventitia is made of fibroelastic connective tissue, and can be as thick as the media in the smaller arteries. The inner part of the adventitia contains more elastic than collagen fibres<sup>5</sup>.

### CARDIOVASCULAR DISEASES:

Cardiovascular diseases (CVDs) have been reckoned amongst the top reasons for early deaths in the country. By the year 2020, CVDs is expected that CVDs will become the leading cause of death and disability worldwide. One of the major risk factors for developing CVDs is hyperlipidemia, an elevated level of lipid in the plasma. At basal levels, lipids have been reported to perform important functions in the body, but may cause various adverse health effects if present in excess levels<sup>6</sup>.

### **HYPERLIPIDEMIA:**

Hyperlipidemia or hyperlipoproteinemia is the condition of abnormally increased levels of any or all lipids and/or lipoproteins in the blood. These lipids include triglycerides, cholesterols, cholesterol esters and phospholipids. They are transported in the blood as a part of large molecules lipoproteins<sup>7</sup>.

Hyperlipidemia is a major cause of atherosclerosis and its associated disorders like CHD, peripheral vascular disease and ischaemic cerebro vascular diseases. The causal relationship has

been well established between increased levels of plasma lipids and development of atherosclerotic plaques<sup>8</sup>.

## **Major Lipids in the Body:**

Lipids are heterogeneous group of compounds which are relatively insoluble in water and soluble in non-polar solvents such as ether and chloroform<sup>9</sup>. Three major lipids in the body are triglycerides, total cholesterols and phospolipids<sup>9</sup>.

- 1. Triglycerides: This group is better known as neutral fats. As their name suggests, the triglycerides are composed of one molecule of glycerol and connected through ester bonds with three molecules of fatty acids. Triglycerols are water insoluble non polar neutral fats. TGs serve as the body's major fuel storage reserve. TG synthesis mostly occurs in Liver and adipose tissue. The triglycerol produced in liver is packaged with cholesterol, phospholipids and apo lipoprotein, apo-100 to form VLDL and released into blood stream and delivered to the peripheral tissue<sup>10</sup>.
- **2. Cholesterol:** It is the major sterol in the body. Liver and intestine are major sites of cholesterol synthesis. It is found in the cell membrane where it helps maintaining cell integrity and fluidity. It also serves as the precursor molecule for the synthesis of other steroids including bile salts (aids in the digestion of fats) and steroid hormones (such as testosterone, estrogen, progesterone, and cortisol). An abnormality in cholesterol levels in the body can lead to atherosclerosis that can lead to myocardial infarction or stroke<sup>7</sup>.
- **3. Phospholipids:** Phospholipids are the major class of membrane lipids. They are composed of a glycerol molecule with two fatty acids (a Diglyceride) they can form lipid bilayers because of their amphiphilic characteristic. It performs important function in maintaining cell permeability<sup>11</sup>.

## **Lipoproteins:**

Fat absorbed from the diet and fat synthesized by the liver and adipose tissue must be transported between the various tissues and organs for utilization and storage. The lipoprotein system evolves in transporting fats in the aqueous environment of the plasma<sup>7</sup>.

A lipoprotein is a water miscible complex containing center core of hydrophobic, non polar lipid (TGs and cholesterol ester) covered in a hydrophilic coat of polar lipids that is phospholipids, free cholesterol and apolipoprotein<sup>11</sup>.

Five main types of lipoproteins are

- a) Chylomicrons
- b) Very low density lipoprotein (VLDL)
- c) Intermediate density lipoprotein (ILDL)
- d) Low density lipoprotein (LDL)
- e) High density lipoprotein (HDL).
- f) Lipoprotein
- a) Chylomicrons: These are principal form in which dietary TGs are carried to the tissues. Dietary lipid is absorbed in the small intestine and incorporated into chylomicrons. Triglycerols are gradually removed from chylomicrons by the action of lipoprotein lipase. After losing TGs, chylomicrons become smaller and richer in cholesterol and cholesterol esters. This is called chlyomicron ruminants.
- b) VLDL: These are triglycerol rich particles. VLDL are secreted by liver and transported TGs to the peripheral tissues.
- c) IDL: These are formed by removal of TGs from VLDL during formation of LDL from VLDL.

- d) LDL: These are cholesterol rich particles, formed from IDL by the removal of more triglycerols and apolipoproteins. They become smaller and denser. Oxidized LDL is more atherogenic. Excess cholestrol is present in the form of LDL hence it is called "Bad Cholestrol"
- e) HDL: These are of two types HDL2 and HDL3. They transport cholesterol from peripheral cells to the liver, prior to excretion. They increase in size as they circulate via the bloodstream and attract more phospholipids and cholesterol molecules from cells and other lipoproteins. Raised plasma levels of HDL is associated with reduced risk of IHD and seems to have protective effect. Hence it is known as "Good Cholestrol".
- f) Lipoproteins: It is synthesized in the liver and has about the same lipid composition as LDL. It has been shown to compete with plasminogen for tissue plasminogen receptors. It also causes proliferation of smooth muscle cells causing generation of clots and atherosclerosis<sup>11</sup>.


## **Pathway for Lipid transport:**

It comprises two cycles; one exogenous and other endogenous. Both are centered on the liver and interconnected<sup>7</sup>.

- a) Exogenous pathway: Dietary lipid is absorbed in the small intestine and incorporated into chylomicrons which are secreted into the lymphatics and reach the blood stream via the thoracic duct. Triglycerol is removed from chylomicrons by lipoprotein lipase and tissues absorb FFA and Glycerol. After losing TGs it gets convert into chylomicron remanant which enrich in cholesterol and cholesterol esters. These remanants are removed by the liver where they are catabolised. In the liver cholesterol may be used to form cell membrane or bile salts or may be excreted in the bile. It enters into endogenous pathway<sup>11</sup>.
  - b) Endogenous pathway: The endogenous pathway comprises transport of cholesterol and TGs from liver to muscle, adipose tissue in the form of VLDL. The lipoprotein particles

become smaller but they increase in density to IDL cholesterol and ultimately LDL particles. Cells take up LDL by endocytosis through LDL receptors. Tissue receives cholesterol in the form of HDL particles. After esterification of cholesterol, they are transferred to VLDL or LDL<sup>11</sup>.

## LIPOPROTIEN METABOLISUM



### **Atherosclerosis:**

Atherosclerosis, a chronic inflammatory disease of the arterial wall, is the major cause of morbidity and mortality from CVD (Cardiovascular Disease). The disease involves the formation of plaques in arterial walls that narrow the arterial passage, obstructing blood circulation and increasing the risk of occlusion of blood flow by a myocardial infarction. Recent information is that atherosclerosis shows a state of heightened oxidative stress characterized by lipid and protein oxidation in the vascular wall<sup>12</sup>.

### Role of lipids in atherogenic process:


LDLs are the major cholesterol transporters and consist of a hydrophobic core containing cholesteryl ester molecules i.e. Triacylglycerols; a surface monolayer of polar lipids (primarily Phospholipids) and ApoB (Apolipoprotein-B)<sup>13</sup>. LDL in the plasma originates from VLDL (very-Low Density Lipoprotein) produced by the liver. VLDL is transformed to LDL by the action of LPL (Lipoprotein Lipase), an enzyme which hydrolyzes triglycerides in VLDL, The removal of triglycerides from VLDL by LPL leaves a greater proportion of cholesterol, enhancing the density of the particle and changing it to LDL. One of the first steps in the development of atherosclerosis is the passage of LDL out of the arterial lumen into the arterial wall. Plasma LDL is transported across the intact endothelium and caught in the ECM (Extracellular Matrix) of the subendothelial space where it is subjected to oxidative modifications to produce highly oxidized and aggregated LDL, referred to as OxLDL (Oxidized LDL).

### **Pathogenesis of atherosclerosis:**

OxLDL stimulates inflammatory signaling by endothelial cells, releasing chemotactic proteins such as MCP1 (Monocyte Chemotactic Protein-1) and growth factors such as mCSF (Monocyte

Colony Stimulating Factor), which help in the recruitment of monocytes into the arterial wall<sup>13</sup>. OxLDLs also promote the differentiation of monocytes into macrophages that take-up the oxidized LDL in a process that converts them into foam cells. It is the hallmark cell of atherosclerosis. Apart from that, OxLDL also has other effects, such as inhibiting the production of NO (Nitric Oxide), an important mediator of vasodilation and expression of endothelial leukocyte adhesion molecules. The macrophages take up the OxLDLs, become enlarged and full of lipid. These cells accumulate in tissue and are transformed into lipid-laden Foam cells, dying and forming part of the atherogenic plaque (Atherosclerotic Plaque) in the 8fatty streak lesions<sup>14</sup>. Activated macrophages express a range of cytokines (such as TNF-Alpha (Tumor Necrosis Factor-Alpha), IL-1Beta (Interleukin-1Beta), MIP1Alpha (Macrophage Inflammatory Protein-1Alpha) etc.), which stimulate endothelial cells to express adhesion proteins (like VCAM1 (Vascular-Cell-Adhesion Molecule-1), ICAM1 (Intracellular-Adhesion Molecule-1) etc). This facilitates the process of binding of additional blood monocytes to the endothelium and their recruitment into the intima. The cytokines released from the macrophages and foam cells also stimulate the SMCs to migrate into the intima, then proliferate and secrete collagen, elastin and proteoglycans to form a fibrous matrix. This results in the formation of plaques with fibrous caps. The mature plaques protrude into the arterial lumen, and cause obstruction of arterial blood flow. Numerous physiologic triggers: Physical exertion, mechanical stress due to an increase in cardiac contractility, pulse rate, blood pressure and possibly, vasoconstriction initiate the rupture of a vulnerable plaque. Rupture leads to the activation, adhesion, and aggregation of platelets and the activation of the clotting cascade, resulting in the formation of an occlusive thrombus (Clot). Thrombus formation in the lumen of a coronary artery may lead to its partial blockage of blood flow, or, can result in myocardial infarction<sup>13&15</sup>.

Cross-sectional view of an artery depicting steps in development of an atheroma, from left to right.



### NEED FOR NOVEL NATURAL HYPOLIPIDEMIC AGENT:

Presently, five major classes of medications have been mentioned to treat people with detrimental lipid levels that include statins, nicotinic acid derivatives, fibric acid derivatives, bile acid binding resins and cholesterol absorption inhibitors<sup>6</sup>. However, statins have been associated with most common side effects like stomach upset, nausea, vomiting, headache and dizziness. The common side effects of niacin drugs include flushing, hot flashes, itching and headache<sup>6</sup>.

As above mentioned therapy is considered as long term treatment, there may be risk of chronic effects like muscle toxicity, carcinogenic and mutagenic. Hence it is of the hour to explore natural source of medicines those are less toxic, less expensive which can provide better safety and efficacy on a long term usage. Ayurvedic system of medicine consists of various

herbal drugs. Many herbal drugs have been reported to be useful in the treatment of cardiovascular diseases including hyperlipidemea. Among these herbal drugs *Terminalia Arjuna* (Arjuna) and *Emblica Officinalis* (*Amla*) occupy the pride of place in the context of such medicinal values. Recently there has been renewed interest in these plants because of its multimode cardioprotective activity.

### Plant profile of *Terminalia Arjuna* (Arjuna) and biological activities:

**Title of plant:** *Terminalia Arjuna* (Arjuna)

#### Classification:

Kingdom- Plantae, Division- Magnoliophyta,

Class- Magnoliopsida, Order- Myrtales,

Family- Combretacae, Gene- Terminalia

### **Regional names:**

English names- Arjuna, Myroblan, White Marudah, white Murdh

Hindi name- Arjan, Arjun, Arjuna, Kahua, Kahu, Koha

Sanskrit name-Arjuna Kakubha, Indradu viravriksha

Latin name- Terminalia Arjuna. Kannada name- Maddi, Tora Matti

Gujarati name- Arjun sadada, Sadado. Telgu name- Tellamaddi, Yerra maddi

Marathi name- Arjun Sadada, Sadura



Terminalia Arjuna leaf and fruit



Terminalia Arjuna Tree and Bark

Botanical Details: *Terminalia Arjuna* (Arjuna) is a deciduous tree found throughout India. The Arjuna is about 20–25 metres tall; usually has a buttressed trunk, and forms a wide canopy at the crown, from which branches drop downwards. It has oblong, conical leaves which are green on the top and brown below; smooth, grey bark; it has pale yellow flowers which appear between March and June; its glabrous, 2.5 to 5 cm fibrous woody fruit, divided into five wings, appears between september and november. It has huge, often buttressed trunk and horizontally spreading branches. Extent of buttressing in different localities has been found to be due to local factors and is not determined genetically. Among different species of *Terminalia* the bark of *Terminalia Arjuna* (Arjuna) has its own characteristic features. Bark of *Terminalia Arjuna* (Arjuna) is smooth, pinkish grey from outside and flakes off in large, curved and rather flat pieces. The size of each piece may vary up to 15 cm or more in length, 10 cm in width and 3–10mm in thickness. Sapwood is reddish white and heartwood is brown and variegated with dark colored streaks<sup>16&17</sup>.

The histology of *Terminalia Arjuna* (Arjuna) bark reveals the presence of single layered epidermis with hair like projections and few scattered lenticels. Underlying the epidermis is a thin layer of cortex. Periderm and secondary phloem are present in the old bark. Leaves are simple, borne sub-opposite coriaceous, often crenulating, oblong or elliptic. Their upper face is pale or dark green and the lower face is pale brown. It measures 10–15 cm long and 4–7 cm broad. A network of 10–15 pairs of nerves is arranged in reticulate fashion. Petioles are 6–10mm long with yellowish or reddish hairs. Linear, lanceolate-like bracteoles are present. Calyx is glabrous. Its fruit is a drupe, 2.5–5 cm long, ovoid or oblong, fibrous woody, smooth-skinned with five hard angles or wings. The lines of the wings are oblique and curved upwards 16,17&18.

# **Arjunetin:**

# **Arjunolic Acid:**

# **Arjunolic Acid:**

### **Ethno medical uses:**

Arjuna Bark is used as astringent and diuretic<sup>16</sup>. It is used in the treatment of leucorrhea, diabetes and fracture. It is also styptic, antidysentric and expectorant<sup>15</sup>. Chakradatta, the great ancient physician, recommended it to be given as a decoction of bark with milk or as a ghrita (a preparation with ghee or butter)<sup>19</sup>. Decoction of the bark has been used for ulcer cleaning and bark ashes have been recommended for snakebite and scorpion sting. Externally leaves are utilized for applying wounds and sores<sup>20</sup>. It is also used as cardiac tonic and hypolipidemic<sup>21</sup>.

### **Distribution and habitat:**

The Arjuna is commonly found growing on river banks or near dry river beds in West Bengal and south and central India. It is found in aplenty throughout Indo-sub-himalayan tracts of Uttar pradesh, south Bihar, Madhya pradesh, Delhi and deccan region near ponds and rivers. It is also found in forests of Sri lanka, Burma and Mauritius<sup>18</sup>.

## **Chemical composition:**

Terminalia Arjuna (Arjuna) as a medicinal plants contain some organic compounds which provide definite physiological action on the human body and these bioactive substances include tannins, alkaloids, carbohydrates, terpenoids, steroids, flavonoids and phenols<sup>21</sup>. Terminalia's active constituents include tannins, cardenolide, triterpenoid saponins (arjunic acid (AA), arjunolic acid, arjungenin (AG), arjun glycosides), flavonoids (arjunone, arjunolone, luteolin), gallic acid, ellagic acid, oligomeric proanthocyanidins, phytosterols, calcium, magnesium, zinc and copper<sup>22&23</sup>.

# Plant profile of *Emblica Officinalis (Amla)* and its biological activities:

**Title of plant:** *Embilica Officinalis (Amla)* 

### **Classification**:

Kingdom- Plantae

Division- Angiospermae

Class- Dicotyledonae

Order- Geraniales

Family- Euphorbiaceae

Gene- Emblica

Species: Officinalis geartn.

# **Regional names:**

English: Emblic myrobalan, Indian goose berry

Sanskrit: Aamalaki, Hindi: Amla, Kannada: Nelli Kayi, Marathi: Amla, Gujarati: Ambla,

Malayalam: Nelli Kayi, Tamil: Nelli, Telugu: Usirikaya and Kashmir: Aonla.



Emblica Officinalis (Amla) Tree



Emblica Officinalis (Amla) fruit

#### **BOTANICAL DETAILS:**

Amla is a small to medium sized deciduous tree, reaching 8 to 18 in height, which is known for its edible fruit of the same name. The tree has crooked trunk and spreading branches. The leaves are simple, nearly stalk less and closely set along slender branchlets. The leaves are often mistaken for leaflets of pinnate leaves. The genus name phyllanthus is derived greek words meaning leaf flower, an allusion to the apparent bearing of flowers on the leaves. Amla flowers small, greenish- yellow or pinkish. The flowers have six segments, but no real petals. Male and female flowers are carried separately on the same branch. The fruit is nearly spherical, light greenish yellow, quite smooth and hard on appearance, with 6 vertical strips or furrows. Ripening in autumn, the berries are harvested by hand after climbing to upper branches bearing the fruits. The taste of Amla is sour, bitter and astringent, and is quite fibrous<sup>24</sup>.

**Distribution and habitat:** *Emblica Officinalis (Amla)* is an evergreen tree which is highly prized in tropical Asia. Found throughout India, the sea-coast districts and on hill slopes up to 200 meters, also cultivated in plains. It is common all over tropical and sub-tropical India and also found in Burma. It is abundant in deciduous forests of Madhya pradesh, the deccan, the sea-coast districts and Kashmir. Grows in tropical and subtropical parts of Ceylon, Malay Peninsula, Pakistan, Bangaladesh, Shrilanka and China. In Ceylon, it is very common in exposed places on patana land in the moist regions up to 4000 feet altitude<sup>25</sup>.

### **Chemical composition:**

Emblica Officinalis (Amla) primarily contains tannins, alkaloids, phenolic compounds, amino acids and carbohydrates. Its fruit juice contains the highest vitamin C (478.56 mg/100 mL). Compounds isolated from Emblica officinalis (Amla) were gallic acid, ellagic acid, 1-O-galloylbeta- D-glucose, 3,6-di-O-galloyl-Dglucose, chebulinic acid, quercetin, chebulagic acid,

corilagin, 1,6-di-O - galloyl beta D glucose, 3 Ethylgallic acid (3 ethoxy 4,5 dihydroxy benzoic acid) and isostrictiniin. It also contains flavonoids, kaempferol 3 O alpha L (6'' methyl) rhamnopyranoside and kaempferol 3 O alpha L (6''ethyl) rhamnopyranoside. A new acylated apigenin glucoside (apigenin 7 O (6'' butyryl beta glucopyranoside) was isolated from the methanolic extract of the leaves of Phyllanthus emblica together with the known compounds; gallic acid, methyl gallate, 1,2,3,4,6-penta-Ogalloylglucose and luteolin-4'-Oneohesperiodoside were also reported<sup>26</sup>.

# **Ethno medical uses:**

*Emblica* enjoys a hallowed position in Ayurveda, an indigenous system of medicine in India<sup>27</sup>. It is proved to be effective against diabetes, cough, asthma, bronchitis, dyspepsia, colitis, hyper acidity, peptic ulcer, skin diseases, inflammations, anemia, hepatopathy, jaundice, diarrhoea, dysentery, haemorrhage, leucorrhoea, cardiac disorders, intermittent fevers and greying of hair and is given to cancer. The plant is known for digestion power, improving liver functions and is liver protective. It is also a very good blood purifier which in turn improves the health of liver by keeping the toxins and infections away. It is also used as antioxidant, cardioprotective, strengthen heart and hypolipidemic<sup>28</sup>.

# Terminalia Arjuna (Arjuna):

### 1) Cardioprotective effect:

The cardinal benefits of *Terminalia Arjuna (Arjuna)* are enhancement of cardiac muscle function and subsequent improved pumping activity of the heart. Studies reported that the saponin glycosides could be responsible for the inotropic effects of *Terminalia*, where as the flavonoids and OPCs spare free radical antioxidant activity and vascular strengthening<sup>29&30</sup>.

Kumar et al reported in their study that *Arjuna* protects the heart by beta receptor stimulation against myocardial changes<sup>31</sup>.

### 2) Hypolipidemic and antiatherogenic activity:

Animal studies suggest *Terminalia* might reduce blood lipids. Rats made hyperlipidemic by feeding them an atherogenic diet were given an oral ethanolic extract *Terminalia*. Animals given *Terminalia* had a significant, dose-related decrease in levels of LDL-cholesterol and TGs compared to rats received atovastatin<sup>32</sup>.

Khanna A K reported in their study that rats fed cholesterol (25 mg/kg body weight) alone or along with *Terminalia* bark powder (100 mg/kg) for 30 days, *Terminalia* feeding caused a smaller increase in blood lipids and an increase in HDL cholesterol compared to the cholesterolonly group. The researchers felt inhibition of hepatic cholesterol biosynthesis, increased fecal bile acid excretion, and stimulation of receptor mediated catabolism of LDL cholesterol caused *Terminalia's* lipid-lowering effects<sup>33</sup>.

# 3) **Endothelial Dysfunction:**

Hydroalcoholic extract of bark of *Terminalia Arjuna (Arjuna)* has shown marked regression of endothelial abnormality amongst smokers compared to age matched non smokers<sup>34</sup>.

### 4) Hepatoprotective:

The literature survey reported that the ethanolic extract of *Terminalia Arjuna* (*Arjuna*) bark are found to be used in the traditional system of medicine as a liver tonic. *Terminalia Arjuna* (*Arjuna*) is widely used in the treatment of liver diseases like hepatitis, cirrhosis, and loss of appetite. Arjuna is best hepatitis reliever. Leaves of *Terminalia Arjuna* (*Arjuna*) are best healing for hepatitis<sup>18</sup>.

### Emblica Officinalis (Amla): Amla as antioxidant:

Oxidative stress is occurring mainly due to imbalance between pro-oxidant and antioxidant homeaostatic phenomenon in the body. Pro-oxidant increase in the body due to generation of free radicals or poor scavenging in the body. Free radicals are mainly produced during normal respiration and by cell mediated immune functions. Any overburden of free radicals leads to decrease in antioxidant. This may result in damage to tissues and subsequent diseases<sup>26</sup>.

Amla as has been shown to possess good antioxidant property. Evaluation of *Emblica Officinalis* (Amla) in rodents has proved it to be ameliorative against increased lipid peroxidation as well as a decreased activity of enzymatic antioxidants and non-enzymatic antioxidants in both the organs<sup>35</sup>.

### Cardioprotective Activity of *Emblica Officinalis (Amla)*:

It has shown an increase in the cardiac glycogen suggesting a cardio protective action. *Emblica Officinalis (Amla)* has shown its role against isoproterenol-induced cardiotoxicity showed cardioprotective potential along with antioxidant activity and favourable improvement in hemodynamic and contractile function<sup>36</sup>.

Chronic *Emblica Officinalis* (*Amla*) administration produces myocardial adaptation by augmenting endogenous antioxidants and protects rat hearts from oxidative stress associated with ischaemic reperfusion injury<sup>37</sup>.

### **Role of Emblica Officinalis in Hyperlipidemia:**

Many experiments on animals demonstrated improved lipid profile and reduced hypertension in induced metabolic syndrome in rats<sup>38</sup>. Flavonoids extract from the fruits of Amla inhibited synthesis and increased degradation of cholesterol via increased hepatic HMG-CoA reductase<sup>38</sup>. Cu(2+)-induced LDL oxidation and cholesterol-fed rats were used to examine the effects of amla

on low-density lipoprotein (LDL) oxidation and cholesterol levels *in vitro* and *in vivo*. It was concluded that Amla can be effective for hypercholesterolemia and prevention of atherosclerosis<sup>39</sup>.

### **Hepatoprotective Effect:**

Emblica Officinalis (Amla) acts as hepatoprotective in various liver disorders. Arsenic exposure in mice also caused a significant change in serum biomarkers in the SGOT, SGPT and creatinine as compared to the controls. There were no significant changes in the serum levels of total protein in these mice. Co-administration of arsenicand fruit extract of amla (500 mg/kg body weight/day for 30 days) caused a significant reduction of arsenic transference associated with significantly decreases hepatic arsenic levels and balanced the antioxidant enzyme and levels of serum hepatic enzymes like SGOT and SGPT. This clearly demonstrates the antioxidant property of amla that could be responsible for its protective efficacy in arsenic induced hepatic toxicity<sup>40</sup>.

### **REFERENCES:**

- Gray's Anatomy, "The Anatomical basis of clinical practices" Editor, Susan Standring, edition 40:2008. Publisher, Churchill Livingstone Elsevier, P.No104
- 2. Gray's Anatomy, "The Anatomical basis of clinical practices" Editor, Susan Standring, edition 40: 2008. Publisher, Churchill Livingstone Elsevier, Page No142
- 3. Gray's Anatomy, "The Anatomical basis of clinical practices" Editor, Susan Standring, edition 40: 2008. Publisher, Churchill Livingstone Elsevier, P.No152
- 4. Gray's Anatomy, "The Anatomical basis of clinical practices" Editor, Susan Standring, edition 40: 2008. Publisher, Churchill Livingstone Elsevier, P.No131
- 5. Gray's Anatomy, "The Anatomical basis of clinical practices" Editor, Susan Standring, edition 40: 2008. Publisher, Churchill Livingstone Elsevier, P.No132
- 6. Rohilla A, Dagar N, Rohilla S, Dahiya A, Kushnoor A. Hyperlipidemia- A deadly pathological Condition. International Journal Current Pharmaceutical Research 2012; 4(2): 15-18.
- 7. Pankaja Naik. Lipid Metabolism. In Text Book of Biochemistry. 2<sup>nd</sup> ed.Jaypee Medical Publisher;2007.P 265-318.
- 8. Jain K S, Kathiravan M K, Somani R S, Shishoo C J. "The biology & Chemistry of Hyperlipidemia" Bioorganic and Medicinal chemistry. 2007;15:4674-99.
- Mayes P A, Botham K M. Lipids of Physiologic significance. In: Murray R K, Garner D K,
   Mayes P A, Rodwell V W editors. Harper's illustrated Biochemistrey.26<sup>th</sup> ed.New York:
   Lange medical Books; 2003. P 111-22
- 10. www.http://www.austincc.edu/emeyerth/lipids.htm. Accessed on 18/10/2015.

- 11. Satyanarayan U. Biochemistry. 2<sup>nd</sup> ed. Vijaywada. Uppala author- publishers interlinks; 2002.
- 12. Stocker R, Keaneya J F Jr. Role of oxidative modifications in atherosclerosis, Physiological Review. 2004; 84(4): 1381-478.
- 13. Catapano A L, Maggi F M, Tragni E. Low density lipoprotein oxidation, antioxidant, and atherosclerosis, Current opinion in cardiology. 2000 Sep; 15(5): 355-63.
- Libby P. Prevention and treatment of Atherosclerosis. In Principles of Internal Medicine.
   Dr Fauci and Dr Longo editors, 17<sup>th</sup> ed. Newyork Mc Graw Hill;2008.p-1430-31.
- 15. Asmis R, Begley JG, Jelk J, Everson WV. Lipoprotein aggregation protects human monocyte derived macrophages from oxLDL- induced cytotoxicity. The Journal of Lipid Research. 2005 Jun: 46(6):1124-32.
- Dwivedi S, Chopra D. Revisiting Terminalia Arjuna- An ancient cardiovascular Drug.
   Journal of Traditional, Complementary Medicine. 2014 Oct Dec: 4(4) 224-31.
- 17. Kaur N, Shafiq N, Negi H, Pandey A, Reddy S, Kaur H, et al. *Terminalia Arjuna* in chronic stable Angina: Systemic review and meta-analysis. Cardiology Research and Practice 2014: 1-7.
- Narendra Kumar. Phytopharmacological overview on Terminalia Arjuna Wight and Arn.
   World Journal of Pharmaceutical sciences 2014;2(11): 1557-66.
- 19. Chopra RN, Chopra IC, Handa KL, Kapur LD, Chopra RN, Chopra IC et al. Chopra's Indigenous Drugs of India. 1<sup>st</sup> ed. Calcutta, India: UN Dhur and Sons; 1958. Terminalea Arjuna W and A (combretaceae) pp421-4.

- Jain S, Yadav PP, Gill V, Vasudeva N, Singala N. Terminalia Arjuna a sacred medicinal plant Phytochemical and Pharmacological profile. Phytochemistry Review. 2009;8:491-502.
- 21. Mandal S, Patra A, Samanta A, Roy S, Mandal A, Das TM et al. Analysis of phytochemical profile of Terminalia Arjuna bark extract with antioxidative and antimicrobial properties. Asain Pacific Journal of Tropical Biomedicine 2013; 3(12):960-66.
- 22. Varghese A, Pandita N,Gaud RS. *In vitro* and *in vivo* Evaluation of CYP1A Interaction Potential of *Terminalia Arjuna* Bark. Indian Journal of Pharmaceutical Sciences. 2014 Mar Apr: 76(2): 138–47.
- 23. Saha A, Pawar VM, Jayaraman S. Characterisation of Polyphenols in *Terminalia Arjuna*Bark Extract. Indian Journal of Pharmaceutical Sciences. 2012;74 (4): 339-47.
- 24. Kumar KPS, Bhowmik D, Dutta A, Yadav A, Paswan A, Srivastava S, etal. Recent Trends in Potential Traditional Indian Herbs Emblica officinalis and Its Medicinal Importance. Journal of Pharmacognosy and Phytochemistry 2012;1(1):24-32.
- 25. Lama A, Saikia H. Effects of *Emblica Officinalis*(AMLA) on Serum Lipids and Atherogenesis in Albino Rats Fed with High Fat Diet. Indian Medical Gazette 2013 July: 271-275.
- 26. K.H. Khan. Roles of *Emblica officinalis* in Medicine A Review. Botany Research International 2009; 2 (4): 218-28.
- 27. Varghese L.S, Alex N., Ninan M.A., Soman S. and Jacob S. Evaluation of *in vitro* antibacterial activity whole plant(fruits, seeds, stem, leaves and roots) of *emblica*

- officinalis gaertn. International journal of ayurvedic & herbal medicine2013 Nov-Dec; 3(6):1420-25.
- 28. Neelima N, Sudhakar M, Lakshmi BVS. Antistress activity of Ethanolic extract of Emblica Officinalis fruits in stress induced biochemical and physiological perturbations. International Journal of Research in Pharmacology and Pharmacotherapeutics. 2014 Jan-March; 3(1):72-79.
- 29. Miller AL. Botanical Influences on Cardiovascular Disease. Alternative Medicine Review 1998; 3(6): 422-31.
- 30. Yadav RN, Rathore K. A new Cardinolide from the roots of *Terminalia Arjuna*. Fitoterpia 2001; 72:459-61.
- 31. Kumar S, Enjamoori R, Jaiswal A, Ray R, Seth S, Maulik SK. Catecholamineinduced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.) Journal of Pharmacy and Pharmacology. 2009;61:1529–36.
- 32. Subramaniam S, Subramaniam R, Rajapandian S, Uthrapathi S, Victor R, Dubey G P. Anti-Atherogenic Activity of Ethanolic Fraction of *Terminalia Arjuna* Bark on Hypercholesterolemic Rabbits. Evidence-Based Complementary and Alternative Medicine 2009; 2011
- 33. Khanna AK, Ramesh C, Kapoor NK. *Terminalia Arjuna*: an Ayurvedic cardiotonic regulates lipid metabolism in hyperlipidaemic rats. *Phytotherapy Research*. 1996;10:663-665
- 34. Bharani A, Ahirwar LK, Jain N. Terminalia Arjuna reverses impaired endothelial function in chronicsmokers. Indian Heart Journal. 2004;56:123–8.

- 35. Chakraborty D, Verma R. Ameliorative effect of *Emblica officinalis* aqueous extract on ochratoxin-induced lipid Peroxidation in the kidney and liver of mice. International Journal Occupational Medicine and Environmental Health. 2010; 23(1):63-73.
- 36. Ojha A, Yaduvanshi SK, Srivastava N. Effect of combined exposure of commonly used organophosphate pesticides on lipid peroxidation and antioxidant enzymes in rat tissues. Pesticide Biochem Physiol.2011; 99:148–156
- 37. Rajak, S., S.K. Banerjee, S. Sood, A.K. Dinda, Y.K.Gupta, S.K. Guptaand S.K. Maulik, 2004. Emblica officinalis causes myocardial adaptation and protects against oxidative stress in ischemic-reperfusion injury in rats. Phytotherapy Research., 18(1): 54-60.)
- 38. Kim H Y. Okubo T, Juneja LR, Yokozawa T. The protective role of Amla( Emblica Officinalis Gaertn. Against fructose- induces metabolic syndrome in a rat model. British Journal of Nutrition.2010; 103(4):502-12.
- 39. Anila L. and Vijayalakshmi NR. Flavonoids from Emblica officinalis and Mangifera indica- effectiveness for dyslipidemia. Journal of Ethnopharmacology. 2002; 79(1): 81-7.
- 40. Singh MK, Dwivedi S, Yadav SS, Sharma P, Khattri S. Arsenic-Induced Hepatic Toxicity and Its Attenuation by Fruit Extract of *Emblica Officinalis* (Amla) in Mice. Indian Journal of Clinical Biochemistry 2014 Jan-Mar; 29(1):29–37

# **CHAPTER 4**

MATERIAL AND METHODS

**EXPERIMENTAL ANIMALS:** Albino Wistar rats weighing 180 to 250gms were obtained from animal house of Shri B M Patil Medical college Hospital & Research Centre, BLDE University, Bijapur. All the five group animals were acclimatized for 7 days to the laboratory conditions at 22-24°C and maintained 12 HR. Light/dark cycle. All the experimental procedures were performed in accordance with the approval of the Institutional Animal Ethics Committee (IAEC) of Shri B M Patil Medical college Hospital & Research Centre, Bijapur.

All the care has been taken on animals during experimental as well as at the time scarification as per the guidelines of ICMR (Indian Council of Medical Research) on animal research 2006. An experiment was performed according to the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), INDIA. After completion of the experimental protocol, animals were sacrificed by cervical dislocation and incinerated electrically<sup>1</sup>.

### **AUTHENTICATION OF DRUGS:**

Fresh fruits of *Emblica Officinalis* (*Amla*) and Bark of *Terminalia Arjuna* were collected from the local market in Bijapur and obtained the botanical authentication of these drugs in the Dept of Botany, KCP Science College, Bijapur.

# PERMISSION EXTRACTION OF DRUGS:

Obtained permission for ethanolic extraction of *Emblica Officinalis* (*Amla*) and *Terminalia* (Arjuna) drugs from the Department of Pharmacology BLDEA College of Pharmacy Bijapur

# **EXTRACTION OF DRUG:**

Ethanolic extract preparation: Powder of dry bark of *Terminalia Arjuna* and powder of dry fruits of *Emblica Officinalis (Amla)* was extracted with 99% ethanol using a soxhlet

apparatus at a temperature below 60° C for 22 hours. The solvent was evaporated under vacuum which gave semisolid mass with respect to the dried powder.

Percent of Yield was calculated as follows:

Extract yield 
$$\% = \frac{W1}{W2}$$
 100

Where, W1= Net weight of powder in grams after extraction and W2= Total weight of wood powder in grams taken for extraction<sup>2</sup>.



Extraction of drugs by Soxhlet apparatus

# **Phytochemical Screening**

Different extracts were screened for the presence of phenols, flavonoids, tannin, saponin, alkaloids, glycosides, phytosterols and carbohydrate by using standard protocols<sup>3</sup>.

### **Phytochemical Investigations:**

**Chemical and reagents:** Laboratory grade chemicals were used for routine work.

Analytical grade reagents (A.R.) were used for analytical work

**Absorbents:** Silica gel GF254 (RFCL Ltd Renkem production, New Delhi) was used for TLC

**Preliminary Phytochemical studies:** The crude extract obtained by extraction from ethanolic extraction was subjected phytochemical studies

# A. Detection of Carbohydrates

Extracts were dissolved individually in 5 ml distilled water and filtered. The filtrates were used to test for the presence of carbohydrates.

- 1.Molisch"s test: To 1 ml of test solution added a few drops of 1 % alpha-napthol and 2-3 ml concentrated sulfuric acid along the side of test tube. The reddish violet or purple ring formed at the junction of two liquids confirmed the test.
- 2. Benedict's test: Filtrates were treated with Benedict's reagent and heated on a water bath. Formation of an orange red precipitate indicates the presence of reducing sugars.
- 3.Fehlings test: Dissolved 2 mg dry extract in 1 ml of distilled water and added 1ml of Fehling's (A+B) solution, shooked and heated on a water bath for 10 minutes. The brick red precipitate formed confirmed the test
- B. Detection of fixed oils & fats
- 1. Stain Test: Small quantities of extracts were pressed between two filter papers. An oily stain on filter paper indicates the presence of fixed oil.
- C. Detection of phytosterols
- Salkowski's Test: Extracts were treated with chloroform and filtered. The filtrates were
  treated with a few drops of Conc. Sulphuric acid, shaken and allowed to stand.

  Appearance of golden yellow colour indicates the presence of triterpenes.
- 2. Libermann Burchard's test: Extracts were treated with chloroform and filtered. The filtrates were treated with few drops of acetic anhydride, boiled and cooled. Conc. Sulphuric acid was added carefully along the sides of the test tube. Formation of brown ring at the junction indicates the presence of phytosterols.

# D. Detection of glycosides

Extracts were hydrolysed with dil. HCl, and then subjected to test for glycosides.

 Modified Borntrager's Test: Extracts were treated with a ferric chloride solution and immersed in boiling water for about 5 minutes. The mixture was cooled and shaken with an equal volume of benzene. The benzene layer was separated and treated with ammonia solution. Formation of rose-pink colour in the ammoniacal layer indicates the presence of anthranol glycosides.

### E. Detection of flavonoids

- Alkaline Reagent Test: Extracts were treated with a few drops of sodium hydroxide solution. Formation of intense yellow colour, which becomes colourless on addition of dilute acid, indicates the presence of flavonoids.
- 2. Lead acetate Test: Extracts were treated with a few drops of lead acetate solution. Formation of a yellow colour precipitate indicates the presence of flavonoids.
- 3. Shinoda Test: To the alcoholic solution of extracts, a few fragments of magnesium ribbon and Conc. HCl was added. Appearance of magenta colour after few minutes indicates presence of flavonoids. Alcoholic solution of extracts, a pinch of zinc dust and conc. HCl was added. Appearance of magenta colour after few minutes indicates presence of flavonoids.

### F. Detection of alkaloids

Approximately 50 mg of extract was dissolved in 5 ml of distilled water. Further 2M hydrochloric acid was added until an acid reaction occurred and filtered. The filtrate was tested for the presence of alkaloids as detailed below. Extracts were dissolved individually in dilute hydrochloric acid and filtered. The filtrates were used to test for the presence of alkaloids.

Mayer's Test: Filtrates were treated with mayer's reagent (Potassium Mercuric iodide).
 Formation of a yellow, cream precipitate indicates the presence of alkaloids.

- 2. Wagner's Test: Filtrates were treated with wagner's reagent (Iodine in potassium iodide)

  Formation of brown/reddish brown precipitate indicates the presence of alkaloids.
- 3. Dragendorff's Test: To 2 ml of the filtrate was added 1 ml of dragendorff's reagent along the side of the test tube. Formation of orange or orange reddish brown precipitate indicated the test as positive.
- 4. Hager's Test: Filtrates were treated with Hager's reagent (saturated picric acid solution). Formation of a yellow coloured precipitate indicates the presence of alkaloids.
- G. Detection of saponins
- Froth Test: Extracts were diluted with distilled water to 20ml and this was shaken in a graduated cylinder for 15 minutes. Formation of 1 cm layer of foam indicates the presence of saponins.
- 2. Foam test: Small amount of extract was shaken with little quantity of water. If foam produced persists for ten minutes it indicates the presence of saponins.
- 3. Olive oil test: Added a few drops of olive oil to 2ml of the test solution and shaken well.

  The formation of a soluble emulsion confirmed the test.
  - H. Detection of resins
- 1. Acetone-water Test: Extracts were treated with acetone. Small amount of water was added and shaken. Appearance of turbidity indicates the presence of resins.
  - I. Detection of phenols
- Ferric Chloride Test: Extracts were treated with few drops of ferric chloride solution.
   Formation of bluish black colour indicates the presence of phenols.
  - J. Detection of tannins
- 1. Ferric chloride Test: Added a few drops of 5% ferric chloride solution to 2 ml of the test solution. Formation of blue colour indicated the presence of hydrolysable tannins.

2. Gelatin Test: Added five drops of 1% gelatin containing 10% sodium chloride to 1 ml of the test solution. Formation of white precipitates confirmed the test.

### **STUDY DESIGN**

**Experimental protocol:** All the rats were divided into following five groups with 6 rats in each group. Group-I, fed Iso-caloric diet and serve as a control, the Group II Fed with high fat diet, Group-III fed with high fat diet with ethanolic extract of *Terminalia Arjuna (Arjuna)*, Group IV fed with high fat diet with ethanolic extract of *Emblica Officinalis (Amla)* and Group V fed with high fat diet with ethanolic extract of *Terminalia Arjuna and Emblica Officinalis (Amla)*. It was given daily *Terminalia Arjuna (Arjuna)* 500mg/kg B<sup>2</sup>. wt and *Emblica Officinalis(Amla)* 100mg/kg B.Wt, I.P. for three weeks<sup>4</sup>.

Rats Group	Normal & Food Hyperlipidemic	Dosages Terminalia Arjuna	Dosages Emblica Officinalis
		(Arjuna)	(Amla)
Group1.	a. Carbohydrate 62%.		
Normal diet	b. Protein 18%.		
	c. Fat 20%.		
	d. Salt 4%.		
	e. Multi vitamins 1%		
Group 2.	a. Carbohydrate 52%.		
Hyperlipidemic diet	b. Protein 18%.		
	c. Fat 30%.		
	d. Salt 4%.		
	e. Multi vitamins 1%		
Group 3.	a. Carbohydrate 52%.	100mg/200gm	
Hyperlipidemic diet	b. Protein 18%.	of Rats.	
Treated with Terminalia	c. Fat 30%.	For 3 weeks	
Arjuna (Arjuna)	d. Salt 4%.		
	e. Multi vitamins 1%		
Group 4.	a. Carbohydrate 52%.		100mg/Kg
Hyperlipidemic diet	b. Protein 18%.		For 3 weeks
Treated with <i>Emblica</i>	c. Fat 30%.		
Officinalis (Amla)	d. Salt 4%.		
	e. Multi vitamins 1%		
Group 5.	a. Carbohydrate 52%.	100mg/200gm	100mg/Kg
Hyperlipidemic diet	b. Protein 18%.	of Rats.	For 3 weeks
Treated with Terminalia	c. Fat 30%.	For 3 weeks	
Arjuna(Arjuna) and	d. Salt 4%.		
Emblica	e. Multi vitamins 1%		
Officinalis(Amla)			

### PREPARATION OF ISO-CALORIC AND HYPERLIPIDEMIC DIET

# **PREPARATION OF ISO-CALORIC DIET:**

Normal diet (Group 1) 1kg of Iso-caloric diet contains 620gms of carbohydrate, 180gms of protein, 200gms of fat, 2gms of Na+ and 1% of multivitamins.

In this group each rat fed with Iso-caloric diet per day on and average 50gms. We observed that all rats consumed not more than 40gms. Each rat consumed 35gms instead of 40gms, the left over 5gms of food discarded and next day fresh 40gms of food was served<sup>5</sup>.

# PREPARATION OF HYPERLIPIDEMIC DIET:

Hyperlipidemic diet (Group 2 to 5) 1kg of hyperlipidemic diet contains 520gms of carbohydrate, 180gms of protein, 300gms of fat, 2gms of Na+ and 1% of multivitamins.

In these groups, each rat fed with hyperlipidemic diet per day on and average 50gms. We observed that few of rats consumed more than 45gms of diet and a few of them consumed less than 40gms of diet<sup>6</sup>.

#### **GENERAL**

# Sample collection

Every alternate week (six rats) one group of animals was sacrificed by cervical dislocation at the end of the last dose with an overnight fast. Blood was collected in normal tubes for the separation of serum, by doing retro-orbital puncture, before sacrificing the animals

#### Cervical dislocation method

- 1. Restrain the rodent in a normal standing position on a firm, flat surface and grasp the base of the tail firmly with one hand. Performing the procedure on a surface that the animal can grip (such as the wire bar grid of the cage top) may make it easier to gain access to the base of the skull because rodents often stretch themselves forward when held by the tail.
- 2. Place a sturdy stick-type pen, a rod-shaped piece of metal, closed scissors/hemostats or the thumb and first finger of the other hand against the back of the neck at the base of the skull.
- 3. To produce the dislocation, quickly push forward and down with the hand or object restraining the head while pulling backward with the hand holding the tail base.
- 4. The effectiveness of dislocation can be verified by feeling for a separation of cervical tissues. When the spinal cord is severed, a 2-4 mm space will be palpable between the occipital condyles and the first cervical vertebra. Occasionally, however, the dislocation occurs between thoracic vertebrae.
- 5. Check closely to confirm respiratory arrest, and when possible verify, by palpation, that there is no heart beat<sup>7</sup>.

#### HAEMATOLOGY

After the experimental period blood was collected from the rats by retro orbital venous puncture and blood was collected in heparinized tubes and non heparinized tubes.

Haematological parameters were evaluated by XS-1000i closed tube sampling sysmax automated analyzer (Calibrated by Sysmex division of MYCO Instrumentation Ltd).

Measurement principle:

RBC/PLT- sheath flow direct current on XE and XT series. WBC-semicoductor laser flow cytometry, HGB-clorometric method (SLS).

Testing parameters CBC and S-Part differential 21 parameters like Hb% RBC WBC Platelet PCV & MCHC were analyzed<sup>8</sup>.

### LIPID PROFILE

Serum triglycerides (TG), Serum total cholesterol (TC), High-density lipoprotein (HDL), Low-density lipoprotein (LDL) and Very Low-density lipoprotein (VLDL) were analysed.

# i) Total cholesterol

**Principle:** Enzymatic determination of total cholesterol was performed according to the following equation

# **Cholesterol reagent**

Pipes buffer, pH 6.7- 50 mmol/l

Phenol- 24 mmol/l

Sodium cholate- 0.5 mmol/l

4- aminoantipyrene- 0.5 mmol/l

Cholesterol esterase > 180U/l

Cholesterol oxidase > 200U/l

Peroxidase > 1000U/l

Cholesterol standard solution 200 mg/dl

The reagent is stable for 18 months when stored at 2-8 $^{\circ}$  C. Animal serum was used as the sample. 10  $\mu$ l of serum was mixed with 1000  $\mu$ l of reagent, incubated for 5 min at 37  $^{\circ}$ C and estimated at 630 nm using a Biochemical Analyzer.

#### Calculation

# ii) Triglycerides

**Principle:** Enzymatic determination of triglycerides was performed according to the following equation<sup>9</sup>.

Triglyceride + H2O Glycerol + Fatty acids

Glycerol + ATP glycerol-3- phosphate + ADP

Glycerol-3-PO4 + O2 \_\_\_\_\_ dihydroxy acetone phosphate+ H2O2

H2O2 + 4- aminoantipyrine + p- chlorophenol Red quinoneimine

# **Reagent Composition**

Pipes buffer, pH 7.0- 50 mmol/l

p-chlorophenol- 5.3 mmol/l

Potassium ferrocyanate- 10 mmol/l

Magnesium salt- 17 mmol/l

4- aminoantipyrine- 0.9 mmol/l

ATP- 3.15 mmol/l

Lipoprotein lipase > 1800 U/l

Glycerol kinase > 450 U/l

Glycerol-3- phosphate oxidase > 3500 U/l

Peroxidase > 450 U/l

Triglyceride standard solution- 200 mg/dl

The reagent was stable for 18 months when stored at 2-8° C. Animal serum was used as the sample. 10  $\mu$ l of serum was mixed with 1000  $\mu$ l of reagent, incubated for 5 min at 37 ° C and estimated at 630 nm using a biochemical analyzer.

### **Calculation:**

Triglyceride (mg/dl) = 
$$\frac{\text{Absorbance of sample} \quad \text{x 200}}{\text{Absorbance of standard}}$$

### iii) HDL cholesterol

**Principle:** The chylomicrons, VLDL and LDL of serum were precipitated by phosphotungstic acid and magnesium ions. After centrifugation, HDL in the supernatant solution was measured by enzymatic method<sup>10</sup>.

### **HDL** cholesterol reagent

Phosphotungstate- 14 mmol/l

Magnesium chloride- 1 mmol/l

### **Preservative**

HDL cholesterol standard- 50 mg/dl.

Animal serum was used as the sample. 300 µl of serum was mixed with 300µl of HDL reagent, allowed to stand for 10 min at room temperature, mixed again and centrifuged for 10 min at 4000 rpm. After centrifugation the clear supernatant was separated from the precipitate within 1hr and HDL was determined using cholesterol reagent. 50 µl of supernatant was mixed with 1000 µl of cholesterol reagent, incubated for 5 min at 37 ° C and estimated at 630nm using a biochemical analyzer.

#### **Calculation**

N= Standard concentration (50 mg/dl)

### iv) Estimation of LDL

Formula: LDL = 
$$TC/1.19 + TG/1.9 - HDL/1.1 - 38 \text{ (mg/dl)}^{11}$$
.

# v) Estimation of VLDL

#### **Formula**

$$VLDL = \frac{triglycerides}{5} (mg/dl)^{11}.$$

### 1. LIVER FUNCTION TEST:

#### 1 Assessment of liver function test

Serum was separated by centrifuging blood at 2500 rpm for 10 minutes and the levels of SGOT, SGPT, bilirubin, ALP, albumin, A/G ratio and total protein were analyzed by using a commercially available enzymatic kit (AGAPPE, India) and an autoanalyser (Chemistry Analyser (CA 2005), B4B Diagnostic Division, China).

### i) Estimation of Serum Glutamate Pyruvate Transaminases (SGPT/ ALT)

Principle: Alanine aminotransferase catalyses the transfer of amino group from alanine to 2-oxoglutarate, resulting in the formation of pyruvate and glutamate. The catalytic concentration is determined from the rate of decrease of NADH, measured at 340nm, by means of lactate dehydrogenase coupled reaction<sup>12</sup>.

The enzymatic reaction employed in the assay of SGPT is as follows.

L- Alanine + 2-oxoglutarate 
$$ALT$$
 Pyruvate + L- Glutamate Pyruvate + NADH+ H<sup>+</sup>  $LDH$  D- Lactate + NAD<sup>+</sup>

**Reagent Preparation: Reagent A:** Tris 150 mmol/l, L- Alanine 750 mmol/l, lactate dehydrogenase >1350U/l, pH 7.3. **Reagent B:** NADH 1.3 mmol/l, 2-oxoglutarate 75 mmol/l, sodium hydroxide 148 mmol/l, sodium azide 9.5 g/l. Auxillary Reagent **Reagent C:** 

Pyridoxal phosphate 10 mmol/l. Working Reagent: Reagent A (4 parts) is mixed with 1 part of Reagent B. The combined reagent was stable for 2 months at 2-8° C. The mixed reagent was stored in a dark place and protected from light. Working Reagent with Pyridoxal phosphate: 10ml of working reagent was mixed with 0.1 ml of reagent C. The solution was stable for 6 days at 2-8° C.

**Procedure:** Animal serum was used as the sample. 50 µl of serum was mixed with 1000 µl of mixed reagent and estimated in kinetic mode using a Biochemical Analyzer.

#### **Calculations**

SGPT/ ALT concentration (U/I) =  $\frac{\text{delta A/min x Vt x } 10^6}{\text{E x L x Vs}}$ Molar absorbance (E) of NADH at 340 nm is 6300

L - Light path 1cm

Vt - Total reaction volume is 1.05 at 37° C

Vs - Sample volume is 0.05 at 37° C

### ii) Estimation of Serum Glutamate Oxaloacetate Transaminases (SGOT/AST)

**Principle**: Aspartate aminotransferase catalyzes the transfer of the amino group from aspartate to 2-oxoglutarate, forming oxaloacetate and glutamate. The catalytic concentration is determined from the rate of decrease of NADH, measured at 340nm, by means of malate dehydrogenase (MDH) coupled reaction<sup>12</sup>.

The enzymatic reaction employed in the assay of SGOT is as follows.

2-oxoglutarate Glutamate + Oxaloacetate

Oxaloacetate + NADH+ H+ D-Malate + NAD+

**Reagent Preparation:** Reagent A: Tris 121 mmol/l, L- aspartate 362 mmol/l, malate dehydrogenase >460 U/l, lactate dehydrogenase > 660 U/l, sodium hydroxide 255 mmol/l, pH 7.8. Reagent B: NADH 1.3 mmol/l, 2-oxoglutarate 75 mmol/l, sodium hydroxide 148 mmol/l, sodium azide 9.5 g/l.

Auxillary reagent – Reagent C: Pyridoxal phosphate 10 mmol/l.

Working reagent: **Reagent A** (4 parts) is mixed with 1 part of **Reagent B**. The combined reagent is stable for 2 months at 2-8° C. The mixed reagent was stored protected from light. Working reagent with pyridoxal phosphate: 10ml of working reagent was mixed with 0.1 ml of **Reagent C**. Stable for 6 days at 2-8° C. Animal serum was used as the sample.

**Procedure:** 50 μl of serum was mixed with 1000 μl of mixed reagent and estimated in kinetic mode using a biochemical analyzer.

### **Calculations:**

SGOT/ AST concentration (U/l) = 
$$\frac{\text{delta A/min x Vt x } 10^6}{\text{E x L x Vs}}$$

Molar absorbance (E) of NADH at 340nm is 6300

L - Light path 1cm

Vt - Total reaction volume is 1.05 at 37° C

Vs - Sample volume is 0.05 at 37° C

### iii) Estimation of Alkaline Phosphatase

**Principle:** Alkaline Phosphatase catalyses in alkaline medium the transfer of phosphate group from 4-nitrophenyl phosphate to 2-amino-2-methyl-1-propanol, liberating 4-nitrophenol. The catalytic concentration is determined from the rate of 4-nitrophenol formation, measured at 405nm<sup>13</sup>.

The enzymatic reaction employed in the assay of alkaline phosphatase is as follows.

4- Nitrophenyl phosphate +  $H_2O$  ALP Phosphate + 4- Nitrophenol

Reagents: Reagent A: 2- Amino-2- methyl- 1- propanol 0.4 mol/l

Zinc sulphate 1.2 mmol/l

N hydroxy ethylene diamine tri aceticacid 2.5 mmol/l

Magnesium acetate 2.5 mmol/l, pH 10.4.

**Reagent B:** 4- Nitrophenyl phosphate 60 mmol/l.

Working reagent: 4 parts of reagent A is mixed with 1 part of reagent B. The combined reagent is stable for 2 months at 2-8° C. Animal serum was used as the sample 20 µl of serum was mixed with 1000 µl of mixed reagent and estimated in kinetic mode using a biochemical analyzer.

Calculations

ALP concentration (U/l) = 
$$\frac{\text{delta A/min x Vt X } 10^6}{\text{E X L X Vs}}$$

Molar absorbance (E) of NADH at 405nm is 18450

L- Light path 1cm

Vt - Total reaction volume is 1.02 at 37° C

Vs - Sample volume is 0.02 at 37° C iv)

### iv. Total bilirubin

**Principle:** Direct bilirubin in the sample reacts with diazotised sulfanilic acid forming a coloured complex that can be measured by spectrophotometry. Both direct and indirect bilirubin couple diazo in the presence of cetrimide<sup>14</sup>.

The terms direct and total refer to the reaction characteristics of serum bilirubin in the absence or presence of solubilizing reagents. The direct and indirect bilirubin is approximately equivalent to the conjugated and unconjugated fractions.

Composition (Bilirubin)

Reagent A: Sulfanilic acid 29 mmol/l

Hydrochloric acid 0.2 mol/l

Cetrimide 50 mmol/l

**Reagent B:** Sodium nitrite- 11.6 mmol/l. Stored at 15-30° C. Reagents were stable until the expiry date shown on the label when stored tightly closed and if contaminations was avoided during use. Presence of particulate matter, turbidity, absorbance over 0.05 at 540nm, indicate deterioration.

Working Reagent preparation: Mixture of 1 ml of Reagent B and 4 ml of Reagent A. This was Stable for 20 days at 2-8° C.

Particulars		Reagent Blank	Sample Blank	Sample	Standard
Distilled	water	100 μ1			
Sample			100 μ1	100 µl	
Standard					100 μl
Reagent	Α		1000 μ1		
Working		1000 μ1		1000 μ1	1000 μl
Reagent				-	-

Mixed thoroughly and was allowed to stand for 2 min at room temperature. Absorbance of Sample Blank was read at 540nm against distilled water and absorbance of Sample was read at 540nm against reagent blank.

### Calculations

$$Bilirubin content in the sample = \frac{A \ (sample) - A \ (sample \ blank)}{A \ (standard)} \ X \ C \ (standard)$$
 Mass concentration (mg/dl) x 17.1 = Substance concentration in  $\mu$ mol/l.

# v) Total protein estimation

**Principle:** The enzymatic reaction sequence employed in the assay of total protein was as follows:

Protein + Cu2+ Cu - Protein complex

Total proteins were estimated using Total protein reagent from AGAPPE Diagnostics, Kerala, India<sup>15</sup>.

# **Composition of Total protein reagent**

Potassium iodide- 6 mmol/l. Potassium sodium tartrate- 21 mmol/l. Copper sulphate- 6 mmol/l. Sodium hydroxide- 58 mmol/l. Total Protein Standard- 6 g/dl.

The reagent was stable for 18 months when stored at 2-8° C. To 20 µl of serum, 1ml of total protein reagent was added and mixed. The mixture was incubated at 37oC for 15 minutes and the absorbance was measured at 546 nm using a biochemical analyzer.

The protein content was calculated by using the following formula and expressed as total protein in g/dl.

Total protein in 
$$g/dl = \frac{Absorbance \text{ of sample x C}}{Absorbance \text{ of standard}}$$

Where C refers to the protein concentration in standard protein solution in g/dl.

# vi) Albumin estimation

**Principle:** The reaction between albumin in serum or plasma and the dye bromocresol green produces a change in colour, which is proportional to albumin concentration<sup>16</sup>.

### **Reagent Composition**

**Albumin reagent:** Succinate buffer (pH- 4.2) 75 mmol/l. Bromocresol green 0.14 g/l.

Albumin Standard: Albumin Standard concentration 3 g/dl. The reagent is stable for 18 months when stored at 2-80 C. Animal serum was used as sample. 10  $\mu$ L of serum was mixed with 1000  $\mu$ L of reagent, mixed and incubated for 1 minute. The absorbance was measured against blank at 630 nm.

### **Calculation**

Albumin (g/dl) = 
$$\frac{\text{Absorbance of sample x C}}{\text{Absorbance of standard}}$$

Where C refers to the albumin concentration in standard albumin solution in g/dl

#### 2. SERUM ELECTROLYTE

Serum Na<sup>+</sup> (Sodium), K<sup>+</sup> (Potassium) and Ca<sup>++</sup> (Calcium) were analysed by Meril Diagnostic Kit Method: Merilyzer Cliniquant easylyte analyzer

# 3. **GLUCOSE ESTIMATION:** Random blood sugar glucose oxidase method

**Principle:** The substrate  $\beta$ -D-glucose is oxidized by glucose oxidase to from gluconic acid and hydrogen peroxide. The hydrogen peroxide so generated oxidizes the chromogen system consisting of 4-aminoantipyrine and phenolic compound to a red quinoeimine dye. The intensity of the colour produced is proportional to the glucose concentration and is measured at 505 nm (490-530 nm) or with green filter<sup>17</sup>.

Glucose

**Kit contents** Reagent1: Glucose reagent. Reagent 2: Glucose standard (For calibration)

Procedure for estimation of glucose

Pipetted into	Blank (µl)	Standard (µl)	Test (µl)
microcentrifuge			
tubes			
Glucose Reagent	500	500	500
Calibrator (Standard)		5	
Sample (Serum)			5
Distilled water	5		

Mixed and incubated at 37oC for 10 minutes. Absorbance of the Test (AT), Standard (AS) and Reagent Blank (AB) at 505 nm was read against distilled water using biochemical analyzer.

**Calculations:** Glucose  $(mg/dl) = (AT-AB/AS-AB) \times 100$ 

Where  $100 = \text{Standard concentration of Glucose } (\text{mg/dl})^{18}$ .

4. **ESTIMATION OF NITRIC OXIDE:** Method: Griess method (Kinetic cadmium reduction)

Nitric oxide was determined as nitrite in serum by a kinetic cadmium reduction method by

Najwa cortas and Nabil wakid<sup>19</sup>.

**Principle:** Nitrate the stable product of nitric oxide is reduced to nitrite by cadmium reduction method after deproteinization of sample by somogyi reagent. The nitrite produced is determined by diazotization with sulphanilamide and coupling to Nnaphthylethylenediamine. The intensity of coloured complex is measured at 540 nm.

### **Reagents:**

- 1. Cadmium granules (2.5 3 gram granules in assay, stored in 0.1M/L H2SO4)
- 2. Glycine–NaOH buffer (pH 9.7): 7.5 gm of glycine was dissolved in 200ml deionised water, then the pH was adjusted to 9.7 by 2M NaOH and was diluted to 500 ml by deionised water.

- 3. Sulfanilamide: 2.5 gm of sulfanilamide was dissolved in 250 ml of warm 3M/L HCl and allowed to cool.
- 4. N-naphthylethylenediamine: 50 mg of N-naphthylethylenediamine was dissolved in deionised water and the volume was adjusted to 250 ml.
- 5. Stock standard sodium nitrite solution (0.1 mol/L): 690 mg sodium nitrite was dissolved in 100 ml of 10 mmol/L of sodium borate solution.
- 6. Working standard solution (10 μmol/L): 10μl of stock was diluted to 100 ml with 10mmol/L solution of sodium borate.
- 7. ZnSO4 solution (75 mmol/L)
- 8. NaOH solution (55 mmol/L)
- 9. H2SO4 solution (0.1 mol/L)
- 10. CuSO4 solution (5 mmol/L): 125 mg of CuSO4 was dissolved in 100 ml of glycine NaOH buffer.

**Procedure: Part I:** - Deproteinization: A centrifuge tube was taken and additions were made as follows:

Serum.	0.5 ml
75 mM ZnSO4	2.0 ml
55 mM NaOH	2.5 ml

Tube was centrifuged at the speed of 1500 rpm for 10 min. and supernatant was collected.

## **Part II:** Activation of Cadmium granules

- 1. Cadmium granules were stored in 0.1 mol/L H2SO4 solution.
- 2. At the time of assay the acid from granules was rinsed three times with deionized water.
- 3. Then the granules were swirled in 5 mmol/L CuSO4 solution for 1-2 minutes.
- 4. These copper coated granules were drained and washed by glycine NaOH buffer.
- 5. These activated granules were used within 10 minutes after activation.

6. The granules after use were washed by deionized water and stored in 0.1 mol/L H2SO4 solution. Same procedure for activation was followed each time.

**Part III**: Nitrite assay a set of three test tubes was arranged as follows and respective additions were made as follows.

Reagent	Test	standerd	Blank
Glycine-NaOH Buffer	500 μl.	500 μl.	500 μl.
Supernatant	500 μl.		
Standard 10 µmol/L		500 μl.	
D/W			500 μl.
Cadmium granules	2	2	2
Cadmium granules were swirled	and tubes were k	ept at RT for 90	min.
D/W	1.0 ml.	1.0 ml.	1.0 ml.
Content from all this tube was	s mixed well a	nd diluted solut	tions were taken in
following tubes			
Above diluted solutions	1.0 ml.	1.0 ml.	1.0 ml.
Sulfanilamide	0.5 ml.	0.5 ml.	0.5 ml.
N-napthylethylendiamine	0.5 ml.	0.5 ml.	0.5 ml.
After 20 minutes waiting all tube	s were read at 54	0 nm.	

**Calculation:** Serum Nitrite ( $\mu$ m/L) = (T-B)  $\div$  (S-B) X 100

#### **SPECIAL**

#### HISTOLOGY

## **Fixation of tissues:**

The fixation of tissues in 10% of formalin

## **Dissection and Fixation of Tissues:**

Rats were carefully dissected. Taking midline incision opened the anterior of the chest wall and neck. The thoracic cage opened and muscles were separated and the collected the blood directly from the heart and heart was removed. Then it was weighed immediately and fixed in 10% formalin. The heart was cut into pieces and fixed in bouins medium for 24 hrs. After fixation, it was placed in 70% alcohol for 6-8 hours during the day, then in 90% alcohol for overnight. Next day three changes of absolute alcohol were given for one hour each <sup>19</sup>.


The tissue was blotted with blotting paper and placed in xylene for about 30 min for clearing. Then tissue was subjected to 3 changes of paraffin wax at 56° c temp 60° C for one hour each. Then tissue was embedded. 'L' shaped moulds were smeared with glycerine and fresh filtered wax poured into it to fill it almost. Any air bubbles formed were removed by hot spatula. Then the tissue was fixed on one side of the mould and label was placed on the opposite side of the mould. After a skin of wax has formed completely over the surface of the block, its solidification was hastened by careful immersion in cold water, for 15 min. Then the block was removed from the mould<sup>19</sup>.

The blocks were prepared for cutting. Finally tissue was cut in the sizes of 5 to 7  $\mu$  in the form of a ribbon.

The individual sections were gently lowered onto the surface of water at  $5^{0}$  C to  $10^{0}$  C to remove the folds. The sections were taken on egg albumin coated slides. Slides were kept for drying on a hot plate at  $45^{0}$  c -  $50^{0}$  C for 2 hours or more as per requirement<sup>19</sup>.



Microtome



Water bath



**Hot Plate** 



**Automatic tissue processing** 

## **Tissue collection:**

Tissue collection for histopathology: after proper dissection of the animal heart (Atrium & Ventricle), aorta and muscular artery was isolated immediately and fixed in 10% neutral buffered formalin solution for 24 hours. <sup>22</sup> The fixed tissues were processed routinely and then embedded in paraffin, sectioned to 3–5 μm thickness, de-paraffinized, and rehydrated using standard techniques. The extent of hyperlipidemic (high fat diet) induced variations was evaluated by assessing morphological changes in the heart (Atrium & Ventricle), aorta and muscular artery sections stained with hematoxylin and eosin (H and E), using standard techniques<sup>21</sup>.



## **Staining preparation:**

- 1. Removal of paraffin wax was done by dipping into xylene one or two min in each of two changes of xylene.
- 2. Removal of xylene was done by dipping into two changes of absolute alcohol for one half to one min. each.
- 3. Then it was followed by treatment for a minute or two with 90% alcohol and then 70% alcohol.
- 4. After this, slides were kept under running tap water for about 5 minutes.
- 5. Then stained in haematoxylin for about 10-15 min and again kept under tap water for 5 min.
- 6. Excess stain was removed by dipping into acid alcohol for a few seconds. Here the blue colour was changed to red because of acid.
- 7. The blue colour (bluing) was regained by washing in alkaline, running tap water for 5-10 min. The stain was checked.
- 8. The slides were stained by eosin for 3-5min, surplus stain was washed off in water.
- 9. Dipping into ascending grades of alcohol did the dehydration of slides and clearing was done by two changes of xylene for about 1 min each.
- 10. The slides were mounted with DPX and cover slips were applied. The slides were kept at room temperature for some hours to allow, firm adhesion of the cover slip to the section.
- 11. The slides were observed under light microscope for microscopic differentiation and the photographs were taken
- 12. Few slides, were stained by verhoeffs stain technique.

### **VERHOEFF'S SPECIAL STAIN**

This stain is useful in demonstrating atrophy of elastic tissue in cases of emphysema, and the thinning and loss of elastic fibres in arteriosclerosis, and other vascular diseases.

**PRINCIPLE:** The tissue is stained with a regressive hematoxylin, consisting of ferric chloride and iodine. The differentiating is accomplished by using excess mordant (ferric chloride) to break the tissue-mordant dye complex. The dye will be attracted to the larger amount of mordant in the differentiating solution and will be removed from the tissue. The

elastic tissue has the strongest affinity of the ironhematoxylin complex and will retain the dye longer than the other tissue elements.

**CONTROL:** skin.

FIXATIVE: Any well fixed tissue.

**TECHNIQUE:** Cut paraffin sections 4μ or 5μ.

**EQUIPMENT:** Rinse glassware in DI water: coplin jars, graduated cylinders

## **REAGENTS:** Alcoholic Hematoxylin:

Hematoxylin 5.0 gm

Absolute alcohol 100.0 ml

Dissolve hematoxylin into alcohol with the aid of gentle heat, do not boil. Label with date and initials, solution are stable for 1 year.

**CAUTION:** Flammable, avoid contact and inhalation.

## 10% Ferric Chloride:

Ferric chloride 10.0 gm

Distilled water 100.0 ml mix well. Label with date and initials, solution are stable for 1 year.

**CAUTION**: Avoid contact and inhalation

Verhoeff's Hematoxylin:

Alcoholic hematoxylin 20.0 ml

10% ferric chloride 8.0 ml

Lugol's iodine 8.0 ml

Add in the order given, mixing between additions. Make fresh, discard.

Caution: Avoid contact and inhalation.

Differentiating Solution:

(2% Ferric Chloride) 10% ferric chloride 10.0 ml

Distilled water 40.0 ml make fresh, discard.

CAUTION: Avoid contact and inhalation 5% Hypo: See stock solutions

## **PROCEDURE:**

- 1. Deparaffinize and hydrate to distilled water.
- 2. Verhoeff's hematoxylin for 30 minutes (save solution until stain is completed)
- 3. Wash in tap water.
- 4. Differentiate in 2% ferric chloride solution, check microscopically for black fibers on a gray background.
- 5. Rinse in water.
- 6. Hypo for 1 minute to remove iodine.
- 7. Wash in water.
- 8. Counterstain in van gieson's for 5 minutes.
- 9. Dehydrate, clear in xylene, and coverslip.

**RESULTS**: Elastic fibers and nuclei black collagen red other tissue elements yellow<sup>22,23&24</sup>.







#### VASCULAR INTEGRITY PARAMETERS

Morphometric study

Elastic arterial wall thickness

> Tunica intima and media

Muscular arterial wall thickness

> Tunica intima and media

Coronary arterial wall thickness

Lumen diameter

- > Anteroposterior
- > Transverse
- > Arterial lumen

Normalized wall index

## Morphometry of Arterial Wall Thickness, Lumen Diameter and Calibration:

## Procedure of Arterial Wall Thickness measurement in Histological:

Morphometry of arterial wall thickness & lumen diameter

- Arterial wall Thickness and its lumen diameter was measured by using Digimizer image analyzer version 4.3.0 copyright 2005-2014 Medclac software
- ➤ 8 megapixel Picture in 10X and 40X of microscopic (MIPS)and calibrated with Digimizer image and measured the thickness of arterial wall
- ➤ Whereas arterial lumen diameter was measured in 4X

Digimizer version 4.3.0 copyright C 2005-2014 Medclac softwere and following things were used

- 1. Strengthen the image.
- 2. Calibrate measurement
- 3. Performed the measured manually like: Length, Area, Centre, Unit, Area etc

## 4. Analyse the object

Average Intensity defined using the circle tool, area tool, rectangle tool digimizer can calculate the average intensity

Normalized wall index of coronary artery

#### > Normalized Wall Index

- ➤ The outer and inner vessel wall counters were manually traced for the coronary artery using the digimizer image analyzer software.
- ➤ Wall area, lumen area, and total vessel area were automatically calculated based on the counters drown by the software program.
- The normalized wall index was calculated by dividing the wall area by the total vessel area.
- $\Rightarrow \frac{\text{Wall area}}{\text{Total Vessel Area}} = \text{Normalized wall Index}^{25}.$

Before manual tracing the counter on arterial wall the 40X of microscopic image of the artery was calibarated with digimizer image analyzer.

**DESCRIPTION OF CAMERA:** ZEN 2 core package hardware license key with Axiocam 105 color (D) consisting of the camera Axiocam 105 color and the ZEN 2 core basic software plus the ZEN module image analysis camera specification: microscopy camera with driver software 64bit, USB 3.0 PCIe x1 interface, USB 3.0 connection cable 3.0 m, SATA power cable and molex power cable Sensor: Aptina CMOS color sensor basic resolution: 2560 (H) x 1920 (V) = 5.0 mega pixels color pixel size: 2.2 μm x 2.2 μm chip size: 5.70 mm x 4.28 mm, equivalent to 1/2.5" (diagonal 7.1 mm) Live frame rates (depending on hardware and software configuration): H x V binning factor frame rate@1ms 2560 x 1920 1 15 1280 x 960 2 37 640 x 480 4 47 frame rates for time series recording (depending on hardware and software configuration): H x V binning factor frame rate@1ms 2560 x 1920 1 8 1280 x 960 2 16 640 x 480 4 19 readout of sensor sub- regions ("ROI"):

Adjustable digitization: 3 x 8 Bit / Pixel integration Time: 100 μs up to 2 s interface (camera): USB 3.0 Micro-B Interface (PC / board): USB 3.0 standard a spectral range: Approx. 400 nm - 650 nm, IR filter read-out mode: Progressive optical interface: C-Mount (adapter 0.5x recommended) Size / Weight: approx. 2.9 cm x 2.9 cm x 4.76 cm / 50 g Housing: Aluminum, magnesium, stainless steel registration: CE, FCC class B, RoHS power supply: via USB 3.0 interface, max. 1.7 W (5 V, 0.34 A)<sup>26</sup>.



MIPS (Magnified Image Processing System)

Environmental conditions:  $0^{\circ}$  ...  $+50^{\circ}$  celsius, max. 80% relative air humidity, no condensation, free air circulation required Supported operating systems: Windows 7 x64 Prof./Ultimate SP1

## **REFERENCE:**

- 1. www.http://icmr.nic.in/bioethics/final\_cpcsea.pdf (accessed on 24.7.2014)
- 2. Patil U.H., Gaikwad D.K., 2010. Phytochemical evaluation and bactericidal potential of *Terminalia arjuna* stem bark. International Journal of Pharmaceutical Sciences and Research.2 (3): 614-619.
- 3. Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical screening and Extraction: A Review. International Pharmaceutica Sciencia 2011; 1: 103-104.
- 4. Pingali U, Fatima N, Muralidhar N. Effects of *Phyllanthus emblica* extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013; 6: 275–284.
- American Institute of Nutrition. Report of the AIN adhoc committee on standards of nutritional studies. Journal of Nutrition 1977; 107: 1340-1348.
- Mani DN, Bawankule DU, Saroj BK. Hyperlipidemic model: Studying lipid profile in small experimental animal. International Journal of Pharmacy and Pharmaceutical Sciences 2012; 4(2): 337-340)
- 7. http://www.utexas.edu/research/rsc/iacuc/forms/guideline04.pdf (accessed on 24.07.2014)
- 8. http://www.myco-instrumentation.com/?equipments=hematology-analyzer-40
- 9. Schettler, G., Nussel, E. (1975). Massnahmen Zur Prevention der Artherosklerose. Arb.Med.Soz. Med. Prav. Med, 10: 25.
- 10. Gordon,G.B., and Southren,A.L., 1977, Metabolic effects of alcohol on the endocrine system, in "Metabolic Aspects of Alcoholisum" (C.S. Lieber,ed.), PP.249-272, University park press, Baltimore.

- 11. Ahmadi, R., Khalighi, A., Kalateh, K., Amani, V. & Khavasi, H. R. (2008). Acta Cryst. E64, m1233
- 12. Gella, F.J., T. Olivella, M. Crus-pastor, J. Arenas, R. Moreno, R. Durban and J.A. Gomez, 1985. A simple procedure for routine determination of aspartate aminotransferase and alanine aminotransferase with pyridoxal phosphate. Clin. Chem. Acta., 153: 241-24
- 13. Rosalki SB, Foo AY. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin Chem 1984; 30: 1182-6.
- 14. Pearlman, P.C. and Lee, R.T. Detection and measurement of total bilirubin in serum, with use of surfactants as solubilizing agents. Clinical Chemistry. (1974), 20: 447-53.
- 15. Gomall AG, Bardawill CJ, David MM, (1949). Determination of serum proteins by means of biuret reaction. Journal of Biological Chemistry. 177(2):751-766.
- 16. Doumasa BT, Watson WA, Biggs HG 1971. Albumin standards and measurement of serum albumin with bromocresol green. Clin Chim Acta 31: 87-96.
- 17. Trinder, P. (1969) Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor, Ann. Clin. Biochem. 6, 24-27
- 18. Bailey CJ, Day C.Traditional plant medicines as treatment for diabetes. Diabetes care 1989; 12(8).
- 19. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by kinetic cadmium reduction method. Clinical chemistry 1990; 36 (8): 1440-1443.
- 20. Sheehan D, Hrapchak B, Theory and practice of Histotechnology, 2nd Ed, 1980, pp 194, Battelle Press, Ohio
- 21. Bancroft J, Stevens A, Theory and Practice of Histological Techniques, 2nd Ed, 1982,pp 125, 139, Churchill Livingstone, NY

- 22. Luna L, Manual of Histologic Staining Methods of the AFIP, 3rd Ed, 1968, pp 76, McGraw Hill, NY
- 23. Carson F, Histotechnology: A Self-Instructional Text, 1990, pp 147-149, ASCP, ILL
- 24. Crookham, J, Dapson, R, Hazardous Chemicals in the Histopathlogy Laboratory, 2nd ED, 1991, Anatech)
- 25. Katsumi Hayashi, Venkatesh Mani, Ajay Nemade, Silvia Aguiar, John E Postley, Valentin Fuster et al. "Variations in atherosclerosis and remodeling patterns in aorta and Carotids" Journal of Cardiovascular Magnetic Resonance 2010, 12:10
- 26. <a href="https://www.microshop.zeiss.com/?l=en&p=hr&f=e&i=10290&o=&h=25&n=0&sd=410135-1019-200">https://www.microshop.zeiss.com/?l=en&p=hr&f=e&i=10290&o=&h=25&n=0&sd=410135-1019-200</a> Accessed on 26.02.2015.

STATISTICAL ANALYSIS

## STATISTICAL ANALYSIS:

- $\triangleright$  Values are expressed as Mean  $\pm$  SD.
- > To determine the significance between 5 groups, One Way ANOVA was applied.
- ➤ If one way ANOVA shows significant difference, then Post Hoc test was used to find the difference between two groups..
- ➤ Statistical significance was established at P≤0.05.
- > Data were analysed by using SPSS software version 16.

Statastical Analysis Page 67

## **CHAPTER 5**

**RESULTS** 

## **RESULTS:**

Table 1. Photochemistry of *Terminalia Arjuna (Arjuna) & Emblica Officinalis (Amla)*<u>PHOTOCHEMICAL SCREENING OF ETHANOLIC EXTRACT OF *TERMINALIA ARJUNA (ARJUNA)* AND *EMBLICAL OFFICINLAIS(AMLA)*</u>

ARJUNA (ARJUNA) AND EMBLICAL OFFICINLAIS(AMLA)
CHEMICAL CONSTITUENTS PRESENT IN 99% ETHANOLIC EXTRACT OF TERMINALIA ARJUNA AND EMBLICAL
OFFICINLAIS

<b>a</b>	CTTT TT CL T	OFFICINLAIS	000/ 5007 13/07 70
S.	CHEMICAL	99% ETHANOLIC	99% ETHANOLIC
NO	CONSTITUENTS	EXTRACT	EXTRACT EMBLICAL
<u> </u>	Comb abundantes Test	TERMINALIA ARJUNA	OFFICINLAIS
A	Carbohydrates Test		
1	Molisch's Test	Negative (-ve)	Negative (-ve)
2	Benedict Test	Negative (-ve)	Negative (-ve)
3	Fehling's Test	Negative (-ve)	Negative (-ve)
В	Protein and Amino Acid Test		
1	Xynthoproteic Test	Negative (-ve)	Negative (-ve)
2	Ninhydrin Test	Negative (-ve)	Negative (-ve)
3	Biuret Test	Negative (-ve)	Negative (-ve)
C	Fixed Oil And Fats Test		
1	Stain Test	Negative (-ve)	Negative (-ve)
2	Solubility Test	Negative (-ve)	Negative (-ve)
D	Phytosterols Test		
1	Solkowski's test	Positive(+ve)	Positive(+ve)
2	Libremenn Burchard's	Positive(+ve)	Positive(+ve)
	Test		
$\mathbf{E}$	Glycosides Test		
1	Modfied Borntrager's Test	Positive(+ve)	Positive(+ve)
2	Legal Test	Positive(+ve)	Positive(+ve)
F	Flavonoids Test		
1	Alkaline Reagent Test	Positive(+ve)	Positive(+ve)
2	Lead Acetate Test	Positive(+ve)	Positive(+ve)
3	Shinoda Test	Positive(+ve)	Positive(+ve)
4	Zinc Hydrochloric acid	Positive(+ve)	Positive(+ve)
	reduction test		
G	Alkaloids Test		
1	Mayers Test	Positive(+ve)	Positive(+ve)
2	Wagner's Test	Positive(+ve)	Positive(+ve)
3	Dregandroff's Test	Positive(+ve)	Positive(+ve)
4	Hager's Test	Positive(+ve)	Positive(+ve)
H	Tannins And Phenolic		
1	Compounds Test Test With Dil. HNO3	Positive(Lye)	Positive ( Lyra)
2	Test With 5% of FeCl3	Positive(+ve) Positive(+ve)	Positive(+ve) Positive(+ve)
3	Lead Acetate Teast	Positive(+ve)  Positive(+ve)	` /
3	Leau Acetate Teast	Positive(+ve)	Positive(+ve)

# Table 1. Phytochemical Analysis of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)*:

After extractions the extracts were subjected to a vacuum rotary evaporator and concentrated extracts were obtained along with solvent recovery. (Positive) + = indicates present and (Negative) - = indicates absent

Different compounds of the *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* its phytochemical constituents are carbohydrates, tannins, phynoils, alkaloids, and saponins are identified.

### **GRAVIMETRY OF RATS**

Table 2. Effect of Ethanolic Extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Gravimetry

% of Body Weight gain	Group1	Group 2	Group 3	Group 4	Group5	ANOVA f. Value	p. Value
1 <sup>st</sup> day	14.2±4.7	18.5±4.1	21±1.0°	15±3.8 <sup>a,c</sup>	19.8±1.7 <sup>a</sup>	5.2	0.003
21 <sup>st</sup> day	14.5±2	16.8±1,4	8.9±3 <sup>a,b</sup>	8.9±3 <sup>a,b</sup>	14.6±2.1 <sup>c,d</sup>	12.2	0.000

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c, d express significant difference between groups. A depicts a comparison with group 1, b depicts a comparison with group 2, c depicts a comparison with group 3 and d depicts a comparison with group 5. (\*p  $\leq$ 0. 05).

**Table 2. Gravimetry:** Showing 1<sup>st</sup> day result there is a significant increase in % body weight gain in group 3, 4 and 5 compared to group 1(  $p \le 0.05$ ). We observed significantly decrease in % body weight gain in group 4 compared to group 3(  $p \le 0.05$ ).

At  $21^{st}$  day there is a significant decrease in % body weight gain in group 3 and 4 compared to group 1 and 2 (p  $\leq$ 0. 05). We observed a significant increase in % body weight gain in group 5 compared to group 3 and 4.

**GENERAL** 

#### **GENERAL**

Table 3. Effect of Ethanolic Extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Haematology

Parameters	Group I	Group II	Group III	Group IV	Group V	ANOVA	
	_	_	_	_	_	f. value	p. value
Hb%	12.8±1.1	12.9±1.2	12.8±0.5	13.3±0.14	12±0.8	1.682	0.18
WBC	7783±2806	7266±2084	5633±1723	7383±2918	6566±1538	0.82	0.52
RBC	7.4±0.9	7.3±0.8	7.3±0.3	8±0.2	6.8±0.3 <sup>d</sup>	2.667	0.03
Platelet	8.1±2.6	6.4±2.2	7.6±1.2	9.7±0.3	8.2±2.7	2.041	0.11
PCV	44.6±5.4	43.6±4.8	42.1±2.3	47.9±1.9	39.8±2.5 <sup>d</sup>	3.895	0.01
MCHC	28.9±1.3	29.6±0.6	30.5±0.8	28.1±1.1°	30.3±1.7 <sup>d</sup>	4.286	0.009

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*p  $\leq$ 0.05).

**Table 3**. Haematological parameters: there are no significant changes observed for Hb%, WBC and platelet among all groups. We have observed significant decrease in RBC, PCV and MCHC in group 5 when compared with group 4.

## **Biochemical Investigations:**

LIPID PROFILE ANALYSIS

**Table 4. Effect of Ethanolic Extract of** *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Lipid Profile

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	ANOVA	1
						F	P
						value	value
TG mg/dl	140±35.9	200±93.2	110±23.5 <sup>b</sup>	129±32.2	$108\pm14.2^{b}$	3.58	0.01
TCmg/dl	122.8±16.1	123±17.5	131±15.8	185±17 <sup>a,b,c</sup>	127.6±12.6 <sup>d</sup>	16.5	0.000
HDLmg/dl	30±1.89	41.8±14 <sup>a</sup>	29.6±1.8 <sup>b</sup>	36.8±2.5	31±1.2	3.9	0.013
LDLmg/dl	64.7±18.5	39.0±7.12 <sup>a</sup>	$79.8\pm12.8^{b}$	122±14.13 <sup>a,b,c</sup>	$77\pm8.1^{b,d}$	33.3	0.000
VLDLmg/dl	28±7.18	40±18.6	22±4.7 <sup>b</sup>	25.8±6.4	23±3.6 <sup>b</sup>	3.2	0.02

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. A depicts a comparison with group 1, b depicts a comparison with group 2, c depicts a comparison with group 3 and d depicts a comparison with group 5. (\*p  $\leq$ 0. 05).

**Table 4:** We observed significantly lesser values of TG and VLDL in group 3 and 5 compared to group  $2(*p \le 0.05)$ . There was a significant increase in the values of TC and LDL compared to group 1, 2 and 3. TC levels have shown significant decreased values in group 5 compared to group 4. HDL levels have shown higher values in group 2 compared to group1. Also, we observed lesser levels of HDL in group 3 compared group  $2(*p \le 0.05)$ .

### LIVER FUNCTION TEST:

**Table 5. Effect of Ethanolic Extract of** *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Liver Function Test

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	ANOVA	
						f. value	p. value
Serum	0.61±0.1	0.78±0.1	0.8±0.1	0.68±0.19	0.8±0.1	1.96	0.13
bilirubin mg%							
Direct mg%	0.35±0.08	0.5±0.1	0.46±0.1	0.45±0.16	0.4±0.1	1.44	0.24
Indirectmg%	0.28±0.07	0.28±0.04	0.3±0.08	0.25±0.05	0.3±0.08	1.65	0.19
SGOT U/L	73±6.5	70±28	51.3±8.16	18.6±5 <sup>a,b,c</sup>	51±8.1 <sup>d</sup>	13.7	0.000
SGPTU/L	60±19.7	64.5±12	47±5.67	$22.8\pm4^{a,b,c}$	47±5.6 <sup>d</sup>	12.36	0.000
Serum	5.7±0.2	5.7±0.2	5.6±0.24	6±0.3	5.6±0.2	1.67	0.18
protein							
gm/dl							
Serum	2.9±0.1	3±0.19	2.8±0.13	$3.4\pm0.3^{a,b,c}$	2.8±0.1 <sup>d</sup>	7.08	0.001
albumin							
gm/dl							
A/G ratio	1±0.1	1±0.1	0.98±0.04	$1.3\pm0.2^{a,c}$	$0.9\pm0.04^{\rm d}$	5.79	0.002
gm/dl							
Alkaline	153±16.2	187±50	161±18.2	174±26	161±18	1.30	0.29
phos U/L							

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*p  $\leq$ 0.05).

Table 5: We observed non significant differences for serum bilirubin, direct and indirect serum bilirubin, serum protein and alkaline phosphate between all groups. Serum SGPT and SGOT has shown significant decrease in levels in group 4 compared to group 1, 2 and 3( p $\leq$  0.05). There is a significant increase in SGPT and SGOT in group 5 compared to group 4. Levels of serum albumin have shown significantly higher values in group 4 compared to group 1, 2 and 3 (p $\leq$  0.05). There is a significant decrease in level of serum albumin in group 5 compared to

group 4. There is significantly increased in A/G ratio in group 4 compared to group 1 and 3 (p $\leq$  0.05). We observed significantly lesser levels of A/G ratio in group 5 compared to group 4.

TABLE 6. Effect of Ethanolic Extract of Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla) on Serum Na+, K<sup>+</sup> & Ca<sup>++</sup>

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
Na+	143±5.07	140±1.5	139±1.86	141±4.9	139±1.6	1.26	0.31
K+	9.9±0.51	4.6±0.15 <sup>a</sup>	4.86±0.7 <sup>a</sup>	$4.7\pm0.6^{a}$	$4.9\pm0.7^{a}$	53.6	0.000
Ca++	5.4±2.18	8.7±0.1 <sup>a</sup>	8.6±0.12 <sup>a</sup>	8.7±0.2 <sup>a</sup>	8.6±0.12 <sup>a</sup>	13.18	0.000

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*p  $\leq$ 0.05).

Table 6: Levels of Na<sup>+</sup> has shown non significant differences among all groups. There is significant decrease in K<sup>+</sup> levels in group 2, 3, 4 and 5 compared to group  $1(p \le 0.05)$ . There is significant increase in values of Ca<sup>++</sup> in group 2, 3, 4 and 5 compared to group  $1(p \le 0.05)$ .

Table 7. Effect of Ethanolic Extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Glucose Regulations

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
RBS mg/dl	98.5±26.8	118.8±13.8	100±18.6	115.6±15.7	96.1±15.6	1.94	0.134

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*p  $\leq$ 0.05).

To find out whether there is any impact of high fat diet on metabolic changes, we have estimated RBS (Random Blood Sugar) levels. RBS level in all the groups were found within normal range (table 7).

**SPECIAL** 

## **SPECIALIZED**

## 1. Histology:

- a. Atrium
- b. Ventricle
- c. Elastic Artery
- d. Muscular Artery
- e. Coronary Artery

## **HISTOLOGY OF ATRIUM:**

## G1. H&E stain 10X




Figure 1: Atrium section of the control group revealing no pathological changes. HE **10x**.

S

## G2. H&E stain 10X




Figure 3: Atrium section of Hyperlipidemic group revealing no pathological changes. HE **10x.** 

## G3. H&E stain 10X




Figure 5: Atrium section of Hyperlipidemic Treated with Terminalia Arjuna group revealing no pathological changes. HE **10x**.

## G1. H&E stain 40X




Figure 2: Atrium section of the control group revealing no pathological changes. HE **40x**.

## G2. H&E stain 40X




Figure 4: Atrium section of Hyperlipidemic group revealing no pathological changes. HE **40x.** 

## G3. H&E stain 40X




Figure6: Atrium section of Hyperlipidemic group Treated with Terminalia Arjuna revealing no Pathological changes. HE **40x**.

## G4. H&E stain 10X




Figure 7: Atrium section of Hyperlipidemic Treated with Emblica Officinalis group revealing no pathological changes. HE **10x.** 

## G4. H&E stain 40X




Figure8: Atrium section of Hyperlipidemic group Treated with Emblica Officinalis revealing no Pathological changes. HE **40x**.

## G5. H&E stain 10X




Figure9: Atrium section of Hyperlipidemic Treated with Terminalia Arjuna and Emblica Officinalis group revealing no pathological changes. HE **10x.** 

## G5. H&E stain 40X




Figure 10: Atrium section of Hyperlipidemic group Treated with Terminalia Arjuna and Emblica Officinalis revealing no Pathological changes. HE **40x.** 

#### **HISTOLOGY OF ATRIUM:**

We have examined the histopathological study on atrium of different groups like Group 1 fed with Isocaloric diet, Group 2 fed with hyperlipidemic diet, Group 3 fed with hyperlipidemic diet and treated with Terminalia arjuna, Group 4 fed with hyperlipidemic diet and treated with Emblica Officinalis and the Group 5 rats fed with hyperlipidemic diet and treated both the drugs i.e. *Terminalia Arjuna (Arjuna) and Emblica Officinalis(Amla)* 

The H&E stained section studied under the compound microscope and We observed that Atreal architecture of rats fed with Isocaloric diet i.e., group 1 showing healthy morphology of tissue.

The hyperlipidemic diet fed rats of group 2 showing normal architecture as such there is no damage, edema, leukocyte infiltration and necrosis was observed. The endocardial layer of atrium showing mild fat vacuoles is present in inner aspect of the wall.

We have even observed that the 3, 4 and 5 treated groups showing normal architecture or morphology of atrium hence there is no significant changes were observed in all groups of rats when compared to group 1.

## **HISTOLOGY OF VENTRICLE:**

## G1. H&E stain 10X




Figure 1: Ventricle section of the control group revealing no pathological changes. HE **10x.** 

## G2 H&E stain 10X




Figure 3: Ventricle section of Hyperlipidemic group revealing no pathological changes. HE **10x.** 

## G3 H&E stain 10X




Figure 5: Ventricle section of Hyperlipidemic group Treated with *Terminalia Arjuna* revealing no pathological changes. HE **10x**.

## G1. H&E stain 40X




Figure 2: Ventricle section of the control group revealing no pathological changes. HE **40x.** 

## G2 H&E stain 40X




Figure 4: Ventricle section of Hyperlipidemic group revealing no pathological changes. HE **40x.** 

## G3 H&E stain 40X




Figure 6: Ventricle section of Hyperlipidemic group Treated with *Terminalia Arjuna* revealing no pathological changes. HE **40x**.

## G4 H&E stain 10X




Figure 7: Ventricle section of Hyperlipidemic group Treated with *Emblica Officinalis* revealing no pathological changes. HE **10x**.

## G4 H&E stain 40X




Figure 8: Ventricle section of Hyperlipidemic group Treated with *Emblica Officinalis* revealing no pathological changes. HE **40x**.

## G5 H&E stain 10X




Figure 9: Ventricle section of Hyperlipidemic group Treated with *Terminalia Arjuna and Emblica Officinalis* revealing no pathological changes. HE **10x.** 

## G5 H&E stain 40X




Figure 10: Ventricle section of Hyperlipidemic group Treated with *Terminalia Arjuna Emblica Officinalis* revealing no pathological changes. HE **40x.** 

## **HISTOLOGY OF VENTRICLE:**

The H & E stained section studied under the compound microscope and all the five groups of rats Ventricle we have examined the histopathological studies on myocardial tissue. The control group rats fed with Isocaloric diet showing the healthy morphological architecture of basal part of myocardial tissue within normal limits.

The group 2 hyperlipidemic diet fed rats showed no myocardial damage like edema, leukocyte infiltration and necrosis were observed. We observed in few slides, myocardium containing coronary artery showing an early change of atherosclerosis. However, these changes significantly decreased or not observed in treating groups.

We have observed that the group 3, 4 & 5. Are showing normal, healthy morphology of Ventricular musculature (Myocardium) when compared to group2

## **HISTOLOGY OF ELASTIC ARTERY:**

## **G1 H&E STAIN 10X**



Figure 1: Elastic Artery section of the control group revealing no pathological changes. HE **10x** 

## **G1 H&E STAIN 40X**




Figure 2: Elastic Artery section of the control group revealing no pathological changes. HE **10x** 

## **G1 VEHEROFF'S STAIN 10X**




Figure 3: Elastic Artery section of the control group revealing no pathological changes. Veheroff's 10x


## **G1 VEHEROFF'S STAIN40X**



Figure 4: Elastic Artery section of the control group revealing no pathological changes. Veheroff's 40x

## G1 Elastic Artery 40x H&E stain

## G2 Elastic Artery 40x H&E stain



Smooth muscle
Eiber decreased

Endothelium

Lumen


Plaque

Figure 5: Elastic Artery section of Hyperlipidemic group revealing thin elastic fibre HE 10x

Figure 6: Elastic Artery section of Hyperlipidemic group revealing subintimal fat deposition HE 40x

## G1 Elastic Artery 40x Veheroff's stain

## G2 Elastic Artery 40x Veheroff's stain








Figure 8: Elastic Artery section of Hyperlipidemic group group revealing less reticular fibres and space increased space between reticular fibres Veheroff's 40x

## G3 H&E stain 10X




Figure 9: Elastic Artery section of Hyperlipidimic group treated with Terminalia Arjuna revealing no pathological changes. HE 10x

## G3 H&E stain 40X




Figure 10: Elastic Artery section of Hyperlipidimic group treated with Terminalia Arjuna revealing no pathological changes. HE 40x

## **G3 VEHEROFF'S STAIN 10X**




Figure 11: Elastic Artery section of Hyperlipidemic group treated with Terminalia Arjuna revealing no pathological changes Veheroff's **10x** 

## G3 VEHEROFF'S STAIN40X




Figure 12: Elastic Artery section of Hyperlipidemic group treated with Terminalia Arjuna. revealing no pathological changes Veheroff's **40**x

## G4 H&E stain 10X




Figure 13: Elastic Artery section of Hyperlipidimic group treated with *Emblica Officinalis* revealing no pathological changes. HE 10x

## G4 H&E stain 40X




Figure 14: Elastic Artery section of Hyperlipidimic group treated with *Emblica Officinalis* revealing no pathological changes. HE 40x

## **G4 VEHEROFF'S STAIN 10X**



Figure 15: Elastic Artery section of Hyperlipidemic group treated with *Emblica Officinalis* revealing no pathological changes Veheroff's 10x

## **G4 VEHEROFF'S STAIN40X**




Figure 16: Elastic Artery section of Hyperlipidemic group treated with *Emblica Officinalis*. revealing no pathological changes Veheroff's 40x

### G5 H&E stain 10X



Figure 17: Elastic Artery section of Hyperlipidimic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes. HE 10x

## G5 H&E stain 40X




Figure 18: Elastic Artery section of Hyperlipidimic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes. HE 40x

## **G5 VEHEROFF'S STAIN 10X**




Figure 19: Elastic Artery section of Hyperlipidemic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes Veheroff's 10x

## **G5 VEHEROFF'S STAIN40X**




Figure 20: Elastic Artery section of Hyperlipidemic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes Veheroff's 40x

#### **HISTOLOGY OF ELASTIC ARTERY:**

#### General microscopic structure of aorta in control and experimental groups

The H&E stained 10X and 40X section of the control/Isocaloric group showed typical 3 layers/tunicae of the aorta; the tunica intima with endothelial cells lining the tunica media with the normal arrangement of elastic lamellae and the horizontally oriented spindle-shaped nuclei of the smooth muscle cells and finally the tunica adventitia.

All the rats fed with a high fat diet group presented with morphological alterations of the smooth muscle cell nuclei in the tunica media. The tunica media showed the degeneration round shape and hyperplasia of the smooth muscle cell nuclei.

In addition to this, we observed subintimal atheromatus plaques were observed in some rats of (Fig 5 & 6 G2 H&E stain 10X and 40X) picture G2 H&E Stain 40X. In the hyperlipidemic fat fed rat group the histological structure of a rat was similar to that of the control group.

The H&E stained 10X and 40X microscopic structure of all 3 layers of the aorta (Tunica Intima, Media and Adventitia) of group 3 rats fed with high fat diet and treated with *Terminalia Arjuna (Arjuna)*, group 4 rats fed with high fat diet and treated with Emblica Officinalis and group 5 rats were fed with high fat diet and treated with *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)*, showing healthy architecture of elastic artery and significantly normal when compared with group 2.

# Histological structure of rat aorta in control and experimental groups as revealed by Veheroff's stain

The Veheroff's stained sections showed the arrangement of elastic fibres of different studied groups, with relatively wide gaps between the elastic lamellae in the hyperlipidemic fat fed rat groups.

As compared with the control group (Fig 1& 2 G2 Veheroff's stain 10X & 40X) an increase of the volume of collagen fibres between two elastic lamellae in elastic artery wall was observed in group2 (Fig 3 & 4 Veheroff's stain 10X & 40X).

In addition to that there is decreased smooth muscle fibres and nucleus also in (Fig 3 & 4 Veheroff's stain 10X & 40X).

The Veheroff's stained sections shown the arrangement of elastic lamellae prominent and abundant in group 3, 4 & 5. Nuclei and smooth muscle fibres have observed normal and healthy. Hence group 3, 4 and 5 are significantly normal when compared to group 2

## **HISTOLOGY OF MUSCULAR ARTERY:**

## G1 H&E stain 10X



Figure 1: Muscular Artery section of the control group revealing no pathological changes. HE 10x

## G1 H&E stain 40X




Figure 2: Muscular Artery section of the control group revealing no pathological changes. HE **10x** 

## **G1 VEHEROFF'S STAIN 10X**




Figure 3: Elastic Artery section of the control group revealing no pathological changes. Veheroff's **10x** 

## **G1 VEHEROFF'S STAIN40X**




Figure 4: Elastic Artery section of the control group revealing no pathological changes. Veheroff's  $\bf 40x$ 

## G2 H&E stain 10X




Figure 5: Muscular Artery section of Hyperlipidemic group revealing no pathological changes. HE **10x** 

## G2 H&E stain 40X




Figure 6: Muscular Artery section of Hyperlipidemic group revealing no pathological changes. HE **10x** 

## **G2 VEHEROFF'S STAIN 10X**




Figure 7: Muscular Artery section of Hyperlipidemic group revealing no pathological changes. Veheroff's 10x

## **G2 VEHEROFF'S STAIN40X**




Figure 8: Muscular Artery section of Hyperlipidemic group revealing no pathological changes. Veheroff's 40x

## G3 H&E stain 10X




Figure 9: Muscular Artery section of Hyperlipidimic group treated with Terminalia Arjuna revealing no pathological changes. HE 10x

## G3 H&E stain 40X




Figure 10: Muscular Artery section of Hyperlipidimic group treated with Terminalia Arjuna revealing no pathological changes. HE 40x

## **G3 VEHEROFF'S STAIN 10X**




Figure 11: Muscular Artery section of Hyperlipidemic group treated with Terminalia Arjuna revealing no pathological changes Veheroff's **10x** 

## G3 VEHEROFF'S STAIN40X




Figure 12: Muscular Artery section of Hyperlipidemic group treated with Terminalia Arjuna. revealing no pathological changes Veheroff's **40x** 

## G4 H&E stain 10X



Figure 13: Muscular Artery section of Hyperlipidimic group treated with *Emblica Officinalis* revealing no pathological changes. HE 10x

## G4 H&E stain 40X




Figure 14: Muscular Artery section of Hyperlipidimic group treated with *Emblica Officinalis* revealing no pathological changes. HE 40x

## **G4 VEHEROFF'S STAIN 10X**




Figure 15: Muscular Artery section of Hyperlipidemic group treated with *Emblica Officinalis* revealing no pathological changes Veheroff's 10x

## **G4 VEHEROFF'S STAIN40X**




Figure 16: Muscular Artery section of Hyperlipidemic group treated with *Emblica Officinalis*. revealing no pathological changes Veheroff's 40x

#### G5 H&E stain 10X




Figure 17: Muscular Artery section of Hyperlipidimic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes. HE 10x

#### G5 H&E stain 40X




Figure 18: Muscular Artery section of Hyperlipidimic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes. HE 40x

## **G5 VEHEROFF'S STAIN 10X**



Figure 19: Muscular Artery section of Hyperlipidemic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes Veheroff's 10x

## **G5 VEHEROFF'S STAIN40X**




Figure 20: Muscular Artery section of Hyperlipidemic group treated with *Terminalia Arjuna* and *Emblica Officinalis* revealing no pathological changes Veheroff's 40x

#### **HISTOLOGY OF MUSCULAR ARTERY:**

#### General microscopic structure of Muscular artery in control and experimental groups

The H&E stained section of the control/Isocaloric group showed typical 3 layers of the Muscular artery; the tunica intima with endothelial cells lining the tunica media with the normal arrangement of elastic fibres and the horizontally oriented spindle-shaped nuclei of the smooth muscle cells and the outermost layer is tunica adventitia.

All the rats of group 2, fed with a high fat diet, presented the normal morphological architecture of the smooth muscle cell and nuclei in the tunica media.

We observed in the high fat fed rat group 2 the histological structure of Muscular artery was similar to that of the control group.

The H&E stained microscopic structure of all 3 layers of the Muscular artery (Tunica Intima, Media and Adventitia) of group 3 rats fed with high fat diet and treated with *Terminalia Arjuna* (*Arjuna*), group 4 rats fed with high fat diet and treated with *Emblica Officinalis*(*Amla*) and group 5 rats were fed with high fat diet and treated *Terminalia Arjuna*(*Arjuna*) and *Emblica Officinalis*(*Amla*), showing healthy architecture of Muscular artery and significantly normal when compared with group 1.

# Histological structure of rat Muscular artery in control and experimental groups as revealed by Veheroff's stain

The Veheroff's stained sections showed the arrangement of elastic fibres of different studied groups, with relatively mild gaps between the elastic lamellae in the high fat fed rat groups.

As compared with the control group (Fig 3. G1 Veheroff's stain 10X and. Fig 4. G1 Veheroff's stain 40X) a slight increase in the volume of collagen fibres between two elastic lamellae in the Muscular artery wall was observed in group2.

In addition to that there is mild decreased smooth muscle fibres and nucleus also in (Fig 7. G2 Veheroff's stain 10X and. Fig 8. G2 Veheroff's stain 40X).

The Veheroff's stained sections of a muscular artery shown the arrangement of elastic lamellae normal in group 3, 4 & 5. Nuclei and smooth muscle fibres were abundantly observed normal and healthy. Hence group 3, 4 and 5 are significantly normal when compared to group 1. (Fig 11, 12, 15, 16 19 and 20. G3, G4 and G5 Veheroff's stain 10X and. Fig 8. G3, G4 and G5 Veheroff's stain 40X).

## **CORONARY ARTERIAL HISTOPATHOLOGY:**

## **GROUP 1 H&E STAIN 10X**




Figure 1: Ventricle section of the control group revealing Coronary Artery Normal histology H&E 10X

## **GROUP 1 H&E STAIN 40X**




Figure 2: Ventricle section of the control group revealing Coronary Artery Normal histology  $\mbox{ H\&E }40\mbox{x}$ 




Figure 3: Ventricle section of the Hyperlipidimic group revealing thickened Coronary Artery. HE 10X




Figure 4: Ventricle section of the Hyperlipidimic group revealing subintimal deposition of fat in Tunica intima and Tunica Media. HE  $40\mathrm{X}$ 

## **GROUP 3 H&E STAIN 10X**




Figure 5: Ventricle section of the Hyperlipidimic group treated with  $\it Terminalia Arjuna$  revealing Coronary Artery pathological changes. HE  $\it 10x$ 

## **GROUP 3 H&E STAIN 40X**




Figure 6: Ventricle section of the Hyperlipidimic group treated with  $Terminalia\ Arjuna\$ revealing Coronary Artery pathological changes. HE 40x

## **GROUP 4 H&E STAIN 10X1**




Figure 7: Ventricle section of the Hyperlipidimic group treated with  $Emblica\ Officinalis$  revealing Coronary Artery pathological changes. HE 10x

## **GROUP 4 H&E STAIN 40X**




Figure 8: Ventricle section of the Hyperlipidimic group treated with  $\it Emblica Officinalis$  revealing Coronary Artery pathological changes. HE  $\it 40x$ 

## **GROUP 5 H&E STAIN 40X**




Figure 9: Ventricle section of the Hyperlipidimic group treated with  $\it Terminalia Arjuna$  and  $\it Emblica Officinalis$  revealing Coronary Artery pathological changes. HE  $\it 10x$ 

## **GROUP 5 H&E STAIN 40X**




Figure 10: Ventricle section of the Hyperlipidimic group treated with  $Terminalia\ Arjuna\$ and  $Emblica\ Officinalis\$ revealing Coronary Artery pathological changes. HE 40x

#### **CORONARY ARTERIAL HISTOPATHOLOGY:**

The H & E stained section Myocardium containing coronary artery of control/Iso-caloric diet fed rats group 1, showing normal and healthy microscopic architecture. The tunica intima with the endothelial cells lining the tunica media with normal arrangement of internal elastic lamellae and the well defined spindle shaped smooth muscle cells in 10X and 40X. (Fig No 1 & 2 G1 H&E stain of CA)

(Fig No 3 & 4 G2 H&E stain of CA) Coronary artery of group 2 rats fed with high fat diet presented with morphological alterations in the lumen and arterial wall. We have observed that the morphologic appearance of coronary arterial lumen in group 2 rats fed with high fat diet showing an early change of atherosclerotic plaques. The atherosclerotic plaques are in the form of fatty changes in the Subendothelial layer as well as in the arterial wall. Hence coronary arterial wall showed mild degeneration, round shaped hyperplasia of smooth muscle cells nuclei.

We even observed that the coronary arterial wall thickness is significantly increased in group 2 compared to group 1. Whereas coronary artery wall thickness group 3, 4 and 5 (Fig No G3 5&6, G4 7&8 and G5 9&10 H&E stain of CA) significantly decreased and showing healthy normal architecture when compared to group 2.

Group 3 high fat diet fed rats treated with *Terminalia Arjuna* (*Arjuna*), group 4 high fat diet fed rats with treated *Emblica Officinalis* (*Amla*) and group 5 high fat diet fed rats treated with *Terminalia Arjuna* (*Arjuna*) and *Emblica Officinalis* (*Amla*) shows a remarkable improvement of architecture of coronary arterial wall as compared to group 2.

#### 2. VASCULAR INTEGRITY BASED ON HISTOLOGICAL FROFILE:

a. **Estimation of Elastic artery Thickness:** Tunica Intima, Tunica Media.

Estimation of Elastic Artery lumen Diameter

- i. Transverse ii. Anteroposterior and iii. lumen diameter
- b. **Estimation of Muscular artery Thickness:** Tunica Intima, Tunica Media wall thickness.
- c. Estimation of Coronary Artery Thickness: Wall thickness

Estimation of Coronary artery lumen Diameter

- ii. Transverse ii. Anteroposterior and iii. lumen diameter
- d. Normalized Wall Index

TABLE8. Effect of Ethanolic Extract of Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla) on Elastic Artery Thickness


Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
Tunica	35.8±2.1	29±4.2 <sup>a</sup>	37.8±3.8 <sup>b</sup>	37.5±4.2 <sup>b</sup>	38±4.7 <sup>b</sup>	7.28	0.002
Intima µm							
Tunica	196±47	191±32	211±41	193±48	211±55.9	0.26	0.89
Media µm							

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*p  $\leq$ 0.05).

Table 8. shows effect of ethanolic extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Elastic arterial thickness.

The result of group 2 rats fed with high fat diet indicates significant decrease of tunica intima thickness in Elastic artery as compared group 1normal/Isocaloric diet fed rats. Whereas, both *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* supplemented groups shows near normal elastic artery thickness. Interestingly tunica media thickness in group 2 rats did not show any significant alteration in thickness.

# ELASTICARTERY WALL THICKNESS MEASUREMENT



## **VEHEROFFS STAIN ELASTIC ARTERY**




TABLE 9. Effect of Ethanolic Extract of Terminalia Arjuna (Arjuna) and Emblica

Officinalis (Amla) on Morphometry of Elastic Arterial Lumen

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F	P
						value	value
Antiro-Post	765.9±76	571.9±42 <sup>a</sup>	777.3±37 <sup>b</sup>	777.5±27 <sup>b</sup>	802±15 <sup>b</sup>	26.6	0.000
μm							
Transverse	212.5±109	168.2±60 <sup>a</sup>	217.6±40 <sup>b</sup>	$221.8\pm40^{b}$	216.8±103 <sup>b</sup>	53.7	0.000
μm							
Arterial	722.7±28	577.3±27 <sup>a</sup>	$788.7 \pm 15^{a,b}$	775.3±36 <sup>a,b</sup>	777.2±27 <sup>a,b</sup>	59.4	0.000
Lumen µm <sup>3</sup>							

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*p  $\leq$ 0.05).

Table 9. shows effect of ethanolic extract of *Terminalia Arjuna (Arjuna) & Emblica Officinalis (Amla)* on Elastic arterial lumen morphology.

Results clearly indicate significantly decrease of luminal Anteroposterior diameter, transverse diameter and area of arterial lumen in group 2rats fed with high (Hyperlipidemic diet) fat diet. Supplementation of drug 1 is *Terminalia Arjuna (Arjuna) & Emblica Officinalis (Amla)* and combination of both show significant improvement of liman area, anteroposterior and transverse diameter.

TABLE 10. Effect of Ethanolic Extract of Terminalia Arjuna (Arjuna) and Emblica

Officinalis (Amla) on Muscular Artery Thickness

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
Tunica Intima µm	25.4±7.3	25.8±5.3	31.2±3,7	24.7±7.9	26.2±4.1	1.13	0.36
Tunica Media µm	139±58	99±17	167±70	137±60	131.4±30.5	1.32	0.28

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*p  $\leq$ 0.05).

Table 10. Depicts Effect of ethanolic extract of Terminalia Arjuna (Arjuna) & Emblica Officinalis (Amla) on muscular artery thickness, results shows insignificant changes in tunica intima and tunica media thickness in group 2 hyperlipidemic rats

TABLE 11. Effect of Ethanolic Extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Coronary Arterial Wall Thickness Measurement

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
Coronary	192.4±6.7	251.9±18.4	ь 199.4±16.6	193.8±9.8	212.2±4.9 b	23.32	0.000
Artery		231.9±10.4	199.4±10.0	193.6±9.6	212.214.9		
Thickness µm							

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5. (\*p  $\leq$ 0.05).

Table 11. Effect of ethanolic extract of *Terminalia Arjuna (Arjuna) & Emblica Officinalis* (*Amla*) on coronary arterial wall thickness measurement. Shows significant increase of coronary arterial wall thickness in group 2 rats compared its control group 1.

Supplementation of drug in group 3 fed with high fat diet treated with *Terminalia Arjuna* (*Arjuna*), group 4 fed with high fat diet treated with *Emblica Officinalis* (*Amla*), group 5 fed with high fat diet treated with both the drug *Terminalia Arjuna* (*Arjuna*) & *Emblica Officinalis* (*Amla*) shows remarkable improvement in coronary arterial wall thickness.

### **CORONARY ARTERY WALL THICKNESS**




TABLE12. Effect of Ethanolic Extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Analysis of Coronary Arterial Lumen Measurement

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
Antiro-Post	793.9±57.7	569±117	638.3±194	726.7±136	1106 ±100 b,c,d	7.76	0.004
μm							
Transverse	591.8±35	499.1±45	1208.4±98.1	1027.7±166 a,b	1588±260 a,b,c	27.8	0.000
μm			a,b				
Arterial	366.9±45	268.1±46 b	496±29.4 b	653±124 a,b	741.8±56 a,b,c	24.08	0.000
Lumen µm <sup>3</sup>							ļ

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5. (\*p  $\leq$ 0.05).

Table 12. Effect of ethanolic extract of *Terminalia Arjuna (Arjuna) & Emblica Officinalis* (*Amla*) on analysis of coronary arterial lumen measurement depicts a significant narrowing of vascular integrity by reducing Anteroposterior diameter, transverse diameter and compromising area of coronary arterial lumen. Interestingly, group 3, 4 and 5 showed amelioratic effect on lipid induced impact on coronary arterial vascular integrity.

TABLE 13 Effect of Ethanolic Extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Normalized Wall Index (NWI)

<b>Parameters</b>	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
Normalized wall Index (NWI)	$0.30 \pm 0.01$	0.44 ±0.03	$0.30 \pm 0.02$	$0.31 \pm 0.02$	$0.31 \pm 0.26$	37.4	0.000


Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5. (\*p  $\leq$ 0.05).

Table 13. Effect of ethanolic extract of *Terminalia Arjuna (Arjuna)* & *Emblica Officinalis* (*Amla*) on normalized wall index (NWI) shows the results clearly indicate significant in group 2 rats fed with hyperlipidemic diet.

In case of supplementation of drug 1 (Group 3), drug 2 (Group 4) and Drug 1&2 (Group 5) normalized wall index had brought back to near control group.

## ARTERIAL LUMEN AREA

## ARTERIAL LUMEN DIAMETER TRANSVERSE & ANTEROPOSTERIOR






TABLE 14. Effect of Ethanolic Extract of *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* on Serum Nitric Oxide (NO)

Parameters	Group1	Group 2	Group 3	Group 4	Group 5	Anova	
						F value	P value
NO	$73.8 \pm 22.6$	87.1±19	69±16.2	62.8±27.9	78.2±22.7	1.04	0.4

Values are expressed as mean  $\pm$ SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c, d express significant difference between groups. a depicts comparison with group 1, b depicts comparison with group 2, c depicts comparison with group 3 and d depicts comparison with group 5.(\*  $\leq$ 0.05).

Table 14. Effect of ethanolic extract of *Terminalia Arjuna* (*Arjuna*) & *Emblica Officinalis* (*Amla*) on serum nitric oxide (No). We observed decreased level of NO in group 3 and 4 compared to group 1 although it was non -significant. There was an insignificant increase in NO levels of group 5 compared to group 1 ( $p \le 0.05$ ).

## **CHAPTER 6**

•••••

**DISCUSSION** 

#### DISCUSSION

#### **Phytochemistry:**

Phytochemical analysis shows both the drugs *Terminalia Arjuna (Arjuna) and Embilica Officinalis (Amla)* does not have any toxic ingredients.

## **Gravimetry:**

Increased body weight levels in hyperlipidemic diet clearly indicate lipid induced additional fat synthesis. The supplementation of *Terminalia Arjuna (Arjuna) and Emblica Officinalis* (Amla) shows protection against lipid induced lipogenesis.

### Haematology:

Unchanged hematological profile in all the groups indicated both these two drugs *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* are not having any adverse effect on hematopiosis. It also indicates *Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla)* are safe to consume as per hematology concerned. Our findings are corporate with Arumugam Shivagurunathan et al<sup>1</sup>.

#### **GENERAL**

## **Lipid Profile:**

Our result from lipid profile clearly indicates dyslipidemia in case of high lipid fed diets rats in group2, but surprisingly, both the drugs *Terminalia Arjuna (Arjuna) and Emblica Officinalis* (Amla) shown a protective action against lipid induced hyperlipidemia. Possibly, presence of high flavonoids and polythenol compounds with its antioxidant property act as hyperlipidemic agent<sup>2</sup>.

Feeding of high fat diet (group 2) may also result in excess hepatic triglycerides due to increased synthesis of triglycerides and increased de novo lipogenesis (DNL). The

supplementation of *Terminalia Arjuna* (*Arjuna*) and *Emblica Officinalis* (*Amla*) may induce an inhibitory effect on intestinal dietary fat absorption that leads to decrease triglyceride accumulation<sup>3</sup>. In addition, it may also possibly due to ability of greater functioning insulin to stimulate glucose transport mechanism in adipocyte and in skeletal muscle which is impaired due to hyperlipidemia resulting in insulin resistance. Impairment of insulin sensitivity or possibly insulin resistance leads to dyslipidemia<sup>4</sup>.

Hence, in our study the presence of beneficial phytoconstituents of *Terminalia Arjuna* (*Arjuna*) and *Emblica Officinalis* (*Amla*) inhibit effectively fat accumulation and ameliorate dyslipidemia in high lipid fed rats.

#### **Liver function test:**

Liver function tests clearly indicate no such changes of any parameters that is serum bilirubin, direct and indirect serum bilirubin, SGOT, SGPT, serum protein and alkaline phosphatase indicate the high lipid fat diet did not alter hepatocellular function in our study.

Both these two drugs *Terminalia Arjuna (Arjuna)* and *Emblica Officinalis (Amla)* cause no alteration in liver function test which indicates both these two drugs *Terminalia Arjuna (Arjuna)* and *Embilica Officinalis (Amla)* are non toxic to Liver function tests and may be used as safe ingredients.

Usually most of the drugs based on pharmaceutical substances cause contraindication effects on hepatic function test. Hence major safety concerned any drug use in any research protocol is essential. Hence, both *Terminalia Arjuna (Arjuna)* and *Embilica Officinalis (Amla)* may be considered as safe as per Liver function concerned<sup>5</sup>.

#### **Serum electrolytes:**

No change in levels of electrolytes in our study indicates neither hyperlipidemic diet nor Terminalia Arjuna (Arjuna) and Embilica Officinalis (Amla) any influences on electrolytes and its homeostasis

#### **Glucose regulation:**

No change in Random Blood Sugar level in any groups in our study indicates unimpaired glucose homeostasis among all the groups, including the group of rats fed with hyperlipidemic diet.

#### **SPECIAL**

## **Histology of Atrium:**

Normally, high fat diet causes remodeling the Atrial structure, but it is not confirmed whether high fat diet induces changes in histology of Atrial texture. In our study, we did not find any change in Atrial histological architecture in high fat diet fed rats.

Histological architecture of atrium of group 2 findings of high fat diet induced rats clearly indicate that short term, high fat diet feeding may not alter the Atrial wall architecture in our study.

Normally, excess lipid may stimulate mitochondria overload and activate myocardial molecular intimal cardiac remodeling.

#### Ventricle:

In our study on ventricular histology did not show any significant change of ventricular histology in group 2 rats, except we observed in few rats myocardium containing coronary artery showing an early changes of atherosclerosis which indicate minimal cardiac metabolic disturbances by high dietary fat.

#### **Elastic artery:**

We observe that in the endothelial layer of elastic artery shows an early change of atherosclerotic plaque and even we observe that there is a mild alteration in the arterial wall histology. These alterations may include arterial wall modification with component changes in the arterial wall and same in stiffer aorta. This study has been conducted on short term fat diet basis.

In our study early atherosclerotic changes in group 2 rats reflect less elasticity in arterial wall which may lead to increase in peripheral resistance and blood pressure<sup>6</sup>.

It has been already reported that elastic artery changes of tunica intima and tunica media increase with high fat diet and it leads to increase arterial stiffness from small arteries to large arteries<sup>7</sup>.

Increase thickness of elastic artery; tunica intima and tunica media are partly due to increase in smooth muscle cells. It was reported that aortic intima and media thickness was an earlier marker of preclinical atherosclerosis, which had been observed in group 2 in our study<sup>8</sup>.

The function of elastic fibers in the arterial wall is the maintenance of tension without constant expenditure of energy. According to Burton the arterial tension has a correlation to the amount of elastic tissue present in the vessel wall. Since coronary arteries arise from the root of aorta, they are subjected to maximum pressure during each cardiac cycle and hence have abundant elastic fibers to maintain arterial tension<sup>9</sup>.

From table no 8 and 9 we have clearly found decreased lumen, increased arterial wall thickness which again bring back to the normal in case of group 3, 4 and 5 with supplementation of drugs *Terminalia Arjuna (Arjuna)* and *Emblica Officinalis (Amla)*.

The result indicates loss of arterial compliance with possible stiffening accompanied by histological modification of arterial wall due to high fat diet. Perhaps the internal elastic lamina or media component might be enriching fibers components such as collagen and elastin. The high fat diet induces changes in this vascular integrity and induces loss of elasticity. This increase in collagen was partly an addition to the bulk of the media but in later life it was partly at the expense of smooth muscle<sup>9</sup> Thus, alteration of mechanical priority which may lead to severe cardiovascular dysfunction<sup>10</sup>.

Although the mechanism is reinitiating arterial remodeling in high dietary lipid which induce metabolic disorder but earlier studies have reported that high lipid causes concomitant reduction in arterial luminal diameter<sup>11</sup>.

In our study the supplementation of *Terminalia Arjuna (Arjuna)* and *Emblica Officinalis (Amla)* and both drugs groups, show a significant improvement in lumen diameter accompanied by a significant decrease of arterial wall thickness in rats fed with high lipid diet.

These results clearly show that improvement of elastic arterial property by treatment with *Terminalia Arjuna (Arjuna)* in group 3 and *Emblica Officinalis (Amla)* in group 4 and both the drug *Terminalia Arjuna (Arjuna)* group and *Emblica Officinalis (Amla)* treated group 5.

## **Muscular Artery:**

High lipid fat diet did not show any alteration of a muscular artery of the table shows (Table No 10) at any level of tunica adventitia, tunica media or tunica intima. It clearly indicates the short term effect of high lipid diet apparently does not have any adverse impact on muscular arterial integrity.

#### **Coronary artery:**

Smoking, hypertension, diabetes, fibrinogen, and low density lipoprotein cholesterol (LDL cholesterol) are widely accepted coronary heart disease (CHD) risk factors. These risk factors are also associated with preclinical atherosclerosis, generally measured as the intima-media thickness (IMT)<sup>12</sup>.

In our observation of coronary arterial wall and lumen integrity; changes have shown in the lumen area as an early change of atherosclerosis in tunica intima as well as tunica media in high fat fed rats.

Atherosclerosis is common condition which leads to inflammatory status of the micro vessels leading to the development of ischemic heart diseases or cerebrovascular disease or peripheral vascular disease. One of the common risk factor for atherosclerosis is high dietary lipid which induces pathophysiological vascular phenotypic alterations<sup>13</sup>.

Atherosclerosis is a disease of the tunica intima. The tunica intimal layer is separated from the tunica media layer by the internal elastic lamina (membrane) (internal elastic lamina, elastica interna), which is a fenestrated sheet of elastic tissue<sup>14</sup>.

The tunica media consists of multiple layers of smooth muscle cells and connective tissue (elastic fibers, collagen, proteoglycans). The amount of elastic tissue is less and the number of smooth muscle cells is greater in the epicardial coronary arteries than in other elastic vessels<sup>15</sup>.

The tunica media consists of up to 40 layers of circumferentially or helically oriented smooth muscles. The normal tunica media ranges in thickness from 125-350 pm (average 200 pm)<sup>16</sup>.

Tunica media thickness underlying diseased intima (atherosclerotic plaque) is considerably thinner, ranging from 16 to 190 pm (mean 80 pm)<sup>16</sup>. The smooth muscle cells are embedded in a glycoprotein mix that stains heavily with the periodic acid-Schiff reactions (being PAS positive).

Collagen and elastic fibers are also present in this layer. The tunica media layer is separated from the tunica adventitial layer by the external elastic lamina (membrane) (external elastic lamina, elastica externa). The external elastic membrane is composed of interrupted layers of elastin and is considerably thinner than the internal elastic membrane<sup>14</sup>

The increase in tunica intima was found to be the basic pathological change which ultimately progress to atherosclerosis<sup>9</sup>.

One of the most important initial events in the development of atherosclerosis is accumulation of cells containing excess lipid within the arterial wall which are mostly macrophages and transformed monocytes, those engulfs oxidized LDL to become foam cell of fat laden macrophages<sup>17</sup>.

The tunica intima and greater part of the tunica media lack capillaries and receive nutrition by diffusion; hence oxygen and other nutrients including soluble blood lipids must diffuse from lumen through the intercellular substance of the intima and most of the media. With abnormal increase in intimal thickening this diffusion mechanism gets very much deranged resulting in insufficient oxygen tension in tissues of arterial wall<sup>9</sup>.

Internal elastic lamina showed splitting, fraying, fragmentation and reduplication in various age groups<sup>9</sup>.

Most of the drugs against atherosclerosis are basically the inhibitor of HMG CoA reductase which is important for regulating relimiting step for cholesterol biosynthesis. The substantially important of coronary arterial wall thickness and lumen diameter and lumen area after treatment with these two drugs *Terminalia Arjuna* (Arjuna) and *Embilica Officinalis* (*Amla*) might be due to their potential impact of HMG CoA reductase on pathways.

In our study increased coronary arterial wall thickness with concomitant reduction of the coronary arterial wall area (change of Antiroposterior and transverse diameter) also in group 2 rats attributed a possibility of high oxidized LDL, oxidative stress that results from ROS leads to transform monocytes to macrophage and further develop foam cell, which fills subintimal layer and form fatty streak in the coronary artery<sup>18</sup>.

The fat induced injury on subintimal layer may also initiate various cytokines and growth factors which stimulate migration and proliferation of smooth muscle cell that became intermix with the area of inflammation to form intermediary lesion. If these response continue further causes increase in thickness of coronary arterial wall with compensatory slow dilatation<sup>19</sup>.

It has been noticed that stimulation of proinflammatory markers, cytokines, chemokines activate atherosclerotic plaque. The antioxidant effect of *Terminalia Arjuna* (Arjuna) and *Embilica Officinalis* (*amla*) observed in present study of groups 3, 4 and 5 may be mediated by protecting LDL oxidation which is one of the early changes of atherosclerosis<sup>20</sup>.

Thickening of coronary arterial wall definitely compromise coronary arterial lumen diameter and surface area which we have noticed in our observation in case of high lipid fed rats. There is reduction in coronary arterial diameter, structural area with increase in wall thickness.

#### Normalized wall index:

It has been reported that normalized wall index indicator of cardiovascular diseases of and mean wall index might be useful to assess the atherosclerotic disease burden. Although in our study mean lumen area showed a significant change in group 2 as compared to normal. But many other cardiovascular diseases lumen area does not show any changes. Hence simply assessing lumen or area may be considered as less sensitive marker of the atherosclerotic disease burden than normalized wall index<sup>21</sup>.

Decrease in group 2 normalised wall index also indicate negative remodeling and in our study supplementation of drug *Terminalia Arjuna (Arjuna)* and *Emblica Officinalis(Amla)* both the drugs shows a remarkable improvement in normalized wall index which may be considered as passive indicator for coronary arterial structural integrity.

#### REFERENCES:

- 1. Arumugam Shivagurunathan et al. "Immunostimulatory potential of dietary *Amla* (*Phylanthus Emblica*) in growth and Haematology of Tilapia mossambicus challenged with pseudomonas aeruginosa" International Research Journal of Pharmacy 2012, 3(7); 165-68.
- 2. Saravanan Subramaniam et al. "Anti-Atherogenic Activity of Ethanolic Fraction of *Terminalia Arjuna* Bark on Hypercholesterolemic Rabbits" Evidence-Based Complementary and Alternative Medicine, Volume 2011, Article ID 487916, 8 pages.
- 3. C. H. Liu, M. T. Huang and P.C. Haung "source of triglycerides' accumulation in livers of rat fed a cholesterol supllimentated diet" Lipid Vol, 30. No 6. PP 527-531, 1995
- 4. G. M. Reaven "why syndrome X? form Harold himsworth to the insulin resistance syndrome" Cell Metabolism, Vol 1. No 1, PP. 9-14, 2005
- 5. Sheel Sharma et al, "Diminishing effect of arjuna tree (*Terminalia arjuna*) bark on the lipid and oxidative stress status of high fat high cholesterol fed rats and development of certain dietary recipes containing the tree bark for human consumption" Research in Pharmacy 2(4): 22-30, 2012.
- 6. A. O. Rouke, M F and Namisivayam M 2010 "arterial stiffness its assessment prognostics value and multiplication for treatment" American Journal of hypertension, 24(1), 5-17)
- Sentelices L C, Rutaman S J, Ertart J C, pranti RL, hanay J N, Vorp D A and Aharan J M
   "Experimental system for ex vivo measurement of Murine aortic stiffness"
   Physiological measurement. 2007; 28(8), N 39-N49
- 8. Haurington J, Pana, A S, Gent R, Hirtec, Couter J, "Aortic intima media thickness is an early marker of atherosclerosis in children with type 1 diabetes mellitus. Journal of Pedator. 2010; 156: 237-241

- Rashmi Deopujari, Asha Dixit "The Study of Age Related Changes In Coronary Arteries
   And Its Relevance To The Atherosclerosis" Journal of Anatomical Society of India 59(2)


   192-196 (2010)
- 10. Mari Billaud, Scott R John, Stone, Branty E Isakson, "Loss of compliance in small arteries but not in conduct arteries after 6 weeks exposure to high fat diet", Journal of Cardiovascular trans Research. 2012; 5: 256-263.
- 11. Rizzoni D, D Ciuceis, C. Porteri E, Semerarao F and Rosri E A."Structural alterations in small resistance arteries in obesity" Basic and Clinical pharmacology and toxicology. 2011; 1742-1843
- 12. Chambless, et al Association of Coronary Heart Disease Incidence with Carotid Arterial Wall Thickness and Major Risk Factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993) American Journal of Epidemiology Vol. 146, No. 6, 1997
- 13. Leopoid J. A. and Coscarzo J, "Oxidative risk for atherosclerotic cardiovascular disease free radical" Journal biomedical. 2009; 47: 1673-1706.
- 14. Bruce F. Waller. Charles M. Orr. John D. Slack. Cass A. Pinkerton. James Van Tassel. Thomas Peters. "Anatomy, Histology, And Pathology of Coronary Arteries: A Review Relevant to New Interventional and Imaging Techniques-Part I" Clinical Cardiology. 15,451-457 (1992)
- Benditt EP, Schwartz SM. Blood vessels In Pathology (Eds. Rubin E, Farber JL) JB
   Lippincott, Philadelphia (1988) 454- 465
- 16. Waller BF et al. "The eccentric coronary atherosclerotic plaque Morphologic observations and clinical relevance" Clinical Cardiology 12, 14-20 (1989)

- 17. Saleem Hussain DR, Mawafy A R. "Comprehensive impact of different types of a single antioxidant supplementation (B carotene, A- tocopherols and ascorbic acid) on lipid profile in hyperlipidemic rats" Middle East Journal Scientific Research. 2009; 4(4): 354-60.
- 18. Ross R. "Atherosclerosis an inflammatory disease" The New England Journal of Medicine, 1999; 340(2): 115- 126.
- 19. Oubina, M.P. et al, "Synergetic effect of angiotensin converting enzyme ACE 3 hydroxy 3 mythelyne CoA HMG CoA reductase inhibition on inflammatory in atherosclerosis rabbits" Clinical Science 2003; 105, 655-662.
- 20. Stocker R. Keaney J F; "Role oxidative modifications in atherosclerosis" Physiological review. 2004, 84; 1381-1478.
- 21. Tobias saami, Jose G. Raya Z. cleames C. cyram kal JG. Bochanam, et al,. "High resolution carotid black-blood 3TMR with parallel imaging and dedicated 4-channel surface coils" Journal of cadiovescular magnatic resonance. 2009 (1): 4 Doi; 10.1186-1532. 429x-11-41.)



## **SUMMARY CONCLUSION:**

The entire work on the effect of high lipid diet (30%) on general and Cardiovascular impact in albino Wister rats with special reference to drug 1 Terminalia Arjuna (Arjuna), drug 2 Emblica Officinalis (Amla) and Drug 3 both Terminalia Arjuna (Arjuna) and Emblica Officinalis (Amla) may be summarized as following figure



- High fat diet, even alters Vascular properties in adult male albino Wistar rats of approximately 200 days (Average age, middle age).
- The alteration of vascular integrity is mainly reflected by histopathological changes in arterial tissues, elastic artery, Coronary artery without altering the nitric oxide status in rats with high fat diet.

- The early atherosclerotic changes in coronary artery in high fat fed rat perhaps due to age associated vascular disorders
- Both *Terminalia Arjuna & Emblica Officinalis* are found to be cardioprotective to some extent without influencing any metabolic impairment of liver

#### **SUMMARY**

- 10% of additional fat to Iso-caloric diet for short term duration of time on 200 days old rats develops early alteration in vascular integrity reflected by the mild formation of atherosclerosis plaque in coronary vessels along with increase wall thickness.
- This is further correlated that aortic wall in which significant structural changes by observing elastic artery, muscular artery at the level of tunica media the most.
- The adverse changes on vascular integrity were partial recovered by *Terminalia Arjuna*(Arjuna) and Emblica Officinalis (Amla) perhaps through free radical scavenging

  properties at least in histopathological point of view

#### **LIMITATION:**

Certain molecular markers for vascular integrity like nos3 gene expression Akt gene expression were evaluated in this study, hence the molecular mechanism behind these two drugs Terminalia Arjuna (Arjuna) and Emblica Officinalis to regulate hyperlipidemia induced cardiovascular alteration could not be explored.

#### **FUTURE DIRECTION:**

- 1. Molecular markers to be evaluated
- 2. High dietary lipids induce through study on oxidative and nitrosative stress to be done.
- 3. Active compounds of both the drugs further evaluated by HPLC method.

#### **International Journal of Pharmacy and Pharmaceutical Sciences**

ISSN- 0975-1491 Vol 7, Issue 10, 2015

**Original Article** 

### EFFECT OF ETHANOLIC EXTRACT OF *TERMINALIA ARJUNA* ON LIVER FUNCTIONS AND HISTOPATHOLOGY OF LIVER IN ALBINO RATS FED WITH HYPERLIPIDEMIC DIET

#### SHANKREPPA D. DESAI1, BHEEMSHETTY S. PATIL\*2, PALLAVI S. KANTHE3, POTEKAR R. M.4

<sup>1</sup>Sridevi Institute of Medical Science and Research Centre Tumkur, <sup>2</sup>Dept of Anatomy, <sup>3</sup>Dept of Physiology, <sup>4</sup>Dept of Pathology, Shri B M
Patil Medical College Hospital and Research Centre, BLDE University, Bijapur
Email: dr.patilbs@gmail.com

Received: 10 Jun 2015 Revised and Accepted: 24 Aug 2015

#### ABSTRACT

**Objective**: The aim of the present study was to assess the effect of Ethanolic extract of *Terminalia Arjuna* on Liver functions, Lipid profile and histopathology of liver of albino rats fed with Hyperlipidemic diet.

**Methods**: Extraction of *Terminalia arjuna* bark by Soxhlet apparatus using 99% ethanol at 60 ° temp for 22 h and Phytochemical analysis was done. Group 1 served as normal control. Group 2 Fed with Isocaloric diet. Group 3 Fed with Hyperlipidimic diet. Group 4 Hyperlipidemic diet 21 d+*Terminalia arjuna* 21 d.

Dose of Ethonolic extract of Terminalia arjuna: (500 mg/kg Body weight daily).

**Results:** %body weight gain and hepatosomatic index were significantly improved in hyper lipidemic rats treated with *Terminalia arjuna*. There was significant improvement in markers of liver functions. Liver shown microvescicular and macrovesicular fatty changes in hyper lipidemic rats and normal Hepatocytes in Hyperlipidimic rats treated with *Terminalia arjuna*.

Conclusion: It can be summarized that Terminalia arjuna is good, natural therapeutics in hyperlipidemia and liver disorders.

Keywords: Terminalia arjuna, Hyperlipidimic diet, Histopathology of Fatty Liver, LFT and hepatosomatic Index.

#### INTRODUCTION

This is the speed changing world of extreme disparity like over nutrition and starvation, lifestyle changes and its related diseases, development and environmental degradation. The modern system of medicine is no exception. It cures one hand and trigger side effects on the other [1].

There is increasing demand of people towards an Ayurvedic system of medicines which shows reduced adverse effects on health.

Among many precious herbal drugs *Terminalia arjuna* holds the pride place in the reference of such medicinal value. *Terminalia arjuna* is a deciduous and green tree belongs to *Combretaceae family*, also known as *Arjuna or Arjun tree*. *Terminalia arjuna* tree is about 60 to 80 feet in height it is found in Indo-sub Himalayan tracts of Uttar Pradesh, southern Bihar, Barma, Madhya Pradesh and Duccan region. It grows almost in all types of soils, but prefers humid, fertile loam and lethargic soils.

The bark gets flaked off itself in the month of April-May[2] Its stem bark has active principles like glycosides, flavonoids, tannins and minerals [3]. Flavonoids acts like antioxidants, anti-inflammatory and lipid lowering effect where as glycosides are cardio tonic. It also shows hepato-protective effect [4].

The liver is the primary organ which plays an important role in metabolic and excretion and maintains homeostasis of the body[5] Hyperlipidemia is greatest risk factors for prevalence and severity of coronery heart diseases [6] Hyperlipidemia is also one of the major causes of liver injury. Management of liver diseases still challenges to the modern system of medicine.

Terminalia Arjuna is capable of protecting the liver against hyperlipidaemia, oxidative stress and/or toxin effects [7].

Hence the present study was aimed to assess the effect of Ethanolic extract of *Terminalia arjuna* on liver in albino rats fed with hyperlipidemic diet. The effects were evaluated by measuring the levels of the serum marker enzymes followed by liver histo pathology.

#### **MATERIALS AND METHODS**

Materials: Fresh, bark of *Terminalia arjuna* was procured from the herbal garden of Ayurvedic medical college, during the months of Nov–Dec 2012 identified and authenticated by Department of Botany KCP Science College Bijapur

#### **Extraction of drug**

Ethanolic extract preparation: 250 gms of the powder of the dry bark of *Terminalia arjuna* were extracted with 99% ethanol using a Soxhlet apparatus at a temperature below  $60\,^{\circ}\text{C}$  for 22 h. The solvent was evaporated under vacuum which gave semisolid mass with respect to the dried powder [8].

#### Phytochemical screening

*Terminalia arjuna* was screened for the presence of phenols, flavonoids, tannin, saponin, alkaloids, glycosides, phytosterols and carbohydrates by using standard protocols [9].

#### **Experimental animals**

Albino Wistar rats weighing 160 to 250 gms were obtained from animal house of Shri B M Patil Medical College Hospital and Research Centre, Bijapur. All the four group animals were acclimatized for 7 d to the laboratory conditions at 22-24 °C and maintained 12 HR. Light/dark cycle all the experimental procedures were performed in accordance with the approval of the Institutional Animal Ethics Committee (IAEC) of Shri B M Patil Medical college Hospital and Research Centre, Bijapur. All care has taken on animals during experimental as well as at the time sacrificed as per the guidelines of ICMR on animal research 2006

#### **Experimental protocol**

All the rats were divided into following four groups with 6 rats in each group. Group-I, Fed with water and ad libitum serve as a control, the Group II Fed with Isocaloric diet for 42 d Group-III Fed with high fat diet 42 d, the Group IV Fed with high fat diet and Ethanolic extract of *Terminalia arjuna* (21 d high fat diet+21 d with

Ethonolic extract of *Terminalia arjuna*). It was given daily 500 mg/kg Body Weight, I. P [10].

#### Preparation of isocaloric diet

For 1 kg of diet, 180 gm of casein, 620 gm of carbohydrate, 200 gm of fat and 1% of multivitamin and 2% NaCl was taken [11].

#### Preparation of hyperlipidemic diet

For 1 kg of diet, 180 gm of casein, 520 gm of carbohydrate, 300 gm of fat and 1% of multivitamin and 2% NaCl was taken [11].

#### Sample collection and tissue collection

All the four group animals were sacrificed by cervical dislocation at the end of the last dose after an overnight fast. After heart puncture blood was collected in normal tubes for the separation of serum,

Tissue collection for histopathology: liver was isolated immediately and fixed in 10% neutral buffered formalin solution for 24 h. The fixed tissues were processed routinely, and then embedded in paraffin, sectioned into 4–5  $\mu m$  thickness, deparaffinized, and rehydrated using standard techniques. The extent of Hyperlipidimic diet-induced necrosis and steatosis was evaluated by assessing morphological changes in liver sections stained with hematoxylin and eosin (HandE), using standard techniques.

#### Gravimetry

Estimation Body Weight and Hepato-somatic Index of Albino Wistar rats:

The body weight of all rats was recorded at the beginning of the experiment (day 1), treatment with an Ethanolic extract of *Terminalia arjuna* ( $21^{st}$  day) and on the day of sacrifice ( $42^{nd}$  day). Liver weight was measured to the nearest of 0.1 mg in a single pan balance (Digital weighing machine). Further, we calculated Hepatosomatic index by the formula liver weight/total body weight.

#### **Biochemical analysis**

In biochemical analysis, we estimated lipid profile and liver function test

#### **Estimation lipid profile**

Serum triglycerides (TG), Total Cholesterol (TC), High density lipoprotein (HDL), Low density lipoprotein (LDL) and Very low density lipoprotein (VLDL) were analysed by the MESPA automated Analyzer.




Fig. 1: G1,10X. H and E stain showing normal hepatocytes in lobular pattern

#### Estimation of liver function tests

Serum Bilirubin, total, Serum Glutamic Oxalocetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), Serum Protein, Serum bilirubin, Serum albumin, Serum A/G Ratio and Serum Alkaline Phosphatase (ALP) analysed by Meril diagnostic Kit Method.

#### Statistical analysis

Values are expressed as mean±SD. To determine the significance of intergroup differences, One Way ANOVA followed by 'Post Hoc t tests' by SPSS software was done. №0.05 was considered statistically significant.




Fig. 2: G140X. H and E stain showing normal architecture of liver with portal tried (Bile Duct, Hepatic Artery, and Vein)




Fig. 3: G2 10X H and E stain showing the normal architecture of the Liver with Central vein surrounded by Hepatocytes and intervening Sinusoids




Fig. 4: G2 40X H and E stain showing the normal architecture of the liver with central vein surrounded by hepatocytes and intervening sinusoids

#### RESULTS

We observed a significant increase in levels of TG and VLDL in group 3 (Hyperlipidemic diet fed rats) compared to group 1 (Normal control rats). Group 4 (hyperlipidemic rats treated with ethanolic extract of *Terminalia arjuna*) rats showed a significant increase in levels of TC and LDL compared to Group 1, 2 and 3 respectively. HDL levels showed a significant increase in group 3 (Hyperlipidemic diet fed rats) compared to groups 1 and 2 respectively. We also observed significant decrease in LDL levels in group 3 (Hyperlipidemic diet fed rats) compared to groups 1 and 2 respectively




Fig. 5: G3 10X HandE stain. architecture of liver showing prominent microvesicular and macrovesicular fatty change




Fig. 6: G3 40X HandE stain architecture of liver showing prominent microvescicular and macrovescicular fatty change




Fig. 7: G4 10X HandE stain architecture of liver showing prominent hapatocytes separated by dilated sinusoids




Fig. 8: G4 40X HandE stain architecture of liver showing prominent hapatocytes separated by dilated sinusoids

Table 1: Effect of ethanolic extracts Terminalia arjuna on lipid profile

Parameters	Group 1	Group 2	Group 3	Group 4 ANOVA		
					F value	P value
TG mg/dl	104.5±13.8	134.3±25.1	206.5±90.7a	129±32	4.58	0.013
TC mg/dl	130.6±13.6	122.8±16	123.1±17.5	185±17 <sup>a,b,c</sup>	20.48	0.000
HDL mg/dl	30.3±1.8	30±1.9	$41.8 \pm 14^{a,b}$	36.8±2.5	3.64	0.03
LDL mg/dl	80.6±12.5	64.7±18.5	33±15.8a,b	122.3±14 <sup>a,b,c</sup>	34.7	0.000
VLDL mg/dl	22.7±4.2	28±7.1	40±18a,	25.8±6.4	3.0	0.05

Values are expressed as mean $\pm$ SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c express significant difference between groups. A depicts a comparison with group 1, b depicts a comparison with group 2, c depicts a comparison with group 3. (\*  $\leq$ 0. 05). Group 1 is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is a hyperlipidemic+Ethanolic extract of *Terminalia Arjuna*.

Table 2: Effect of ethanolic extracts *Terminalia arjuna* on markers of liver function

Parameters	Group 1	Group 2	Group 3	Group 4	ANOVA	
		_	_	_	F value	P value
Serum	0.6±0.1	0.6±0.1	0.7±0.1	0.8±0.1	2.11	0.13
Bilirubin mg%						
SGOT U/l	76.6±6.5	51.3±8a	70±28b	50±8.1 <sup>b</sup>	3.38	0.000*
SGPT U/l	59.5±19	47.1±5.6a	64.5±12 <sup>b</sup>	46±3.6b	3.03	0.000*
Serum	5.7±0.2	6±0.3	$5.7 \pm 0.2$	5.6±0.2	1.38	0.16
Protein gm/dl						
Serum	2.9±0.1	$3.4 \pm 0.3^{a}$	3±0.1b	$2.8 \pm 0.1^{b}$	6.99	0.002*
Alb gm/dl						
Serum	1±0.1	$1.3 \pm 0.2^{a}$	1±0.1	$0.98 \pm 0.04$ b	5.21	0.008*
A/G gm/dl						
Serum	153±16	174±26	187±50	161±18	1.4	0.27
ALP U/l						

Values are expressed as mean $\pm$ SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c express significant difference between groups. A depicts a comparison with group 1, b depicts a comparison with group 2, c depicts a comparison with group 3. (\*  $\leq$ 0.05). The group 1 is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is a hyperlipidemic+Ethanolic extract of *Terminalia Arjuna*.

We observed significant higher levels of SGPT and SGOT in group 3 compared to group 2(\*P<0.05). Similarly, we observed significant changes for SGPT and SGOT in group 2 and group 4.

There was significantly higher values of Serum albumin and the Serum A/G ratio in group 2 compared to group 1(\*p<0.05). Group 4 has shown significant lesser values of Serum albumin and the Serum A/G ratio compared to group 2(\*p<0.05).

We also observed no significant differences for serum bilirubin, serum protein and serum ALP among all groups.

We observed no significant differences for % body weight gain among all groups at  $21^{\rm st}$  day.

Similarly, we observed significantly decreased in % body weight in group 4 compared to group 1, 2 and 3 (\*p<0.05).

Table 3: Effect of ethanolic extracts Terminalia arjuna on % body weight gain

% Body weight gain	Group 1	Group 2	Group 3	Group 4	ANOVA	
					F value	p value
At 21st day	20.6±1.2	22.4±1.7	20.9±2	21.5±1.9	1.27	0.30
At 42 <sup>nd</sup> day	17.5±2	18.6±1.3	19.1±2	$14.4 \pm 1.3^{a,b,c}$	8.68	0.001*

Values are expressed as mean±SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c express significant difference between groups. A depicts a comparison with group 1, b depicts a comparison with group 2, c depicts a comparison with group 3. (\* ≤0.05). Group I is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is a hyperlipidemic+Ethanolic extract of *Terminalia Arjuna* 

Table 4: Effect of ethanolic extracts *Terminalia arjuna* on hepato-somatic index

Oregano somatic index	Group 1	Group 2	Group 3	Group 4	ANOVA	
					F value	p value
Hepato-Somatic Index	0.03±.003	0.026±.002a	0.02±.003a	0.02±0.002 c	14.307	0.000

Values are expressed as mean±SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c express significant difference between groups. A depicts a comparison with group 1, b depicts a comparison with group 2, c depicts a comparison with group 3. (\* ≤0.05). Group I is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is a hyperlipidemic+Ethanolic extract of *Terminalia Arjuna* 

We observed the significant decrease in the hepatic-somatic index in group 2, 3 compared to group 1. Also significant difference was seen in between group 3 and group 4 (\*p<0.05).

#### Effect of Terminalia Arjuna (Ethanolic Extract) on liver histopathology

Fig. 1 and 2, G1 (Group 1) 10X and 40X HandE stain histopathology section of liver shown normal hepatic architecture compressed of hepatic lobules formed by the central vein and the cords of hepatocytes with indistinct sinusoidal dilatation in fig. 3,4,7and8. G2and4 (Group 2and4)10X and 40X HandE stain shown prominent sinusoidal dilatation.

Whereas G3 (Group 3)10X and 40X HandE stain histopathology shown lobular architecture of the liver with enlarged hepatocytes containing microvescicular and macrovesicular fatty changes with sinusoidal congestion.

G4 (group 4) Bark extract of *Terminalia arjuna* (500 mg/Kg body weight) treated rats histopathology section of liver shown normal hepatic architecture

#### DISCUSSION

In the present study Ethanolic extract of *Terminalia arjuna* bark was tested for their hepato-protective activity in albino rats fed with hyperlipidemic diet. The degree of protection was assessed using markers of liver functions like serum albumin, serum globulin, serum A/G, SGPT, SGOT and serum ALP along with histopathological study.

The peculiar sign of hepatic damage is leakage of cellular enzymes into the serum. The SGPT, SGOT and ALP are important cellular enzymes [12].

When there is hepatopathy, these enzymes leak into the blood stream from the cytoplasm with an extent of liver damage. AST, ALT and bilirubin levels are commonly measured as an indication of hepatocellular integrity. ALT is frequently used as the biochemical parameter to asses hepatic injury[Anitha] [13]In the present study, increased levels of serum SGPT, SGOT and ALP in hyperlipidemic rats showed the damage of liver tissue. The decreased level of serum

SGOT, SGPT and ALP in hyperlipidemic rats treated with *Terminalia arjuna* showed repair of hepatic cells by restoring cell permeability. Similar findings were observed in Hardik Soni *et al.* study [9].

In the present study, we observed a nonsignificant increase in bilirubin level in hyperlipidemic rats treated with *Terminalia arjuna* compared to hyperlipidemic rats. In contrast, P Doorika *et al.* reported significant decrease in bilirubin levels in rats treated with *Terminalia arjuna* [4].

The liver plays an important role in the synthesis of protein like Albumin [15].

Akanksha P S, *et al.* reported decreasing level of albumin, total protein level and damage to the normal architecture of the liver. Similar findings were observed in our study [5].

We observed marked structural alteration, i.e. microvescicular and macrovesicular fatty changes in histopathology of liver of rats fed with high fat diet. Hyper lipidemic rats treated with ethanolic extract of *Terminalia arjuna* is shown normal architecture of liver histology. Ragavan, B., *et al.* reported in their study, high fat diet induced rat treated with *Terminalia arjuna* bark extract shown to partially reverse the damage (Fatty changes) [16].

#### CONCLUSION

The present findings demonstrated the hepatoprotective effect of *Terminalia arjuna* bark extracts on hyperlipidemic rat models. This plant can be used as hepato protecting due to the presence of various bioactive compounds such as phenolics, flavonoids, tannins etc. To explore the precise mechanism of action of specific biological active principles, further processing of the ethanolic fraction of *Terminalia arjuna* is required.

#### ACKNOWLEDGEMENT

I sincerely thank to Dr Kusal K Das Prof. Dept of Physiology. Shri B. M. Patil Medical College, Bijapur, for his valuable suggestions in writing the manuscript.

#### CONFLICT OF INTERESTS

Declare None

#### REFERENCES

- Sheel Sharma, Deeksha Sharma, Nidhi Agarwal. Diminishing effect of arjuna tree (*Terminalia arjuna*) bark on the lipid and oxidative stress status of high fat, high cholesterol fed rats and development of certain dietary recipes containing the tree bark for human consumption. Res Pharm 2012;2:22-30.
- Dwivedi, Shridhar, Deepti Chopra. Revisiting Terminalia Arjuna-An ancient cardiovascular drug. J Traditional Complementary Med 2015;4:224-31.
- Saravanan Subramaniam, Ramachandran Subramaniam, Suja Rajapandian, Subasini Uthrapathi, Victor Rajamanickam Gnanamanickam, Govinda Prasad Dubey. Anti-atherogenic activity of ethanolic fraction of terminalia arjuna bark on hypercholesterolemic rabbits. Evidence-Based Complementary Altern Med 2009;2011:1-8.
- 4. P Doorika,T Ananthi. Antioxidant and hepatoprotective properties of *Terminalia Arjuna* bark on isoniazid induced toxicity in albino rats. Asian J Pharm Tech 2012;2:15-8.
- Akanksha PS Vishwakarma, Akash Vishwe, Prashant Sahu, Anand Chaurasiya. Screening of hepatoprotective potential of ethanolic and aqueous extract of *Terminalia Arjuna* bark against paracetamol/ccl4 induced liver damage in Wistar albino rats. Int J Pharm Arch 2013;2:243-50.
- Nabil M taha, Abed Elwhaba Mandour, Mahdy K Mohamed, Rasha T emarha. Effect of sesame oil on serum and liver lipid profile in hyperlipidemic rats. Alexandria J Veterinary Sci 2014.42:17-25.
- 7. Narendra Kumar. Phytopharmacological overview on *Terminalia Arjuna* Wight and Arn. World J Pharm Sci 2014;2:1557-66.

- 8. Shreya Mandal, Arpita Patra, Animesh Samanta, Suchismita Roy, Arpita Mandal, Tapasi Das Mahapatra, *et al.* Analysis of phytochemical profile of *Terminalia arjuna* bark extract with antioxidative and antimicrobial properties. Asian Pac J Trop Biomed 2013;3:960-6.
- 9. Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical screening and extraction: a review. Int Pharm Sci 2011;1:103-4.
- 10. Ram A, Lauria P, Gupta R. Hypocholesterolaemic effects of *Terminalia arjuna* tree bark. J Ethnopharmacol 1997;55:165-9.
- 11. Bheemshetty S Patil, Shankreppa D Desai, Potekar RM. Effect of ethanolic extract of *Emblica Officinalis* (amla) on pathophysiology of liver in hyperlipidemic albino Wister rats. Int J Pharma Bio Sci 2015;6:(b)362–72.
- 12. Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 2005;71:1105-10.
- Anitha Uthandi, Karuppasamy Ramasamy. Hapatoprotective activity of sesame meal on high fat fed wistar rats. Int J Pharm Sci Res 2011;2:205-11.
- 14. Hardik Soni, Priyanka Desai, Natvarlal Patel, Ghanshyam Patel. Pharmacological investigation of polyherbal formulation on carbon tetrachloride (CCl4)-induced liver damage in Wistar rats. Int J Pharmacol Res 2014;4:106-10.
- Kim E Barrett, Sysan M Barman, Scott Boitano, Heddwen L Brooks. Transport and metabolic functions of the liver. 23<sup>rd</sup> ed. In Gannong's Review of Medical Physiology. MC Graw Hill; 2010. p. 479-86.
- Ragavan B, Krishnakumari S. Effect of *T. Arjuna* stem bark extract on histopathology of liver, kidney and pancreas of alloxan-induced diabetic rats. Afr J Biomed Res 2006;9:189–97.

Research Article Allied science



#### **International Journal of Pharma and Bio Sciences**

ISSN 0975-6299

# EFFECT OF ETHANOLIC EXTRACT OF *EMBLICA OFFICINALIS (AMLA)* ON PATHOPHYSIOLOGY OF LIVER IN HYPERLIPIDEMIC ALBINO WISTER RATS.

#### BHEEMSHETTY S. PATIL\*1, SHANKREPPA D. DESAI2 AND POTEKAR R M3

#### **ABSTRACT**

It has been reported that hyperlipidemia plays central role in the development of atherosclerosis, liver disorders and oxidative stress. Embilica officinalis also known as Amla or Indian Gooseberry acts as antihyperlipidemic, antioxidant and liver tonic. It actively contains tannins, gallic acids and flavonoids. Aims: To evaluate the effect of the Ethonolic extract of *Emblica Officinalis* on pathophysiology of liver and on biochemical parameters in Hyperlipidimic albino Wister rats. Extraction of Emblica Officinalis by Soxhlet apparatus using 99% ethanol at 60° temp for 24hrs and Phytochemical analysis was done. Group I served as normal control. Group II Fed with Isocaloric diet. Group III Fed with Hyperlipidimic diet. Group IV. (Isocaloric diet 21 days + Embilica Officinalis 21 days). ok(hyperlipidemic diet 21 days+ Embilica Officinalis 21 days). Dose of ethonolic extract of Emblica Officinalis: (100mg/kg b. wt daily). %body weight gain, liver weight and hepatosomatic index were significantly improved in hyperlipidemic rats treated with Amla. There was significant improvement in lipid profile and markers of liver functions. Liver shown fatty changes in hyperlipidemic rats and normal Hepatocytes in Hyperlipidimic rats treated with Amla. It can be concluded that amla may be effective, natural therapeutics in hyperlipidemia and liver disorders.

**KEYWORDS:** *Emblica Officinalis*, Hyperlipidimic diet, Histopathology of Fatty Liver, LFT, Lipidprofile

**BHEEMSHETTY S. PATIL** 

\*Corresponding author

Lecturer Dept of Anatomy Shri B M Patil Medical College Hospital & Research Centre, BLDE University Bijapur

<sup>&</sup>lt;sup>1</sup>Lecturer Dept of Anatomy Shri B M Patil Medical College Hospital & Research Centre, BLDE University Bijapur <sup>2</sup> Principal Sridevi Institute of Medical Science and Research Centre Tumkur

<sup>&</sup>lt;sup>3</sup>Prof Dept of Pathology, Shri B M Patil Medical College Hospital & Research Centre, BLDE University, Bijapur.

#### INTRODUCTION

According to the model texts Charak Samhita and Shushruta Samhita Embilica Officinalis regarded as "One of the best rejuvenating herbs". The fruits of Embilica Officinalis are used as dietary and medicinal purposes by Indian system of medicine.<sup>2</sup> It is commonly known as Amla or Indian gooseberry. The major principles of Embilica Officinalis are hydrolyzable tannins (embilica A & B), Gallic acid flavonides, flavones and ascorbic acid. The Embilica Officinalis exerts various biological functions such as antioxidant, anti-atherosclerosis, antidiabetic, hypolipidemic, gastroprotective and cytoprotective. Along with these functions Embilica Officinalis also produce beneficial effects on liver functions As well as hyperlipidemia and syndrome.<sup>3</sup> As liver is the major organ of metabolic and energy homeostasis. Its balanced over levels of endogenous actions are metabolites such as TG, TC, HDL and glucose.4 hepatoprotective actions of Embilica Officinalis noticed to be mediated by its free radical scavenging, antioxidant and modulation of lipid metabolism.<sup>2</sup> In the present study we tried to or is it to prove? the effect of Embilica Officinalis on pathophysiology of liver of hyperlipidemic rats. We induced hyperlipidemic diet to the albino wister rats to develop an animal model of metabolic syndrome expressing fatty liver and other cardiovascular risk factors. Hyperlipidemic diets generate atherosclerosis, changes in lipids and hepatic steatosis.<sup>5</sup> Atherosclerosis is a disease that involves the interplay of several factors like oxidation of lipoproteins, formation of atherosclerotic plaques.<sup>6</sup> Amla like statins acta to inhibit HMGcoA reductase activity and ellagic acid acts to inhibit cholesterol biosyn thesis to cholesterol biosynthesis. Hence the present study investigated the therapeutic efficacy of Embilica Officinalis extract on pathophysiology of liver of hyperlipidemic albino wister rats.

#### **MATERIALS AND METHODS**

#### Materials

Fresh, mature, healthy and good quality fruits of *Emblica Officinalis* (Amla) were procured from the local market, during the months of November–December 2012 identified and

authenticated. Ethonolic extract preparation: 300gms of the powder of dry fruits of *Emblica Officinalis* was extracted with 99% ethanol using Soxhlet apparatus at a temperature below 60° C for 24 hours. The solvent was evaporated under vacuum which gave semisolid mass with respect to the dried powder.

#### **Experimental Animals**

Albino wister rats weighing 180 to 250gms were obtained from animal house of Shri B M Patil Medical college Hospital & Research Centre, Bijapur. All the five group animals were acclimatized for 7 days to the laboratory conditions at 22-24°C and maintained 12 hr. light/dark cycle All the experimental procedures were performed in accordance with the approval of the Institutional Animal Ethics Committee (IAEC) of Shri B M Patil Medical college Hospital & Research Centre, Bijapur. All care was taken for animals during experimental as well as at the Time of sacrification as per the guidelines of ICMR on animal research Reference?

#### Experimental protocol

All the rats were divided into following five groups with 6 rats in each group. Group-I, Fed with water and ad libitum serve as control, Group II Fed with Isocaloric diet for 42 days Group-III Fed with high fat diet 42 days, Group IV fed with Ethanolic extract of Emblica Officinalis (EEO) (21 days Isocaloric diet + 21 days with EEO) and Group V Fed with high fat diet and EEO Ethonolic extract of *Emblica Officinalis* (21 days high fat diet + 21 days with EEO). It was given daily 100mg/kg B.Wt, I.P.

#### Sample collection and Tissue collection

All the five group animals were sacrificed by cervical dislocation at the end of the last dose after an overnight fast. After heart puncture blood was quickly collected in 10% EDTA tubes for the separation of serum. Tissue collection for histopathology: liver was isolated immediately and fixed in 10% neutral buffered formalin solution for 24 hours. The fixed tissues

were processed routinely, and then embedded in paraffin, sectioned to 3–5  $\mu$ m thickness, deparaffinized, and rehydrated using standard techniques. The extent of Hyperlipidimic dietinduced necrosis and steatosis was evaluated by assessing morphological changes in liver sections stained with hematoxylin and eosin (H&E), using standard techniques.

#### Gravimetry

#### Estimation Body Weight and Hepatosomatic Index of Albino Wister rats

The body weight of all rats was recorded at the beginning of experiment (day 1), treatment with *Emblica Officinalis* (21<sup>st</sup> day) and on the day of sacrifice (42<sup>nd</sup> day). Liver weight was measured to the nearest of 0.1 mg in a single pan balance (Digital weighing machine). Further hepatosomatic index was calculated by the formula liver weight/ total body weight.

# Determination of Hematological Parameters Hb%, RBC, WBC, Platelet, PCV & MCHC these Hematological parameters like Hb% and MCHC were evaluated in were evaluated in Sysmax -21, automated analyzer.

## Biochemical Analysis Estimation of Lipid profile

Serum triglycerides (TG), Serum total cholesterol (TC), High-density lipoprotein (HDL), Low-density lipoprotein (LDL) and Very Low-density lipoprotein (VLDL) were analyzed by MESPA automated analyzer (Method GOD POD)

#### **Estimation of Liver Function Tests**

Serum Glutamic Oxalocetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), Serum Protein, Serum bilirubin, Serum albumin, Serum A/G Ratio and Serum Alkaline Phosphtase (ALP) were analyzed by Meril diagnostic Kit Method.

#### STATISTICAL ANALYSIS

Values are expressed as Mean ± SD. To determine the significance of inter group differences, One Way ANOVA followed by 'Post Hoc t tests' were done. P≤0.05 was considered statistically significant.

#### **RESULTS**

Table1

Effect of Ethanolic extract of Embilica Officinalis (Amla) on % body weight gain (on 21<sup>st</sup> day and 42<sup>nd</sup> day) on different groups of rats.

% body	Group I	Group II	Group III	Group IV	Group V	ANC	OVA
weight gain						F value	P value
At 21 <sup>st</sup> day	21±1.7	14.7±4.8 <sup>a</sup>	17.5±4.5	21.6±1.2b	15.6±2.2d	5.331	0.003
At 42 <sup>nd</sup> day	15 6+0 7	14.7±2.4	17.1±2.4	8 6+2 6 <sup>a,b,c</sup>	8 8+3 4 <sup>a,b,c</sup>	17.6	0.00

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group I, b depicts comparison with group II, c depicts comparison with group III and d depicts comparison with group IV.(\*  $\leq$ 0.05). GroupI is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is ethanolic extract of Amla

#### Table1 At 21<sup>st</sup> day

We observed significant decrease in % body weight gain in group II compared to group I. Group IV showed significant elevation in % body weight gain compared to group II. There was significant decrease in % body weight gain in group V compared to group IV.

#### At 42<sup>nd</sup> day

Group IV and V depict significant decrease in % body weight gain compared to group I, II and III.

Table 2
Effect of Ethanolic extract of Embilica Officinalis (Amla) on Liver weight and Hepatosomatic index of different groups of rats.

Parameters	Group I	Group II	Group III	Group IV	Group V	ANOVA	
						F Value	P value
Weight of Liver	7.73±0.17	8.87±0.95	6.72±0.36	7.67±0.22	6.68±0.83	2.246	0.093
Organosomatic Index	0.03+0.00	0.03+0.00	0.02+0.00	0.03+0.00	0.02+0.00	1.416	0.258

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group I, b depicts comparison with group II, c depicts comparison with group IV.(\* $\leq$ 0.05). GroupI is normal control rats, Group II is Isocaloric diet fed rats, Group II is hyperlipidemic diet fed rats, Group IV is ethanolic extract of Amla fed rats, Group V is hyperlipidemic + Ethanolic extract of Amla

#### Table 2

depicts no statistical significant differences of liver weight and Hepato somatic index among all five groups of rats.

Table 3

Effect of Ethanolic extract of Emblica Officinalis on Heamatological parameters in different groups of albino wistar rats.

Parameters	Group I	Group II	Group III	Group IV	Group V	ANOVA	
	-	-	-	-	-	F value	P value
Hb%	12.8±1.1	12.9±1.2	12.8±0.5	13.3±0.14	12±0.8	1.682	0.18
WBC	7783±2806	7266±2084	5633±1723	7383±2918	6566±1538	0.82	0.52
RBC	7.4±0.9	7.3±0.8	7.3±0.3	8±0.2	6.8±0.3 <sup>d</sup>	2.667	0.03
Platelet	8.1±2.6	6.4±2.2	7.6±1.2	9.7±0.3	8.2±2.7	2.041	0.11
PCV	44.6±5.4	43.6±4.8	42.1±2.3	47.9±1.9	39.8±2.5 <sup>d</sup>	3.895	0.01
MCHC	28 9+1 3	29 6+0 6	30.5+0.8	28 1+1 1 <sup>c</sup>	30.3+1.7 <sup>d</sup>	4 286	0.009

Values are expressed as mean $\pm$ SD ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a,b,c,d express significant difference between groups. . a depicts comparison with group I, b depicts comparison with group II, c depicts comparison with group IV.(\*  $\leq$ 0.05). GroupI is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is ethanolic extract of Amla fed rats, Group V is hyperlipidemic + Ethanolic extract of Amla

#### Table 3

Values of Hb%, WBC and platelet have shown statistically non significant differences among all groups. RBC and PCV were significantly lower in group V compared to IV. We observed no significant relation for RBC and PCV

between groups III and V. MCHC value has shown significantly higher values in group V compared to IV. Also there was significantly lower MCHC value in group IV compared to group III.

Table 4

Effect of Ethanolic Extract of Embilica Officinalis on lipid profile parameters in different groups of rats.

Parameters	Groupl	roupl Group II	Group III	Group IV	Group V	ANOVA		
	-	-	-		-	F value	P value	
TG mg/dl	160.1±20.8	140.3±35.9	200.3±93.2 <sup>a</sup>	110±23.5°	129±32.2	3.60	0.01	
TCmg/dl	130.6±13.6	122.8±16.1	123.1±17.5	131.5±15.8	185±17.1 <sup>a,b,c,d</sup>	15.8	0.000	
HDLmg/dl	30.3±1.86	30.0±1.89	41.8±14 <sup>a,b</sup>	29.6±1.86°	36.8±2.5	4.08	0.01	
LDLmg/dl	80.6±12.5	64.7±18.5	33±15.8 <sup>a,b</sup>	79.8±12.8°	122.3±14.1 <sup>a,b,c,d</sup>	27.94	0.000	
VI DI ma/dl	22 7+4 2	28+7 1	44+18 6a	22+4 7 <sup>c</sup>	25+6.7	3 319	0.026	

Values are expressed as mean  $\pm$ SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c, d express significant difference between groups. a depicts comparision with group I, b depicts comparison with group II, c depicts comparison with group III and d depicts comparison with group IV.(\*  $\leq$ 0.05). GroupI is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is ethanolic extract of Amla.

#### Table 4

Levels of TG were significantly higher in group III compared to group I. Group IV showed significant decrease in TG levels compared to group III. No significant differences were observed for TG levels between group IV and group V. TC levels were significantly higher in group V compared to group I, II,III & IV. We observed significantly higher values of HDL in group III compared to group I and group II. HDL levels showed significantly lower values in group IV compared to group III. No significant differences were observed between group III

and V although there were decreased in HDL levels in group V. LDL levels were significantly lower in group III compared to group I & II. We observed significantly higher values of LDL in group IV compared to group III. Also, there were significantly higher values of LDL in group V compared to Group I, II, III and IV. Group III showed significant higher levels of VLDL compared to group I. It was shown significant decrease in VLDL levels in group IV compared group III. No significant differences were observed for VLDL between group III and V.

Table 5
Effect of Ethanolic extract of Embilica Officinalis on liver parameters
in different groups of albino wistar rats

Parameters	Groupl	Group II	Group III	Group IV	Group V	ANOVA	
	•	•	•	•	•	F value	P value
Serum bilirubin mg%	0.83±0.1	0.6±0.01	0.78±0.1	0.8±0.1	0.68±0.19	2.55	0.06
SGOT U/L	51.6±8.98	73.6±6.5	70.1±28.9	51.3±8.1	18.6±5.04 <sup>a,b,c,d</sup>	13.5	0.00
SGPT U/L	48.1±4.83	59.5±19.7	64.5±12.5	47.16±5.67	22.83±4.26 <sup>a,b,c,d</sup>	12.52	0.00
Serum protein gm/dl	5.68 ±0.26	5.71 ± 0.25	5.7 ±0.25	5.6 ± 0.24	6.01±0.38	1.58	0.21
Serum albumin gm/dl	2.9±0.16	2.9±0.1	3±0.19	2.86±0.13	3.4±0.34 <sup>a,b,c,d</sup>	6.44	0.001
A/G ratio gm/dl	0.9±0.08	1±0.10	1±0.11	0.98±0.04	1.30 ±0.24 <sup>a,b,d</sup>	6.42	0.001
Alkaline phos U/L	16.3±1.7	15.3±1.6	18.7±5	16.1±1.8	17.2±2.6	1.27	0.30

Values are expressed as mean  $\pm$ SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c, d express significant difference between groups. . a depicts comparison with group I, b depicts comparison with group II, c depicts comparison with group III and d depicts comparison with group IV.(\*  $\leq$ 0.05). Group I is normal control rats, Group II is Isocaloric diet fed rats, Group III is hyperlipidemic diet fed rats, Group IV is ethanolic extract of Amla

#### Table 5

Serum bilirubin, serum protein and alkaline phosphate have shown statistically non significant differences among all groups. SGOT, SGPT and serum albumin levels were significantly lower in group V compared to group I, II, III and IV. A/G ratio was significantly higher in group V compared to I, II and IV

#### THE HISTOPATHOLOGY OF LIVER

Group I histopathology section of liver shown normal hepatic architecture compressed of

hepatic lobules formed by central vein and cords of hepatocytes with indistinct sinusoidal dilatation but whereas Group II,IV& Vhas shown prominent sinusoidal dilatation (Fig. 1.2.4 & 5 H&E A10X and B40X) Group III: histipathology of liver shown lobular architecture of the liver with enlarged hepatocytes containing microvescicular and macrovesicular fatty changes with sinusoidal congestion. (Fig 3 H&E A10X and B40X)

#### FIGURES: Showing Histopathology of Liver]




Figure 1 Group I A. Showing normal Hepatocytes in lobular pattern in 10X




Figure 2 . Group I. B. Showing normal architecture of liver with portal tried (Bile Duct, Hepatic Artery, & Vein) in 40X




Figure 3 Group II. A. Showing normal architecture of Liver with Central vein surrounded by Hepatocytes and intervening Sinusoids in 10X.




Figure 4
Group II. B. Showing normal architecture of Liver with Central vein surrounded by Hepatocytes and intervening Sinusoids in 40X




Figure 5
Group III. A. Architecture of liver showing prominent Macrovesicular & Microvesicular fatty change in 10X




Figure 6
Group III.B. Architecture of liver showing prominent Macrovescicular & Microvescicular fatty change in 40X




Figure 7 Group IV A. Architecture of liver showing prominent Hapatocytes separated by dilated sinusoids in 10X




Figure 8 Group IV B. Architecture of liver showing prominent Hapatocytes separated by dilated sinusoids in 40X




Figure 9 Group V A. Architecture of liver showing Hepatocytes separated by dilated sinusoids in 10X.




Figure 10

Group V. B. Architecture of liver showing Hepatocytes separated by dilated sinusoids in 40X

#### **DISCUSSION**

Animal models offer an appropriate mode to explore and understand the pathophysiology of disease and open the door to prevent or to treat the studied disease. Studies on such models significantly add towards enriching knowledge in the field of medical research. Hyperlipidemic animal models express clinical manifestations of fatty liver and other cardiovascular risk factors. The hyperlipidemic effects of the diet demonstrated in the increased body weight and lipid profile in albino wister rats.<sup>5</sup> And the hyperlipidemic rats treated with Embilica Officinalis showed normal body weight, lipid profile as well as normal liver histology. We observed decrease in % body weight gain in rats treated with Embilica Officinalis compared to Group I at 21st day. Also, there was a significant decrease in % body weight gain in rats treated with Embilica Officinalis compared to hyperlipidemic rats and control at 42<sup>nd</sup> day. There was no significant difference observed hyperlipidemic rats treated with between Embilica Officinalis and rats treated with only Embilica Officinalis at 42<sup>nd</sup> day, this could be due to excessive breakdown of tissue proteins and catabolism of fats and proteins.8 B Antony et al, reported in their study a significant reduction in TC, LDL, VLDL & TG whereas there was significant elevation in the HDL level after treatment with Embilica Officinalis. In addition haemogram showed improved levels of Hb. RBC and other cells. Similar results were

observed in our study. Anju Lama et al showed significant increase in all the lipid parameters (p < 0.01) except HDL following administration of high fat diet. It was also seen that administration of the EEO at a dose of 1 gm/kg body weight along with high fat diet in the experiment animals, showed a significant decrease in all the lipid parameters (p < 0.01) with a significant rise in the value of HDL (p <0.01).6 We found a significant increase in levels of TC and LDL in group V (hyperlipidemic rats treated with Amla) compared to groups I, II, III and IV. SGOT & SGPT are definitive indicators of liver parenchymal injury. The enhanced levels of plasma SGOT and SGPT may be due to the leakage of these enzymes from liver cytosole to the blood stream which is the marker of hepatic toxicity. 9 Manik K Singh et al, reported no significant effect on SGOT and SGPT levels in mice treated with Amla as compared to control. In contrast, we observed significant decrease in levels of SGOT and SGPT in group V( Hyperlipidemic rats treated with Amla) compared to group I, II, III and IV.<sup>10</sup> Rupal A Vasant et al observed significantly reduced plasma ALP levels in the rats treated with Amla (FEo 2.5, FEo 5, FEo 10) compared to normal control and fluoride control groups. In our study, we have shown no significant plasma ALP levels in group V (Hyperlipidemic rats treated with Amla) compared to group I, II, III and IV.11 In our study, histopathological

analysis at the end of 3 weeks showed increased fat deposition in liver of rats fed with hyperlipidemic diet Group II Similar observation was reported by Jasmine Bathera et al in their Thev showed hepatocellular deposition and ballooning in the liver samples of high fat fed hamsters compared to control hamsters. Control hamsters showed normal liver histology.<sup>5</sup> Jitendra Kumar et al, reported significant decrease in albumin concentration in Amla treated chickens compared to control. In contrast, our study has shown significant increase in serum albumin in group V( Hyperlipidemic diet + Amla treatment)compared to all four groups. They have also shown significant increase in levels of serum protein and non significant reduction of A/G ratio in Amla treated group as compared to control group. 12 Whereas our study has shown significant increase in A/G ratio in group V compared to group I, II and IV. The liver samples of Group III Hyperlipidimic rats showed architecture lobular with Hepatocytes containing microvesicular and macrovesicular fatty changes with sinusoidal congestion in (Fig 5. Group III A. H&E 10X, Fig 6 group 3.B H&E 40X). Administration of Hyperlipidimic diet with Emblica Officinalis showed near normal appearance Hepatocytes (Fig. 9. Group V A H&E 10X, Fig. 10. Group V.B. H&E 40X). Similar observation was found in V. Damodara Reddy et al study. 13 Although the exact mechanism by which amla exerts this beneficial effect is presently not clear, it brings about favorable changes in the lipid profile via several mechanisms, including interference with cholesterol absorption. inhibition of HMG-CoA reductase activity, and increase in lecithin cholesterol acvl

transferase activity. 14 The mechanism by which Embilica Officinalis exerts its beneficial effects may be like Statins. Embilica Officinalis is containing phenolic groups like Tannins, Gallic acid which act like Statin. Like Statin, Embilica Officinalis inhibits HMG CoA reductase activity. Ellgitannins and Ellagic acid obtained on hydrolysis of tannins inhibits epoxidase enzyme, a rate limiting enzyme of cholesterol biosynthesis. Embilica Officinalis contains many liver tonic which can be used against acute viral hepatitis and other liver disorders. 15 In our study we tried to investigate positive of Emblica Officinalis influence pathophysiology of liver of hyperlipidemic albino wister rats. We observed Embilica Officinalis hyperlipidemia useful regulating pathophysiology of liver in albino wister rats fed with hyperlipidemic diet.

#### CONCLUSION

It can be concluded from our study that *Embilica Officinalis* may be good, natural potential therapeutics for Dyslipidemia and hepatic dysfunction. However extensive clinical studies are required in large numbers of patients to establish the efficacy and safety *of Embilia Officinalis* in the management of Dyslipidemia and related disorders like atherosclerosis and hepatic dysfunction.

#### **ACKNOWLEDGEMENT**

I sincerely thank to Dr Kusal K Das Prof. Dept of Physiology. Shri B M Patil Medical College, Bijapur, for his valuable suggestions in writing manuscript.

#### REFERENCES

- 1. Patel Snehal S, Goyal Ramesh K. Prevention of diabetes-induced myocardial dysfunction in rats using the juice of the *Emblica officinalis* fruit. Exp Clin Cardiol, Vol 16 No 3:87-91, (2011)
- 2. Thilakchand KR, Mathai RT, Simon P. Hepatoprotective properties of the Indian gooseberry (Emblica officinalis Gaertn): a
- review. Food Funct, 4(10):1431-41(2013 Oct)
- 3. Varghese L.S., Alex N., Ninan M.A. Evaluation of *in vitro* antibacterial activity whole plant (fruits, seeds, stem, leaves and roots) of *Emblica Officinalis* gaertn. International journal of Ayurvedic & herbal medicine, 3(6):1420-1425,(2013 Nov-Dec)

- 4. Tadeja Režen, Viola Tamasi, Anita Lövgren-Sandblom. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics, 10:384, (2009)
- 5. Bhathena Jasmine, Kulamarva Arun, Martoni Christopher. Diet-induced metabolic hamster model of nonalcoholic fatty liver disease. Diabetes, Metabolic Syndrome and Obesity:Targets and Therapy, 4: 195- 203,(2011)
- 6. Anju Lama and Saikia Hiteswar. Effects of *Emblica Officinalis* (AMLA) on Serum Lipids and Atherogenesis in Albino Rats Fed with High Fat Diet. Indian Medical Gazette, 271- 275,(July2013)
- 7. B Antony, M Benny and T N B Kaimal. A pilot clinical study to evaluate the effect of *Emblica Officinalis* extract (amlamaxtm) on markers of systemic inflammation and dyslipidemia. Indian Journal of Clinical Biochemistry, 23 (4): 378-381,(2008)
- 8. Patel Snehal S, Goyal Ramesh K, Shah Rajendra S. Experimental study on effect of hydroalcoholic extract of *Emblica officinalis* fruits on glucose homeostasis and metabolic parameters. AYU, 34(4): 440- 444,(Dec 2013)
- Mazumder S, Mukherjee S, Mitra A, 9. Karmakar S, Das AS, Mukherjee M. Folic acid or combined of folic acid and vitamin12 prevent short term arsenic trioxide-induced systemic and mitrochondrial dysfunction and DNA damage. Biophys,860:277-Environ 85,(2009)
- Singh Manish K., Dwivedi Shailendra, Yadav Suraj S. Arsenic-Induced Hepatic

- Toxicity and Its Attenuation by Fruit Extract of Emblica officinalis (Amla) in Mice. Ind J Clin Biochem, 29(1):29–37,(Jan-Mar 2014)
- 11. Rupal Α. Vasant, Α. ٧. R. Narasimhacharya. Amla as an antihyperglycemic and hepato-renal protective agent in fluoride induced toxicity. Journal of Pharmacy and Bio allied Sciences, Vol 4 Issue 3: 250-254.(July- Sep 2012)
- 12. Jitender Kumar, Singh Vashwant, Verma Pawan K. Effect of dietary supplementation of *Emblica officinalis* on biochemical indices in Vanaraja chicks. Indian Journal of Animal Sciences, 80 (1): 78–80,(Jan 2010)
- 13.) Reddy V. Damodara, P. Padmavathi
   •S. Gopi. Protective Effect of Emblica officinalis Against Alcohol-Induced Hepatic Injury by Ameliorating Oxidative Stress in Rats. Ind J Clin Biochem, 25(4):419–424,(Oct-Dec 2010)
- 14. Pingali Usharani, Nishat Fatima and Nizampatnam Muralidhar. Effects of *Phyllanthus Emblica* extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 6: 275–284,(2013)
- 15. Rehaily AJAI, TAAI Howiriny, Sohaibani MOAI.Gastro protective role of (Amla) Emblica-officinalis on in vivo test models in rats. Phytomedicine, 9:515–22,(2002).

#### **ORIGINAL ARTICLE**

# Effect of Ethanolic Extract of *Emblica officinalis* on Histopathology of Kidney and on Biochemical Parameters in Hyperlipidemic Albino Rats

Bheemshetty S. Patil<sup>1</sup>, Shankreppa D. Desai<sup>2</sup>, Pallavi S. Kanthe <sup>3</sup>, Potekar R. M. <sup>4</sup>, Shivkumar H. <sup>5</sup>

<sup>1</sup>Department of Anatomy, Shri B M Patil Medical College Hospital and Research Centre, BLDE

University, Bijapur-586001(Karnataka)India, <sup>2</sup> Sridevi Institute of Medical Science and

Research Centre Tumkur-(Karnataka)India, <sup>3</sup>Department of Physiology, <sup>4</sup>Department of

Pathology, <sup>5</sup>Department of Pharmacology, BLDEA's College of Pharmacy, Bijapur-586001

(Karnataka)India

#### **Abstract:**

Background: It has been reported that hyperlipidemia plays a central role in the development of atherosclerosis and oxidative stress. Embilica officinalis also known as Amla or Indian Gooseberry acts as antihyperlipidemic and antioxidant. Its active ingredients contains tannins, gallic acid and flavonoids. Aim & Objectives: It was aimed to evaluate the effect of ethanolic extract of Emblica officinalis on histopathology of kidney and on biochemical parameters in hyperlipidemic albino Wistar rats. Material and Methods: Extraction of dried fruits of Emblica officinalis was done by Soxhlet apparatus using 99% ethanol at 60°C for 24 hours and also phytochemical analysis was done. Group I served as normal control. Group II was fed with isocaloric diet. Group III was fed with hyperlipidemic diet. Group IV was fed with isocaloric diet for 21 days + Embilica officinalis for 21 days. Group V was fed with hyperlipidemic diet for 21 days+ Embilica officinalis for 21 days. The dose of ethanolic extract of Emblica officinalis was taken as 100mg/kg body weight daily. Results: Percent body weight gain, kidney weight and nephro-somatic index significantly improved in hyperlipidemic rats treated with Emblica officinalis. There was a significant improvement in serum electrolyte and kidney markers. It was found that there were focal glomerular lesions with thickening of glomerulus in the kidneys of rats on hyperlipidemic diet and normal renal histology of rats on hyperlipidemic diet treated with Emblica officinalis. Conclusion: It can be concluded that Emblica

officinalis may be a good, natural therapeutic agent against hyperlipidemic diet induced oxidative damage and nephrotoxicity.

**Keywords:** *Emblica officinalis*, Hyperlipidemic diet, Histopathology of Kidney, Kidney markers, Nephrotoxicity, Serum electrolyte

#### **Introduction:**

Medicinal plants are nature's gift for human beings to boost a disease free healthy life. Various medicinal plants are present in a class of herbal preparations of the Indian medicine system [1]. Among many of these herbal drugs Embilica officinalis is one of the precious herbal drug, commonly known as Indian gooseberry or Amla which belongs to the family of Euphorbiacae. Amla is very rich in nutrition and can be an important dietary source of Vitamin C, minerals and amino acids etc [2]. The plant also contains phenolic compounds such as tannins, saponins, phyllembelin and embilicanin. The fruit of Amla shows antioxidant, antidiabetic, hypolipidemic, antibacterial and hepatoprotective properties [3]. Along with these functions Embilica officinalis also may produce beneficial effects on kidney functions. Kidney contributes major role in electrolyte balance and Blood Pressure (BP) regulation. BP is regulated by renal handling of substances like Na<sup>+</sup>, Cl<sup>-</sup> and HCO3<sup>-</sup>. It happens

under the control of renin angiotensin mechanism. In this way it maintains homeostasis of the body [4]. In the present study we tried to find out the effect of Embilica officinalis on histopathology of kidney in hyperlipidemic rats. We have given a hyperlipidemic diet to induce hyperlipidemia in albino Wistar rats to develop an animal model expressing changes in kidneys and kidney markers (serum creatinine and blood urea). High fat diets lead to atherosclerosis. It is a condition that involves the interplay of several factors like oxidation of lipoproteins and atherosclerotic plaques formation [5]. This pathogenesis could induce renal vasoconstriction followed by hypoxic condition in the kidney which promotes further ischemic renal injury. The hypoxic tissue produces reactive oxygen species (ROS) more than antioxidant present in the renal tissue. Amla as an antioxidant contains gallic acid which is a multiple hydroxyl group compound. It donates its proton to break the chain reaction of free radicals acting as an inhibitor to lipid peroxidation [6]. It was aimed to explore the nephroprotective effect of ethanolic extract of Embilica officinalis on renal dysfunction and pathological destructions in a hyperlipidemic rat model.

#### **Material and Methods**

#### **Materials:**

Healthy and good quality fresh, mature, *Emblica officinalis* (Amla) fruits were procured from the market, in the months of November–December 2012, and were identified and authenticated by the Department of Botany K.C.P. Science College, Bijapur. Extraction process was conducted in the Department of Pharmacology, BLDEA college of Pharmacy, Bijapur.

#### **Extraction:**

300gms of the powder of dried fruits of *Emblica* officinalis (Amla) was extracted with 99% ethanol using Soxhlet apparatus at a temperature 60° C for 24 hours. The solvent was evaporated under

vacuum which gave semisolid mass with respect to the dried powder.

#### Study design:

#### **Experimental Animals:**

Albino Wistar rats weighing 180 to 250gms were obtained from animal house of Shri B M Patil Medical college Hospital and Research Centre, Bijapur. All animals were acclimatized for 7 days to the laboratory conditions at 22-24°C maintaining a 12- hour light/dark cycle. All the experimental procedures were performed in accordance with the approval of the Institutional Animal Ethics Committee (IAEC) of Shri B M Patil Medical college Hospital and Research Centre, Bijapur. All care of animals was taken as per the guidelines of ICMR on animal research (2006) during the experiment as well as at the time of sacrifice. This study was undertaken in the Department of Anatomy. The newborn and old and diseased rats were excluded.

#### **Preparation of Isocaloric Diet:**

For 1kg of diet, 180gm of casein, 620gm of carbohydrate, 200gm of fat and 1% of multi vitamin and 2% NaCl were taken [7].

#### Preparation of Hyperlipidemic Diet:

For 1kg of diet, 180gm of casein, 520gm of carbohydrate, 300gm of fat and 1% of multi vitamin and 2% NaCl were taken [8].

#### **Experimental Protocol**

All the rats were divided into following five groups with 6 rats in each group.

Group I served as normal control fed with water and food *ad libitum*, Group II was fed with isocaloric diet for 42 days, Group-III was fed with high fat diet for 42 days, Group IV was fed with isocaloric diet for 21 days and ethanolic extract of *Emblica officinalis* (EEO) for 21 days each and Group V was fed with hyperlipidimic diet for 21 days and EEO for 21 days each. 100mg/kg body weight of EEO was given daily. [9]

#### **Sample collection**

Every alternate week (six rats) one group of animals were sacrificed by cervical dislocation at the end of the last dose with an overnight fast. Blood was collected in normal tubes for the separation of serum, by doing retro-orbital puncture, before sacrificing the animals.

#### Tissue collection for histopathology:

After proper dissection of animal kidneys were isolated immediately and fixed in 10% neutral buffered formalin solution for 24 hours [10]. The fixed tissues were processed routinely and then embedded in paraffin, sectioned to 3–5 µm thickness, de-paraffinized, and rehydrated using standard techniques. The extent of hyperlipidemic (high fat diet) induced necrosis was evaluated by assessing morphological changes in kidney sections stained with Hematoxylin and eosin (HandE), using standard techniques.

#### **Gravimetry:**

Estimation of Body Weight and Renal-somatic Index of Albino Wister rats:

#### Procedure 1:

The total body weight of each rat was recorded on the first day (beginning of experiment), Group I was fed with water and food *ad libitum*, Group III and V were fed with hyperlipidemic diet and Group II and IV were fed with iso-caloric diet for 21days and the weight was measured. The same

diet was continued from  $21^{\text{st}}$  to  $42^{\text{nd}}$  day. In addition Group IV and V were treated with EEO.

After 42<sup>nd</sup> day again weight was measured and after overnight fast rats were sacrificed. With proper dissection right side kidney was collected and weight was measured to the nearest of 0.1 mg on a digital weighing machine. Further the renalsomatic index was calculated by the formula of kidney weight/total body weight.

# Estimation of Biochemical Parameters (Renal Markers and Serum Electrolytes):

Blood Urea, Serum Creatinine, Serum Na<sup>+</sup> (Sodium), K<sup>+</sup>(Potassium), Ca<sup>++</sup> (Calcium) and CI were analyzed by Meril Diagnostic Kit Method.

#### **Statistical Analysis:**

Procedure 2:

Values were expressed as Mean  $\pm$  SD. To determine the significance of inter group differences, one way ANOVA followed by 'Post Hoc t tests' were used.  $P \le 0.05$  was considered statistically significant.

#### **Results:**

#### Gravimetry

At 21<sup>st</sup> day: It was observed that there was a significant increase in percent body weight gain in Group III as compared to Group I (p< 0.05). Group IV showed a significant decrease in % body weight gain as compared to Group III (p< 0.05).

Table 1: Effect of Ethanolic Extract of Emblica officinalis on Percent Body Weight Gain

Groups	Cwayn I	Group II	Group III	Cwoun IV	Crown V	ANOVA	
	Group I			Group IV	Group V	F Value	P value
On 21st day	14.2 ± 4.7	$18.5 \pm 4.1$	21±1.0°	15±3.8°	19.8±1.7	5.2	0.0061
On 42 <sup>nd</sup> day	$14.5 \pm 2$	$16.8 \pm 1.4$	8.9±3 <sup>a,b</sup>	8.9±3 <sup>a,b</sup>	14.6±2.1 <sup>c,d</sup>	12.2	0

Values are expressed as mean ±SD. ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c, d express significant difference between groups, a depicts comparison with Group I, b depicts comparison with Group II, c depicts comparison with Group III and d depicts comparison with Group V (\*P value is ≤ 0.05). Group I -normal control rats, Group II - Isocaloric diet fed rats, Group III- hyperlipidemic diet fed rats, Group IV-EEO fed rats, Group V-hyperlipidemic + EEO fed rats

At 42<sup>nd</sup> day: It was observed that there was a significant decrease in percent body weight gain in Group III and IV as compared to Group I and II (p<0.05). Group V showed a significant increase in percent body weight gain as compared to Group III and IV (p<0.05).

It was observed that there was significant decrease in body weight of Group II compared to Group I (p<0.05). There was significant increase in body weight of Group III compared to Group II

(p<0.05). Kidney weights of Group II and Group III were lower compared to group I. Group IV which showed significant increase in kidney weight compared to Group II and Group III. Group V showed a significant relation with Groups I, II, III and IV (p<0.05). There was a significant decrease in renal somatic index of Group II and Group III compared to Group I. Group V showed significant relation of renal somatic index to Group II and III (p<0.05).

Table 2: Effect of Ethanolic Extract of *Emblica officinalis* on Renal Somatic Index

Parameters	Cwayn I	Croup II	Croup III	Crown IV	Crown V	ANOVA	
Tarameters	Group I	Group II	Group III	Group IV	Group V	F Value	P value
Body weight (gm)	253 ± 11.4	$228 \pm 19.3^{a}$	$254 \pm 9.6^{\text{b}}$	$236 \pm 6.2$	$234 \pm 10.2$	6.24	0.002
Kidney weight (gm)	$2.6 \pm 0.1$	$0.8 \pm 0.1^{a}$	$0.6 \pm 0.09^{a}$	$2.5 \pm 0.1^{\text{b,c}}$	$2.1 \pm 0.2^{a,b,c,d}$	223.1	0
Renal somatic Index	$0.01 \pm 0.0$	$0.003 \pm 0.0^{a}$	$0.002 \pm 0.00^{a}$	$0.01 \pm 0.0^{b,c}$	$0.009 \pm 0.0^{b,c}$	229.3	0

Values are expressed as mean  $\pm SD$ . ANOVA followed by Post Hoc Tukey's multiple comparison test. Superscript a, b, c, d express significant difference between groups, a depicts comparison with Group I, b depicts comparison with Group I, c depicts comparison with Group I and d depicts comparison with Group d (\* d). Group d). Group d1 -normal control rats, Group d1 - Isocaloric diet fed rats, Group d1 - New Post d2 - Superscript d3 - Superscript d4 - Superscript d5 - Superscript d6 - Superscript d7 - Superscript d7 - Superscript d7 - Superscript d8 - Superscript d8 - Superscript d8 - Superscript d9 - S

Table 3: Effect of Ethanolic Extract of *Emblica officinalis* on Kidney Markers and Serum Electrolytes

Parameters	Cwayn I	Cwoun II	Group III	Crown IV	Crown V	ANO	OVA
Parameters	Group I	Group II	Group III	Group IV	Group V	F Value	P value
Blood Urea (mg%)	31±4.1	28±6.0	30±6.2	31±5.2	27±7.0	0.7	0.6717
S. Creatinine (mg%)	0.9±0.1	0.8±0.2	0.7±0.3	0.9±0.1	0.8±0.2	0.7	0.376
Na <sup>+</sup> (mEq/L)	139±2.0	143±5.0	140±1.5	139±1.8	141±4.9	2.89	0.2514
K <sup>+</sup> (mEq/L)	4.9±0.7	6.4±0.6 <sup>a</sup>	4.6±1 <sup>b</sup>	4.8±0.7 <sup>b</sup>	4.7±0.6b	4.03	0
Ca <sup>++</sup> (mg/dl)	8.6±0.08	9.9±0.5 <sup>a</sup>	8.7±0.1 <sup>b</sup>	8.6±0.1 <sup>b</sup>	8.7±0.2b	13.2	0
Cl (mEq/L)	98±0.9	97±0.9	97±1.3	97±1.2	98±1.2	0.5	0.2459

Values are expressed as mean ±SD. ANOVA followed by Post Hoc Tukey's multiple comparison test.

Superscript a, b, c, d express significant difference between groups, a depicts comparison with Group I, b depicts comparison with Group II, c depicts comparison with Group III and d depicts comparison with Group V (\* P value is ≤ 0.05). Group I -normal control rats, Group II - Isocaloric diet fed rats, Group III- hyperlipidemic diet fed rats, Group IV-EEO fed rats, Group V-hyperlipidemic + EEO fed rats

#### **Biochemical Parameters:**

No significant differences for Blood Urea, Serum Creatinine and Serum Cl<sup>-</sup> among all Groups was observed. It is observed that the values for Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>++</sup> were all significantly higher for Group II. All the other groups had similar values.

#### Histopathology of Kidney:

Photomicrography of H and E stained kidney of Group III hyperlipidemic (high fat diet) rats showed focal glomerular lesions including thickening of the glomerulus and normal renal tubules, whereas Group I normal control, Group II isocaloric diet, Group IV isocaloric diet with EEO and Group V hyperlipidemic diet with EEO showed normal microscopic architecture of kidney.




Fig. 2: Iso-caloric Group II Rat Kidney showing Normal Architecture of Kidney and No Histopathologic changes
(H and E 40X)




Fig. 1: Control Group showing Normal Parenchyma and No Histopathologic Changes (H and E satin 40X) G-Glomerular, S-Space of Urine, BC- Bowmen's Capsule, P-Proximal tubule, D-Distal tubule, EA- Efferent arteriole, AA- Afferent Arteriole




Fig. 3: H and E stained 10 X kidney of Group III Hyperlipidemic (High fat diet) Rats showing Focal Glomerular Lesions including Thickening of the Glomerular Microscopy. G-Glomerular, BC-Bowmen's Capsule, P-Proximal Tubule, D-Distal Tubule




Fig. 4: Histopathology of H and E Stained 100 X Kidneys of Group III Hyperlipidemic (High Fat Diet) Rats showing Focal Glomerular Lesions Including Thickening of the Glomerulus and Normal Renal (DCT) Tubules




Fig.6: Rat Kidney of Group IV Showing Normal Architecture of Kidney and No Histopathological Changes (HandE 40X)




Fig. 5: Histopathology of H and E Stained 100X Kidney of Group III Hyperlipidemic (High Fat Diet) Rats showing Glomerular Thickening




Fig.7: H and E stained (40 X) Kidney of Group V Hyperlipidemic (High fat diet) Rats Treated with EEO showed Histopathological Changes

#### **Discussion:**

The study was aimed to demonstrate the nephroprotective effect of EEO to prevent the development of renal dysfunction and alteration of histopathology of kidney which are assessed by biochemical and renal markers in a hyperlipidemic rat model. Studies on such models significantly add to the knowledge towards enriching in the field of medical research. Hyperlipidemic animal models expressed changes in renal markers, biochemical parameters and histopathology of kidney. As *Emblica officinalis* being a potent antioxidant it exerts free radical scavenging activity and shows preventive role against fat induced renal toxicity [11].

It was observed no histopathologic change and no alteration of renal markers were found in rat kidneys of Group V and they also retained normal body weight. It indicates that EEO has exerted nephroprotective effect in rat kidney even when it was given hyperlipidemic diet. EEO has revealed to attenuate hyperlipidemia in Group V. EEO may be helpful to restore renal functioning due to its presence of gallic acid and tannins [6]. An increase in percent body weight gain in rats treated with EEO (Group IV) was observed compared to control rats (Group I) at 21st day (p<0.05). Also there was a significant increase in percent body weight gain in rats treated with EEO (Group IV) compared to hyperlipidemic rats treated with EEO (Group V) at 42<sup>nd</sup> day (p<0.05). There was a significant decrease in percent body weight gain in rats treated with Embilica officinalis (Group IV) compared to control rats at  $42^{nd}$  day (p<0.05). Adis et al found that serum creatinine and bilirubin levels increased significantly in contrast media group compared to control group. Pretreatment with EEO demonstrated its nephroprotective effect by attenuating the severity of renal pathological damage and improving renal functioning [6]. In contrast we found non

significant decrease in serum creatinine and blood urea in Group V compared to Group I. Eteng *et al* showed a slight non significant increase in serum (Na+) level for Group I (100mg/kg body weight) Wistar rats [12].

We observed that Na<sup>+</sup> and K<sup>+</sup> levels were significantly lower in Group III, IV and V compared to Group II (p<0.05). Also there was significant increase in levels of K<sup>+</sup> in group II compared to Group I (p<0.05). Ca<sup>++</sup> level was significantly higher in Group II compared to Group I (p<0.05). Increased serum levels of triglycerides and cholesterol causes to lipid accumulation in different organs and tissues like arterial wall, liver, kidney and muscles [13]. In our study we observed the effect of (high fat diet) hyperlipidemia on the kidneys of albino Wistar rats. The hyperlipidemia caused minimum percent of lipid accumulation in kidney tissue. Histopathology of renal corpuscles exhibited normal appearance in Groups I and II (Fig.1, Fig.2) whereas Group III showed the prominent increase in the glomerular capillaries (Fig. 3, 4 and 5). Microscopic study of high fat diet i.e. Group III rat kidney showed focal glomerular lesions including thickening of glomerular changes and completely decreased space (space for urine) between glomerulus and Bowmen's capsule. Epithelial cell lining of renal tubules were hemorrhagic and appeared dilated compared to normal histology of kidney. Fig. 6 and 7 both show normal histopathology, Fig. 4 and 5 show changes due to hyperlipidemia and Fig. 7 shows normal histopathology after high fat diet and treatment with EEO.

Experimental studies have shown that hyperlipidemic diet may be associated with increased oxidative stress in animals [14].

In our study we tried to assess the influences of *Emblica officinalis* on renal functions and histopathology in hyperlipidemic albino Wistar rats. From the results, *Embilica officinalis* is useful in regulating hyperlipidemia and

histopathology of kidneys in albino Wistar rats fed with hyperlipidemic diet.

#### **Conclusion:**

In conclusion, we describe hereby distinctive renal glomerular ultrastructural injury associated with hyperlipidemia and markedly reduced alteration in renal glomerular histopathology when treated with fruit extract of *Emblica officinalis*. We would like to state that fruit extract of *Emblica officinalis* plays a protective role against hyperlipidemic diet induced oxidative damage and nephrotoxicity. The mechanistic pathways by which *Embilica officinalis* acts as a protective therapeutic against that particular toxin

is not fully clear except its antioxidant property. Further investigations are necessary to find the active functional group(s) of the compound(s) of *Embilica officinalis*. However extensive clinical studies are required to establish the efficacy and safety of *Embilica officinalis* for treating multiple pathologies associated with hyperlipidemia.

#### **Acknowledgement**:

I sincerely thank to Dr Kusal K Das, Prof. Dept of Physiology, Shri B M Patil Medical College, Bijapur for his valuable suggestions during conducting present study as well as in writing manuscript.

#### References

- 1. Krishnaveni M, Mirunalini S. Therapeutic potential of Phyllanthus Emblica (Amla): the Ayurvedic wonder. *Indian J Clin Biochem* 2010; 25(4):419-24.
- 2. Anju Lama and Hiteswar Saikia. Effects of *Emblica officinalis* (AMLA) on Serum Lipids and Atherogenesis in Albino Rats Fed with High Fat Diet. *Indian Medical Gazette* 2013; 271-275.
- 3. Patel Snehal S, Goyal Ramesh K, Shah Rajendra S. Experimental study on effect of hydroalcoholic extract of *Emblica officinalis* fruits on glucose homeostasis and metabolic parameters. *Ayu* 2013, 34(4): 440-444.
- 4. Filler J S. Adaptation to Renal Injury. Robert M. Brenner, Barry M. Brenner, Harrison's Principles of Internal Medicine.17<sup>th</sup>ed. New York,NY: McGraw-Hill;2008; 1639-1642.
- Bhathena Jasmine, Kulamarva Arun, Martoni Christopher. Diet-induced metabolic hamster model of nonalcoholic fatty liver disease. *Diabetes Metab Syndr Obes* 2011; 4: 195-203.
- 6. Adis Tasanarong, Supranee Kongkham, Arunporn Itharat. Antioxidant effect of *Phyllanthus Emblica* extract prevents contrast-induced acute kidney injury. *BMC Complement Altern Med.* 2014; 14:138.
- 7. American Institute of Nutrition. Report of the AIN adhoc committee on standards of nutritional studies. *J Nut* 1977; 107: 1340-1348.
- 8. Mani DN, Bawankule D U, Saroj BK. Hyperlipidemic

- model: Studying lipid profile in small experimental animal. *Int J Pharm Pharm Sci* 2012; 4(2): 337-340.
- 9. Devjani Chakraborty and Ramtej Verma. Ameliorative effect of *Emblica officinalis* aqueous extract on Ochratoxin-induced lipid peroxidation in the kidney and liver of mice. *Int J Occup Med Environ Health* 2010; 23(1):63-73.
- 10. Manal K. Abdel Rahman, Elham M. Mahmoud. Reevaluation of individual and combined garlic and flaxseed diets on hyperlipidemic rats. *Pak J Nutr* 2009, 8(1): 1-8.
- 11. Manish K. Singh, Shailendra Dwivedi et al. Arsenic induced hepatic toxicity and its attenuation by fruit extract of *Embilica Officinalis* (Amla) in mice. *Ind J Clin Biochem* 2014; 29(1):29-37.
- 12. M. U Eteng, H. A. Ibekwe et al. Effect of vitamin C on serum lipids and electrolyte profile of albino wistar rats. *Nigerian Journal of Physiological Sciences* 2006, 21 (1-2): 15-19.
- 13. Manar E Selim,Olfat M Yousef et al. Hyperlipidemia aggravates renal disease in bacteremic male albino rats. *Journal of Medical Science*. March 2013,1;(1): 9-22
- 14. Xu L, Liu Y, Wang T et al. Development and validation of a sensitive and rapid non aqueous LC- ESI MS/MS method for measurement of diosgenin in the plasma of normal and hyperlipidemic rats: A comparative study. *J Chrom B* 2009; 877: 1530-6.

\*Author for Correspondence: Dr. Bheemshetty S. Patil, Department of Anatomy, Shri B M Patil Medical College, BLDE's University Bijapur-5860071083 Email: dr.patilbs@gmail.com Cell: 09480117039

#### Paper presentations in Conference and Seminars

#### **ORAL PRESENTATION**

1. 14<sup>th</sup> Karnataka state Anatomy Conference at Shri B M Patil College, Hospital & Research Centre, BLDE University Bijapur 8-9<sup>th</sup> September 2012.

Topic: Effect of Terminalia Arjuna and Emblica Officinalis Extract on Cardiovascular System in Albino Wister Rats

#### POSTER PRESENTATIONS

1. Application to Nanotechnology in Health Care June 13, 2012 at BLDEA's College of Pharmacy, Bijapur

Topic: Effect of Terminalia Arjuna and Emblica Officinalis Extract on Cardiovascular System in Albino Wister Rats

2. International Congress on Ayurvedic Concepts and treatment of Malignant Disorders: at SDM College of Ayurvedic Sciences UJRE Udupi. Karnataka. 15-16<sup>th</sup> December 2012.

Topic: Effect of Terminalia Arjuna and Emblica Officinalis Extract on Cardiovascular System in Albino Wister Rats

3. 14<sup>th</sup> Karnataka state Anatomy Conference at Shri B M Patil College, Hospital & Research Centre, BLDE University Bijapur 8-9<sup>th</sup> September 2012.

Topic: Effect of Terminalia Arjuna and Emblica Officinalis Extract on Cardiovascular System in Albino Wister Rats

From

Dr.R.S. Wali Chairman, Institutional Animal Ethics Committee (IAEC), Prof. & HOD, Dept. of Pharmacology, BLDEU's Shri. B.M.Patil Medical College, BIJAPUR.

No. OUTWARD Date 068/105/MP. SMR. OH LOGIN

To,

Dr. Bheemshetty S Patil, Lecturer, Dept. of Anatomy, BLDEU's Shri. B.M.Patil Medical College, BIJAPUR.

#### ETHICAL CLEARANCE CERTIFICATE

The Institutional Animal Ethics Committee (IAEC) of this College met on 31.05.2011 at 10.30am to scrutinize the Research Project submitted by faculty member of this College.

After scrutiny the following research project has been accorded ethical clearance

Title: "Effect of Terminalia Arjuna and Emblica Officinalis extract on cardiovascular system in albino wister rats"

Principal Investigator: Dr. Bheemshetty S Patil, Lecturer, Dept. of Anatomy.

Dr. R. S. Wali
Chairman, (IAEC)
Prof. & HOD,
Dept. of Pharmacology
BLDEU's Shri. B. M. Patil
Medical College,
BIJAPUR.
Professor & HOD.
Dept. of Pharmacology

BLDEA:s Shri B. M. Patil.
Medical College BIJAPUR.

# EFFECT OF TERMINALIA ARJUNA AND EMBLICA OFFICINALIS EXTRACT ON CARDIOVASCULAR SYSTEM IN ALBINO WISTER RATS